

ISOLATED GENOMIC POLYNUCLEOTIDE FRAGMENTS FROM CHROMOSOME 7**5 PRIORITY CLAIM**

This application claims priority under 35 U.S.C. §119(e) to provisional application serial no. 60/234,422, filed September 21, 2000, the contents of which are incorporated herein by reference.

FIELD OF THE INVENTION

10 The invention is directed to isolated genomic polynucleotide fragments that encode human SNARE YKT6, human liver glucokinase, human adipocyte enhancer binding protein (AEBP1) and DNA directed 50kD regulatory subunit (POLD2), vectors and hosts containing these fragments and fragments hybridizing to noncoding regions as well as antisense oligonucleotides to these fragments. The invention is further directed to methods of using these fragments to obtain SNARE YKT6, human liver glucokinase,
15 AEBP1 protein and POLD2 and to diagnose, treat, prevent and/or ameliorate a pathological disorder.

BACKGROUND OF THE INVENTION

Chromosome 7 contains genes encoding, for example, epidermal growth factor receptor, collagen-1-Alpha-1-chain, SNARE YKT6, human liver glucokinase, human adipocyte enhancer binding protein and
20 DNA polymerase delta small subunit (POLD2). SNARE YKT6, human liver glucokinase, human adipocyte enhancer binding protein and DNA polymerase delta small subunit (POLD2) are discussed in further detail below.

SNARE YKT6

25 SNARE YKT6, a substrate for prenylation, is essential for vesicle-associated endoplasmic reticulum-Golgi transport (McNew, J.A. et al. J. Biol. Chem. 272, 17776-17783, 1997). It has been found that depletion of this function stops cell growth and manifests a transport block at the endoplasmic reticulum level.

30 Human Liver Glucokinase

Human liver glucokinase (ATP:D-hexose 6-phosphotransferase) is thought to play a major role in glucose sensing in pancreatic islet beta cells (Tanizawa et al., 1992, Mol. Endocrinol. 6:1070-1081) and in the liver. Glucokinase defects have been observed in patients with noninsulin-dependent diabetes mellitus (NIDDM) patients. Mutations in the human liver glucokinase gene are thought to play a role in the early
35 onset of NIDDM. The gene has been shown by Southern Blotting to exist as a single copy on

chromosome 7. It was further found to contain 10 exons including one exon expressed in islet beta cells and the other expressed in liver.

Human Adipocyte Enhancer Binding Protein

5 The adipocyte-enhancer binding protein (AEBP1) is a transcriptional repressor having carboxypeptidase B-like activity which binds to a regulatory sequence (adipocyte enhancer 1, AE-1) located in the proximal promoter region of the adipose P2 (aP2) gene, which encodes the adipocyte fatty acid binding protein (Muisse et al., 1999, Biochem. J. 343:341-345). B-like carboxypeptidases remove C-terminal arginine and lysine residues and participate in the release of active peptides, such as insulin, alter
10 receptor specificity for polypeptides and terminate polypeptide activity (Skidgel, 1988, Trends Pharmacol. Sci. 9:299-304). For example, they are thought to be involved in the onset of obesity (Naggert et al., 1995, Nat. Genet. 10:1335-1342). It has been reported that obese and hyperglycemic mice homozygous for the *fat* mutation contain a mutation in the CP-E gene.

 Full length cDNA clones encoding AEBP1 have been isolated from human osteoblast and adipose
15 tissue (Ohno et al., 1996, Biochem. Biophys Res. Commun. 228:411-414). Two forms have been found to exist due to alternative splicing. This gene appears to play a significant role in regulating adipogenesis. In addition to playing a role in obesity, adipogenesis may play a role in osteopenic disorders. It has been postulated that adipogenesis inhibitors may be used to treat osteopenic disorders (Nuttal et al., 2000, Bone 27:177-184).

DNA Polymerase Delta Small Subunit (POLD2)

 DNA polymerase delta core is a heterodimeric enzyme with a catalytic subunit of 125 kD and a second subunit of 50 kD and is an essential enzyme for DNA replication and DNA repair (Zhang et al., 1995, Genomics 29:179-186). cDNAs encoding the small subunit have been cloned and sequenced. The
25 gene for the small subunit has been localized to human chromosome 7 via PCR analysis of a panel of human-hamster hybrid cell lines. However, the genomic DNA has not been isolated and the exact location on chromosome 7 has not been determined.

OBJECTS OF THE INVENTION

30 Although cDNAs encoding the above-disclosed proteins have been isolated, their location on chromosome 7 has not been determined. Furthermore, genomic DNA encoding these polypeptides have not been isolated. Noncoding sequences can play a significant role in regulating the expression of polypeptides as well as the processing of RNA encoding these polypeptides.

 There is clearly a need for obtaining genomic polynucleotide sequences encoding these
35 polypeptides. Therefore, it is an object of the invention to isolate such genomic polynucleotide sequences.

SUMMARY OF THE INVENTION

The invention is directed to an isolated genomic polynucleotide, said polynucleotide obtainable from human chromosome 7 having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:

- 5 (a) a polynucleotide encoding a polypeptide selected from the group consisting of human SNARE YKT6 depicted in SEQ ID NO:1, human liver glucokinase depicted in SEQ ID NO:2, human adipocyte enhancer binding protein 1 (AEBP1) depicted in SEQ ID NO:3 and DNA directed 50kD regulatory subunit (POLD2) depicted in SEQ ID NO:4;
- (b) a polynucleotide selected from the group consisting of SEQ ID NO:5 which encodes
10 human SNARE YKT6 depicted in SEQ ID NO:1, SEQ ID NO:6 which encodes human liver glucokinase depicted in SEQ ID NO:2, SEQ ID NO:7 which encodes human adipocyte enhancer binding protein 1 depicted in SEQ ID NO:3 and SEQ ID NO:8 which encodes DNA directed 50kD regulatory subunit (POLD2) depicted in SEQ ID NO:4;
- (c) a polynucleotide which is a variant of SEQ ID NOS:5, 6, 7, or 8;
- 15 (d) a polynucleotide which is an allelic variant of SEQ ID NOS:5, 6, 7, or 8;
- (e) a polynucleotide which encodes a variant of SEQ ID NOS:1,2, 3, or 4;
- (f) a polynucleotide which hybridizes to any one of the polynucleotides specified in (a)-(e);
- (g) a polynucleotide that is a reverse complement to the polynucleotides specified in (a)-(f)
- and
- 20 (h) containing at least 10 transcription factor binding sites selected from the group consisting of AP1FJ-Q2, AP1-C, AP1-Q2, AP1-Q4, AP4-Q5, AP4-Q6, ARNT-01, CEBP-01, CETS1P54-01, CREL-01, DELTAEF1-01, FREAC7-01, GATA1-02, GATA1-03, GATA1-04, GATA1-06, GATA2-02, GATA3-02, GATA-C, GC-01, GFII-01, HFH2-01, HFH3-01, HFH8-01, IK2-01, LMO2COM-01, LMO2COM-02, LYF1-01, MAX-01, NKX25-01, NMYC-01, S8-01, SOX5-01, SP1-Q6, SAEBP1-01,
25 SRV-02, STAT-01, TATA-01, TCF11-01, USF-01, USF-C and USF-Q6
- as well as nucleic acid constructs, expression vectors and host cells containing these polynucleotide sequences.

The polynucleotides of the present invention may be used for the manufacture of a gene therapy for the prevention, treatment or amelioration of a medical condition by adding an amount of a composition
30 comprising said polynucleotide effective to prevent, treat or ameliorate said medical condition.

The invention is further directed to obtaining these polypeptides by

(a) culturing host cells comprising these sequences under conditions that provide for the expression of said polypeptide and

(b) recovering said expressed polypeptide.

35 The polypeptides obtained may be used to produce antibodies by

(a) optionally conjugating said polypeptide to a carrier protein;

(b) immunizing a host animal with said polypeptide or peptide-carrier protein conjugate of step (b) with an adjuvant and

(c) obtaining antibody from said immunized host animal.

The invention is further directed to polynucleotides that hybridize to noncoding regions of said polynucleotide sequences as well as antisense oligonucleotides to these polynucleotides as well as antisense mimetics. The antisense oligonucleotides or mimetics may be used for the manufacture of a medicament for prevention, treatment or amelioration of a medical condition. The invention is further directed to kits comprising these polynucleotides and kits comprising these antisense oligonucleotides or mimetics.

In a specific embodiment, the noncoding regions are transcription regulatory regions. The transcription regulatory regions may be used to produce a heterologous peptide by expressing in a host cell, said transcription regulatory region operably linked to a polynucleotide encoding the heterologous polypeptide and recovering the expressed heterologous polypeptide.

The polynucleotides of the present invention may be used to diagnose a pathological condition in a subject comprising

(a) determining the presence or absence of a mutation in the polynucleotides of the present invention and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

DETAILED DESCRIPTION OF THE INVENTION

The invention is directed to isolated genomic polynucleotide fragments that encode human SNARE YKT6, human liver glucokinase, human adipocyte enhancer binding protein and DNA directed 50kD regulatory subunit (POLD2), which in a specific embodiment are the SNARE YKT6, human liver glucokinase, human adipocyte enhancer binding protein and DNA directed 50kD regulatory subunit (POLD2) genes, as well as vectors and hosts containing these fragments and polynucleotide fragments hybridizing to noncoding regions, as well as antisense oligonucleotides to these fragments.

As defined herein, a "gene" is the segment of DNA involved in producing a polypeptide chain; it includes regions preceding and following the coding region, as well as intervening sequences (introns) between individual coding segments (exons).

As defined herein "isolated" refers to material removed from its original environment and is thus altered "by the hand of man" from its natural state. An isolated polynucleotide can be part of a vector, a composition of matter or could be contained within a cell as long as the cell is not the original environment of the polynucleotide.

The polynucleotides of the present invention may be in the form of RNA or in the form of DNA, which DNA includes genomic DNA and synthetic DNA. The DNA may be double-stranded or single-stranded and if single stranded may be the coding strand or non-coding strand. The human snare YKT6 polypeptide has the amino acid sequence depicted in SEQ ID NO:1:

5 KLYSLSVLYKGEAKVVLLKAAYDVSSFSFFQRSSVQEFMTFTSQLIVERSSSKGTRASVKEQDYLCH
VYVRNDSLAVVIADNEYPSRVAFTLLEKVLDEFKQVDRIDWPVGSPATIHYPALDGHLSRYQN
PREADPMTKVQAELETKIILHNTMESLLERGEKLLDLVSKSEVLGTQSKAFYKTARKQNSCCAI
M

and is encoded by the genomic DNA sequence shown in SEQ ID NO:5:

10

CCAGACATAGGCAAGGCGCAAGGTGATACAGTAGGCAGCCACCATGGGGGCCAGGAGGCTCC
AGCAGAGGCCACACAACCAGCCCAGAATCCAGGACAGAGAGCTGGAATGGAGACAGGGAAG
CCAGATACCAGGCCAGACTGGCCAGGTGCTACAGGCCTGTGGGCCAGGCCAGGCTTGGGGAC
TTCGTCCTGGGTGTGAAGGAGACAGGCACCCCTGAGGCCTTCCCTCTGCATCTCCAGCCCAAG
15 CTAAGCGCAAACCTCTTAGGTTGGAGTAAGGAGTAACCCCTGCCAAGTTTCTCCTGTCCTCAG
GCTCCACCCACCACCTATGCTGCCTGGCCCCATGGGGCACACGCTCAGGCCCAGCCTGGGAAA
GCAACTGCACCTGCCTGTGCTATGCTGGCCCTTCTCAGCCTCAATGCCCTCCTCCCTCCCCGAC
GCACCCTCGTGGCCCCCGCTGGGCCCCCTGATGCACCCTCATGTCTCCATGGCAACCTGCTCA
GAGTGTGGCCCTGCCCTTGGCTCCCTCCACACCTGTGTCCCAGGCAGTGCCACGGCACTTTCC
20 TAAACAGAAGGATGGGCTTCAAAACAGTCCCAGACACTAAACACACCTGCATTTTGGGTCCA
AGTAACTTCTGACAAGACGAGTGCCCTACACACTCTCAGTCCTATCCACTATGGGCAAGGAG
CCTGAAGGATCCCCCAGAACTGGCTAAAGCCCTCAGTCTCCTCCTCCACCCTGAGCACCTTCA
CGCGGCAGAGTGGCCCTGGATGTCAGCTTCTTGCTCCCCATGGTCTGCACCTGGACAGGTGCT
CTCAGGTGTGTGGGTGGGCAGGTGGCAGGTCCCAAGAGCCAGGTGCAAAGAATCTAGGCCAG
25 TGCCACGAGTGCTGCAGTGTCTGTCCCCAGCATGGTATCTAGGGCTCCACTTGCCTATCAGCT
GTAATCGGAGGAGGCTTTCCAGGCCAGGCCTCCCCAGGAAGGCTGCAGGCACTGCGGATCG
TGCGCCCTCACATGCATTATTCCTGAGGGCCCTTCTGCAGATGCCATCAGGGCAGCAACTCTGA
TGAGGTATTAGGGCACAGCACACAGGGCTAAGCCACCCTGTACTGGGCCAAGCGCTACAGGC
AAAAGGACACCACCGACGGGCATTTCAATTCATCGCTTTTATTTTATATATTTTGTAGAGGGA
30 GCCTCACTCTGTGCCCCAGGCTGGAGTGCAGTGGCGCGATCTTGGCTCACTGCAACTTCTCCCT
CCTGGGTTCAAGTGATTCTCCTGCCTCAGCCTCCCGAGTAGCTGAGATTACAGGTGCCCCGCCA
CCATGCCAGCTAACTTTTGTATTTTAGTAGACATGGGGTTTACCAGTGTGGTCAGGCTGGTC
TCGAACTCCCGACCTCAAATGATCTGCCTACCTCAGCCTCCCAAAGTGCTGGGATTACAGGCA
TGAGCCACTGCACCCGGCCCATTCATCACTTTTAAATAGCACCCCTCTGAACAAAGCTCCCTGG
35 GCCACATGACCCTAAGGGTTACCCCATCCCAACCCCAACCCAGGTCTGGCAGGTCTCAGAACAA

GGAAAAGCTGAGCACTGCCCAAGGCTGCTTGCTGGGCCAGTCAGAGAGGTCTCTGCCTTCCAG
GATCAGAAGTACAGGCTGAAAGCAGCCTTGGGCCCCGCTCCCTGGGAGGCTACAGAGGCTTC
AGAGGGTTCCCTGAACTCAAAACCAGATGTGAGACTTGAATTTGACTTACCCCTGGTTACCT
CCCAACCAAAGCAGGGGTGAGCTTTGGCTCCTCCAGGAACCAGGAAGCTTCCAGGTACCCTGT
5 GGAGCCCCCTCTGCTCCTGAAAAGTTGCCACCTGTGCTTGGTGGGATGCCAGGTGGTCTCAGA
TTGACCCTGGGGTCAGCGGTGAGGGACAGGAAGCCTACAGCGGGATCAGGATGGGGATGGGG
CCTCCTGTCCCATGGCTCTGCAGCTATGAGGCAGCTTTCCTAGGGTGGGTCTCCTGGCTGCAGC
TAAGACCAGGCAACAGGATTCAGCAATGACAGGGCTTCTTCTACTCCAGGGCTCCCTCACCTG
GTTAACAGCAAAAAAGAAAATACAGTTCCTGCTAGCAAGGTCTATAGAAAGGAGGTGAAGGA
10 GTCAGGCCTGCAGCTACCTCTCCTGGACAGGAGCTGGTCAGGATAACTTGGACCCTTGCATGC
GGCAGGCCCCACAGGCACACAGCATGAGGCCACTCTCTCCCCGGGGGAAGGGCTTGGTGAAG
AAAGGATTCCCCTGAAGCACAAAGAAAGCACAGGACCACTGTGAAATTTCAAGACAACTTTA
TCCAGACAGGCGCCTCTCAAATAGAACACAGGGAAGTTAGGCAGCAGTTACTAAAATACAGT
CTCGCCAAATGATTTACAACAGAACACAACAGGAGCAGGGGATCTGTGGGTGGGGCTGGGCT
15 GGGCCCTCTATCTCACAGGGCCTGAGTCAAGCCAGCCCGCCCTGCAAGGCAGGGGCTGACCT
GCAAGCGGAGATCTCACTTCCTCTTACCCCAAATTCATACCTCCATTTTCCCCGCCCCCATCTC
TCCCCAGGGTCTCAAGTGGGAAAGGGAGAGGTAGCATCCCTCGGATCCAGGCCCACTCCAC
TCCGTCTCCGGCACCAAGTGGGCAGGCTGAGTCTGGGCCTCAAGGGGCCCTGGGCTTAGGGTAT
CTATGGCAGTAGGAAAATGACATGGACAGGCTCTTCAGGGGTAGGCTAAAGTCCTCTGGCCA
20 GCAGTACCCAGAGAAAAATGGGCAGCAGCAGGTAAACCAGCCAGGAGGTGGAGTCCTCTGAAC
CCACAGCAGACCCCAACCCTCCTGCCCAGCCCCTGCCACATTGGGGGTGAGGACCACTGAGAC
TCTGGTCAGGACAGTGGGTGCTCTCAGCAGTGTGGCAAGCTCAGAGCAGAGCTCCCAAGGAC
CATACCACACTGGTTCAAAACCCATAGGTGACACCATCCCAGCAGAAGCTTCCATGGGTGCTG
GATCCCAGGGCTGCATCCTGAGCACAGGTGGGCAGACTGGAACATAACACTAGGACCCAAGG
25 GATCCAGAACATTTTAGGCCCATCTCCTGGGCTGCTCCAGCCTGTTGCCATGACTTGGGCAGT
GAGTGGGCCTCCTGCCAGGTGGCAGGGCACAGCTTAGACCAAACCCTTGGCCTCCCCCTCTG
CAGCTACCTCTGACCAAGAAGGAACTAGCAAGCCTATGCTGGCAAGACCATAGGTGGGGTGC
TGGGAATCCTCGGGGCCGGCTGGCACCCACTCCTGGTGCTCAAGGGAGAGACCCACTTGTTC
GATGCATAGGCCTCAGGCGGTTCAAGGCAGTCTTAGAGCCACAGAGTCAAATAAAAAATCAAT
30 TTTGAGAGACCACAGCACCTGCTGCTTTGATCGTGATGTTCAAGGCAAGTTGCAAGTCAAGGC
AAGTGTCCCAGAGGCCCTGGGCAGCTGAGTGCACCTGTGTTTGATCTTCCCCTGATGATGGAC
ACTCCCAGCTGACCATCCAAACACCAGGAAAACATCCCCCTTTCCTGGGCTCAGTTCCTAGTC
TACTTGCTGGTACGAACCCAACCCACACACTCCCCGCCACAATGCAGCTCCTTCCAAATCCT
CCCACAAGCCACCTTTGTGGGACTTGGAAGCTGCTTAGGATGGGCCCTGCCCTCTGCGGGAAG
35 CCAATCCTAGCAGAAAGGTAAGCTAAACAACAGTCTCAGAATCTGAGACCCAGTGACT

GTTCCCCCGCCCCAGGCCTTGGGCCTGAAGTGGGGGCCTGCCTGTGGCCTCTGTGGTGGGCT
 CACTCCCACCCCCAACAGTGGCCCCAGGAGAGGCTTTCCCAAGAGTCTTCAAACCTCCACCCAC
 CCCAGCCCTAGCATCAGGGACTCCCCACCCCCACTGGAGTGTTAATATCATTAAATGTACAAA
 TAAGATCCAAAGATATACCAAAGATCGAGAAACAGCTGGCTCCGACCTCCCTCCCACAGAGC
 5 CTTCCCAGGGTTAGCTGAAAAAGAGCCCTTTGGCATCTACAGAAGCCAGTCGGAGTTTATGGT
 TTCATTTGCCCAAAAATACACCTTTGGGGACCTCAAATTCTTTCCAAGAATCACTACCACACAT
 ATGAATTTGAACATTCGCCACCCTTCCACCATCCATTTCTCGCAGGAACCTTCAAAATAAAAAT
 GGCCAGTCTGCCCCACTCTGGCTCCTCGTCTATGGCTGTCTCTTCTTTTCCAGGGGCTGCAGT
 TCTGATGTGAATGATGGTGCCATTCCAGCATTGGGCCTCTGGCAGGCTGCATCACATGATGGC
 10 ACAGCATGAGTTTTGTTTTCCGGGCCTTGGAaaaaaaCAAAGAGGAGCTGAGAAGGAGGACTG
 ACGAAGTAAGGGAAGCCCCAATCCTGGCAGGCGTGGCAGAGGGAGCTCCACAGGACACAGC
 CAGGCAGAGAACTAGCACTAGAACAGGGTGGGGGTGGAGGCCTTGAGGGAAGCTGTCCAC
 AAGCAATTCCCATCACCAAGCACAAGGCGGGCCCCGGCTTCCAAAAGTCTGGGATCCTTT
 TTCCTTTCTTTTCTCACACCCCATTAATGCTATCAAAAAGTGAGTAAAATTCCTACAGTTAGGC
 15 CAGGTACAAACAAAGGACCAATAATACAAATGGGATTGGCAGAATATCTTAACTTTGCCCCA
 CTCCTGTCTTCACACAATGCTATCTGACCACCACGGTGGTGTCTTCTCCTAGAAGATGGTCCTG
 AGGACAACAGATGTGGTTCCCACTTGGGATGTGGTTTGTGGGGACCACTGTTGCCACCTTCTC
 TCTTGCTTTCTGGTCACAGACTATCTTCCTAATCCCACCTAGCCATCTCCCTCCAATGTGCACA
 TGAAAGCAAATGTGTGTGGACAGACCAAGTAAATTTGTCCCTATGACTATCCAACCATGGGCC
 20 AACAGTGCCATCTCCACATAGGAAGACATGAGCACTGACCTGAGAGAAAGCGGCAGTCAGCA
 GCACCCATCCTTGTCAATTAAATATTTTCTGTCAAAGGGAAATTAAGGCTTAAGAACCTCTT
 CAGGAAGGCTGAATTGCTTGCATCTTAAAGACTTATGTCTACTCAGCAGAAAGAGGAATAAG
 ATTCAACAGTAAATCTCTGGTGATCAGAACTTGAACCAGCCTTCTGGACTGGGAGTAGGAGT
 TCAGAAATCAGCCAGAGCAGCAGAGGGCAGAGCAGAGGCAGGAGTGGAACAAGGCCTCGGC
 25 CCGCATCGACTCCAACGGCGCCCAAGTGAAGTGCCTCCAACCACCTGGGCCTGAGGCGCTCAC
 CTTAGGCTCTTGCCGCACAAGGAATCATCCACCATGATTCAACAGTCTAAGAAAGACCCGTTT
 ATAGTGGAGAGTGCCAGAAGCAGCAAGCTGCGACTGCTCTCTAGAGAGAACACCCAGGAGGC
 AGCAGGTGCTGGGTACTCACAGTTTTATAGAAGGCTTTAGACTGTGTTCCAGCACCTCGGAT
 TTGGACACCAAGTCATCTAGCTTCTCACCTCGCTCTAACAGAGACTCCATGGTGTGTGTGCTGG
 30 ACAAAAAAGAAAAGAGAATCCAGCTCTGTTACGTACGTGCCCTGACATGAGCCCCTCATATTT
 CAGTCATGGGGGAAAGTGCCTTACCTGGGTTCCTCTCCAACACACACAACTTCACCTCTAGG
 TGTGAGACTCGGTCCAAGAATAGTTACTGTCCAAGTGGATGGAACAGAACCTGGTGACATTC
 CCGTGAAATCTAGAAGATCTAACTGGGATGTAGCAGACTTCCCAAAAAGCTGTCCCCAGCAC
 AGGCTTAGATAACCAGCACTCCAGGAAAACCTCATATATATATATACACACACATTTATATATA
 35 CATTTGTGTGTGTGTGTGTGTGTGCACGCACATGTGCGTGTGCATGGAGCTTTGGAAAAAAGA

GTAGCTGGGCACTATATGATTGTACTGGGTTGGAGAGTGACCCACACCGCACCCCCCAACCCC
 AACCGCATCCCAGAAATTAACATCCCCAGAATCTCTGAATGTGACCATATTTAGAAATAGGGT
 CTTGGCAGATGTAAGTCTAGTTAGGAAGAGGTAATACTGGATTAGGGTGGCATCTAATTCATGA
 CTGATGTCCTGGTAAGAAACGGAAACACACACACAGAAGGTCACGTGACGGCAGAGGCAGA
 5 GCCTGAAGTGATGCACCTCTAATCCAAGGAATGCCAAGGATGGCCAGCAGCCACCAGAGGCT
 GGAGAGAGGCCTGGGACAGACACTCAGAGCCCCAAAAGACACCAGCCAGGCCACAGAGCT
 ATCTGTAAAAAGCAAATATTTGAGGGTTTCTGTTGACAGCAGCCACAGGAAACAAAAGGCGG
 TGGGAAATGGCTATTGAGCACTTGATGTGAGGCAAGTCCAACTGAGCAGCGCTCTGAGTAC
 AGACACACCAGATTTTCAGATGCAAACCTCACACATGCTTCATTAGTAAGTTTTATACTGAAAAA
 10 AAAACAAGTTTTATACCGATTACATGTTGGAAAAATTGTATTTGGATATACTGCGTTAAGTAA
 AATATATAATTAAATTAAATTCTACCTATTTTCCTTTTATCATTTTAAAAATATGGCTCCTAGAA
 AATTCTAAGTTACACACATGCCCCAAATATATACCAGACAGCACTATGACAGAACATGTCCTG
 CCTTCTAAATGGGCTATGTCCTAAATGTCATCACTACAACTCTGACTTAGGAAATGAAAACA
 CTGACCCCATGGGAAGGGGTCTAGAGATGGAGACCTCACAAGAGCCAGCAGCTCTGCTGCCA
 15 GGGCCCTCAGGAAGCAGCAGCTCGCTTCTCTCCTCAGATGGCCACTGCTGCAGCAGCTAGATG
 CACACATGAAGCGCCATAGAACAAGGAGCCAGCAAGAATGTCCTTCATCCCTACACACAGCT
 GAGCGACTCAAATTTTTAACACAGAAAGTTAACTGATTCAGATATGCACACCAATCATCTAGA
 TTTTACAACCTGCAGCTAGATGAGGCTGGGTGAATAGGACTCATCCACTCCCCACCGTGGGGAG
 AGGAGAAACAGCGGGTGTCCCAGGTGTCATGGTACTCAGACTAGGACTTGAGCAACAGAAAG
 20 AGATGGCTTGAGGAGAAAACGGAGAAATGCCACCTAGGTGGTAAGAAAGCTCACAAGGTTTC
 AAAAGACACAGATACCATGAGACTTTTCACATCTATCGTTTCATTCCAAAGCCACGTTATTTGGA
 GTGCAGTCAGCACACCTGTGTTTGAAGCCCCTGGGATGCTTTTTATAAAATGCAGGTTCCCAG
 GCTCCATCGCAGGCCAACAACTCCAACCCCAGGAGACGCTGATGTACACACTAAAGCTATGC
 CTGTGTAAATGGTAAAGCTTTGTATGTGGGTTTCAATCCACTCCAGGTATCTATCAACTGCTGA
 25 GCATGGTATAAACTAGGCACTGTATCATGAGCAGGATGGAAAGATGTCCCAGTGCTCATACG
 CTGGTCAGGGAGACATGTAAACAAGCAGTGACAAAACCTGTGACATCTGGTCAGAAAGGCCCA
 ACCTTCAGGCGCCTGTGTGTGAGCTGGGCAAGAAAGGGTATAAGAGAGAACAGGGCCCAGTC
 AGGAGACTGTGAGTTAGTTTGCACTTTATCCTGGGGCGGATCTGAGAGCTGCTGAAGGGTTCT
 AAGTTGTGCAGATCAATGACTACTCTCTGGTGGACAGACTGGAGGTGAGCAGGAGGCAAGGG
 30 GACCACTTAGAGGCAAAGGCTGTAAGAGAAAAACCTGAGAAAAACAGATAGCTGCTTACATT
 CCACTTGTATGCAAAAATTTAAAAAAAAGAGTTGAAGCAACAGTTACAAATCAGGAGATTT
 CAGCTCAAATGCAGGGTTCTGGCTCTTTTCAAAGGGGCCTATGTGACAACCCTGGGCCCATA
 TTCCAGAAGCTGCCCTGTGGTCAGTGCACGGTGCTTCAATCTGTTACCTTCAATGCAAACGCT
 GCAAGGGGAGGCACCTGTGGGGTGTGGAGGCACCCGAAACCCTAACAAAGGCACCAGGGTG
 35 GGAATCCAGGTCTTCAGAAGCCAAACCCTAGGAACCCAGTAAATGGTCAGACAGGCAGTAGC

CATGAGGAAGGGAGACTTGAGGGTTCCTGTTCCAGCTTGGTCCCCTAGAAACAATGGGT
 GCCATTAACCAAGAGAAGGGTATAGGAAAGACAGTCTGATGCCCCGGGTGGGGGAAGGGT
 GGGCAATCCCCTTGCTGGAGAGTGCCGTGGTTACTATTATATTAACGAGGATGGATCTGT
 GCATGCCTGGCCAGTGGAAATCGCACCCCCGCCTCAGTTCTTGGGCTTGCTCTCCATCTTCCTG
 5 CTTACCAGAATGATTTTGGTCTCATCTAGTTCGGCCTGCACTTTAGTCATGGGATCAGCTTCTC
 GTGGGTCTAGGAAAGAGTGAAAAATAATAAAGTCAGGACTGGAGTGGCTACCTGCAAACAA
 AACCTAAACTGAGGAAGCTGGACAACTTTCACAGGTAAAAAACACAGCCTGGGCCGGGC
 ACAGTGGCTCACGCCTGTAATCCCAGCATTTTGGGAGGATGAGGCGGGTGGATCACCAGAGA
 TCAAGAGTTCGAGACCAGCCTGACCAACATGGTGAAACCGTCTCTACTAAAAATACAAAAAT
 10 TAGCCAGGCGTGGTGGCACATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAAT
 CGCTTGAACCCAGGAGGTGCAGGTTGAGTGAGCCGAGATTGCGCCACTGCACTCCAGCCTGG
 GAAACAGAGTGAGACTCCAACCTCAAAAAACAAAAACAAAAAACCACAGCCTGTT
 TAACATGTAACAGAAACCCAAAGCCTGCCTAGAGCTTGGGTTCCTCGGTCTGAACGTAGATTC
 TCTGTTTTCCAAACAGTAAGGCTTGAGAGAGGACACCAGCATCAGAAGCTGTCAGAAGTAATT
 15 AGACCAGAACTATCAGGGCAGTTGGCTTTTTCAGTTTCACATGGATTCTGGGCCACATGGTGT
 CTGCTGAAGCTTCCTTTAACCCCTACCTGGTATCTACTGAGGTGACCATCCAGGGCTGGGTAAT
 GGATTGTAGCAGGGGATCCTACTGGCCAGTCTATCCTGTGACTTGCTTGGAGAATTCATCTA
 GTACCTGCAAGACAAAGGAGACTCAACAAGCCTCCCACTGTGCACTCACCAGTGGTCTCAATG
 ACAGGGCTTCACCCCTGAGCACCTCACCTGAATGAGGCTCCTTGGCCTTCACAGCCCAGGAA
 20 GGAGGAATGAGGGGGACATATAATGGCAACAGAGAAAAATCTAGGCTAAAGTTCTTTCCAAAT
 TTTTATCATTAACATATCCTAAATATTCTGAGAATCAAAAGTATGCCAGCCCGAGATGAA
 CCTCACTTGGGGAGTAATAAAGGTATTTGAATTTTAAACTACAGATTTCCAGAAAAAAGGGGC
 ACTGGTCCTCTAATTTTCCAAAGCAATTTTTTAAAAAGAGAATTAGGTCCCCTAGATTTAAG
 AAACCACCAGATTCCATGTGTTTGGAGGTATTTTGGTGCTCTGGGGTATAGGATGAAGCCTCT
 25 GACTTCAAAGAGTTAATATTAGTAATTAGCACCGTACGCAAAAAATTTAAAGAATGCTTAGG
 TGCTAAGCTCTGTGGTGCAACTGACTGACATCAAGGTAGAGGGATGCAGCAACTGCAGGAGG
 CAATGGGGAGAGTGAAGGCATTCAAGAGGGAGACTCCTTGAGCAGAAGCACAGGGGGCGAG
 AACACAAGGCACAGCTGTCTCCGAGGGTCCCATCCAGAGAATAGATGCTATGACTCAGTGG
 CCTAGACCCAGCTCACATGAGGGACAGCACCGGGGAGGAAACCCATACAGGGATGCCAAATT
 30 GTCTCTTGGGTTGCAGGGAAGGGGGCTGAAAAATGTGTTGACTTTGGACACATCATTTTCATCC
 CTTATGTCTCAGGGACTGCCATCAACCCCTGTCCAGTCCATAAATGTGCCCATTCATCATCCA
 AGTCCAGGAGAGGCAAATAAAAACTCACCTTCTCCAGCAAGGTAAAGGCCACCCGGGATGG
 GTATTTCATTGTCAGCAATGACCACACCTGCAAGACTATCATTCCGGACGTAGACGTGGCACAG
 ATAGTCTAAGGAGACAAGAGATCAGACACATGGATGCTGACATGAGGGCTTCAGACTTCTTTT
 35 AATCCCCCAAATCAAAGCATCCAATGTTAGGCCAAATGAAGCCACTCGGAAGCTCAATAGC

TCTGGGCAAGTCTTGTGGAGAGGCTTAGCAGCACAGCCCAATGGGCCACACACAGGAGCTTG
GCCCAACGCCTGCTTTAGGACCAGTAAATACCCAGAGGCCCAGTATGCAAAGCCAGGGCTTA
AAGAAACAGCCAGTGGTGCAGAAAACACACCCTTGACAACATGGCCCCAGGAGCATTTCCAA
GTGTATTCCTTAAGCTCGGGTCAGGCCAAGCTATATCTTAGGGATCTGGAGCCCTTGGGGCTC
5 TGTGCTGCTCCCAAACCTTAGGGAACCCTGGACAAGCCAAGAGGCCTCTGCTTTCTTAAAAAAT
CTTTTCAGAGCAGCCAAAAGACAGGAAATTACCCCCAGGGCCTCAGTCTTCCATATTATAGC
AACCTGCTGGGTTTGTCTCACTCTGGTGGGTGACTGGGAGTAGGGGGGTAGTCTAGAAAAAG
ATTAGCTACTGCCAGCTAAGGCCTCCAGAGCACTGTGCTAAAATCCTCATATGATTGAAAGGT
ACAGTTGTACAGGTCTTCCGCAAAATATTCACAATCCACAGGATTGTTTCAATTTCCATCACTTTG
10 AAAGGATTACAGAGTTGATACAGCTAACCATATCCCCAAGGAAAGAGAAATGTAAGGATTACA
GCTTACAAATAAGAACCTTCTTGTCTTAAGGATCTGACCCAGAAGATTCCAATGCTAAACAA
CAGAAAAACAAATAAAAGAGGAGGGAATGATGGTGAGCCCCTGAAATCAGAAAAGAGCAGA
GATAAATGAGAACAAGAATGAGGAGGAGGAAGAGGACAGGGGGTTGTCACCAATGCTCTCC
AGATTTTGTATACCATCCCCAATTAAGATTCAAACATGGGGTCAAAGTGCATACCCTCCAAAG
15 AAAGTGAAGAACCTGGTCAAGTGGAGGAATTGTCTTTAAGTAATAAACGTGGGAAGGGCAGGCA
CAGTTTGAAGAACAGAGCAAGAACACTGAAATATTTGTGATGCGATTTCACTTCTATGATGTT
AATAGCACAGAGATCCACATAAAGTGTATATAGTCAATCCTGCCTGTATCATAACTGACATT
TATATCATCAATTCAGTAACTCTATGTCACGTGACTTGAGGTTAGCATAAGTGTGAGATGATC
TTTGTCCCTACCTGATGAAACTCATGTAACCTTTTCTGATCTGTCTGTATAACATACATCT
20 AAATAAATGCCTAAACCTGAATTATCAGAAAGAAAAAATAGTTTTTTCAGATTCTGATCAAA
AAATCTACGATGCACAGAATACATATAGTACCTCAACAGTGCTAGCTGGAAATCCTTTTTTGA
GGGGTCTGCAACTCTGAAGAGGATAGGGAAGAATACGATATGAAGGCTGCTTACTGCTCCAA
AAGAGTCAGACCCTAATCTTAAATGAGTCTAAGTTTGAGGGCAATTTTATCTGGGAAGCTCAG
ACTTCAACAGTGGGCACAGAATTCTGCATAAATAGGAAAAGGAAGAGGTGGGAAGAGAGA
25 ACAAGCTAGAGGAGGAGTAGGGTCCCAGTAGAAAGGAGAAAGCTGGGTGCTATGTGAGGTG
AGGCATGGCAGCCAGGCCAGCACACGCACAGAAGTTGGAGGGTCTTCTTACCTTGTCTTTGA
CAGAAGCTCTAGTGCCTTTTCGATGAGCGCTCCACAATCAGTTGACTCGTGAAGGTCATGAATT
CCTGAACGCTAAGAAACACAAAATGTATTTATTGCCTACTTCTTATCACCTTGTCCCCAACACA
GTGGAAAGTGACCTCTGGGCTTATACATTAAGTAGACATTGCTTCTTGGTTTCATTCCTTTCCC
30 TCCCATCCCTAGTAACAAACACTCTATAAATGAGCACAAATACTGATAATTATGAATTATCAT
CACCATGAAAGCTCCATCTGTTTGCTACCTGGCTACCAAAAACAGGTGAATTTTCTGGGGGGT
TTTTCCACAGGATACAGTCAATTTTACATTTTGGTGAATGCATAATTTGGAATGCAATGGAAA
AACAAGAGGCAGGTCCTGCTCTCAAGGTCCCAATAACTTCCAAGAAGCAGGACATTTATAAG
AACTGCACTAGAAGAATAGTGTGCAAAAACCTGTCAGGCAGAAATGCACAACCATTTATGGCT
35 GTGTCCACATGACAGACCCTCGCAATGCCACATACCCCATAGTGAGTGCTGGCTCAGGTCTG

CTGGGGCTCGTCCACAGAACGAGCGCAAGACACTCTGGATGGAACAAAAGGAAAAGTCTGCTCA
 TCCAAGACAAAGAAGTGGGAAATGGCTCATACAAAGGGTGAAGGGAGAAGGTCCATCATG
 GGCTCAACAGAGAGATCTATCCAGAACAGAACAGTCACAGGAGATGGTACAGCCAGAGGAA
 GAGGTGCTGACAAGGAGCCTCCAACCTGAGGATGTGATATAAAGGGCAACCAGGGCCATCAAA
 5 GCAGGGTGCTCAAATGGGAGTCTGCAGCAGGCTCCAGCAGAGCCATATAGGTAAGTGAAGGC
 CTGACTCTGGGCCTGTGTGCTGTGCCTCCACATTAATAAATCAAGATTTGTGCAACAGTTAA
 ACGAGGTAATACGTGTAAAGCACTTGGAAACAATGCCTGCACACACAGTATTACTTGTTAATAT
 CTTGAGGGACTGAAGTGATCAAAATAACCCCTCAGAAAAGAAGACCTCAAACAAGGAAGGCT
 TTGCAGTAAACCTAGAGACAGCATTTGAGACACGGCTATAAAGAGACAAAGGAAGAACTGCA
 10 TTGTGACAGCATGTATACAAAGACCAAAAAAGCTGGGAAACTACTTTTTCAACTTTGGAATCG
 GGTAATTATAGGGCACAAAGGACGTAAGTAAAGCGGTCTTATAAGAAAACAAGCTCAGGCCG
 GACGTGGTGGCTCAAGCCTGTAATCCTAGCACTTTGGGAGGCCAAGGCAGGCGGATCACTTG
 AGCTCAGGAGTTCGAGACCAGCCTGGCTAACATGGTAAAACCCCATCTCTACTAAAAATACA
 AAAATTAGCCGGGTGTGGTGGTGC GCGCCTGTAATCCCAGCTACTTGGGAGGCTGAGGCAGG
 15 AGAATCACTTGAACCCAGGAGGCGGAGGTTGCAGTGAGCTGACACTGTGCCACTGCACTCCA
 GCCTGGGTGACAGAGCAAGACTCCATCTAAAATAAAATAAATAAATAAATAAATCAGCTGGG
 ACATGTGTTGTTTTAAGACATATTAGTAGAGATGTCCCTTTAGTGTTGCAGCTGTTAGTCATTG
 GAACTAGTGTGGGCATCCCAAGCAGGTGAGGTATAAGTCCTACAAGTGAAATCTCTGAGAA
 TCTTAAGTACTAATGGGAAGGAAAAAGGAAAAAGAATCAGAGCCAAGTTGGCACCAAAAGTT
 20 CCATCTGAGAAAAGCAACAACACAGAGCAGTGAATGTAGGCCATGGTAAAGACTGCAAAGAC
 CAAGAACCCCAAGAAGGAGCTAAAAGATAATGCAGCAATTCCGCTTCTGGGTAAATACCAAA
 AAAATGCGAGCAGGGTCTTGAAGAGATATTTGTACATCCATGTTTCATAGCAGTATCATTCACA
 ATGGCTGAAATGTGGAAGCAACCCAGGTGTCCACTGACAGATGAACAGATAAGCAAAATGTG
 GTGAATAATACAATGGATTATTCAGCCTTAAAAAGGAAAGAAATTCTGATATATGCAACAAG
 25 ATGCATGAGCCTTGAGGACATTATGCTACATGAAATAAGCCAGACACACAAAACTATATGA
 TTCCATTTATCTAAGGTGCGCCAGAAAAGTCAAAATCACAGAGACAAATTAGAATGGCAGTTGC
 CATGGGCTGGGGGAGAAGGGAATGTGTTTAATAGACACGAATTTGATAAAAAGGAGTTCTGG
 AGACGATTGACAGTGATGGCTGCACAACACTATCAATCTATTTTCATATCAATGCACTCACTAC
 ACGCTTAAAGATAGTGAAGATAAATTTTGTGTACCATTTTACCACAATTAAAAATATTTTTTTA
 30 AAAGAACTCAAAGAAGCAGAAAGTTTCAACAAAATAACATTTTTTTTTTTTACATCCAGCAA
 GTCCTTGGCAAAGAACTCTCATCAAGAACCAGCTGCACTGAAGCAGGGAAAACAGAATCCAA
 ACGGCAGATTCCATCAGATTTTGAGACAAGATGACCATAGATACCGACCATGTAGGGTCCCTCC
 TTCTTTTCGTGCCTGAGTCACCCCAATCCCTCCCACGAATGGTCTGGAAGTGTCTGTGTTACTTC
 TAACACGTTCCAGCAATTAAAGCGCCCCAGAAACAAGTAAAAGCCTGTAAGCCCTACAGATC
 35 CCATGCTTCATTTGCATCTTCCGTGTGGAATCCTTTTGTACCACTAGTGTCCAATAAAAAGCG

TTAAACCTGGCTTTTCAGTTCTAGCTGGTTGTGATATAACCTCTTGGTACCTCAGTGACTTCACC
 CATTAAAAACAAACAAAAAAAAGTATATCACTATCTCTCATACAGAATTGTTGGGAAGCCCC
 GCAAGAAAATCAAAATATGGCTCTCAAGATGCGGCACCCAAGCTCCCAGAGTCAGAATCACT
 GGGTGGGAAGTGTTGGTCTAAAATATAAATACCGAGGCCTCAATCTACTAATTCAGAACATCT
 5 TGGCATGAAGCTTGGAATCTGCACTACTTCACAGTCTCCTTAAAATTTTTACACGACAGAAA
 TTTGAAAAACACTGAGTAGAGAACTATATTCTAGAATGGTATAAGCTCTTAAAGAGCTAATGT
 TGGTTCCTCAAAGGTAGAGTCCACGGCCAGATTCCATTATAGGAGACCAAGCCCGGACAGCA
 GACCCCGGGCCCTCCCCACCCCGCCCCGCCTCTGACTCGGACACCAGCCTTCTCAGACCCCGG
 GCACTCGGCCACCCCGCCCTGCCCTACCCTTGGCCTCCTCCACCCTCCCCTCATCCCTCCGCC
 10 GACCCAGGCCCACTCCGACTCGGACCCCAACCCAGTCCTCTCCGCCCGACCGCCACGGCCC
 ACCAGCCTGTGCCGCTCACCTGGATCTCTGGAAAAAGCTGAAGGAAGACACATCGTATGCGG
 CTTTGAGCAGCACCACTTGGCCTCGCCTTTGTAGAGGACGCTGAGGCTGTACAGCTTCATGG
 TCCGGCCCTCAGGCCGCCCGCCTGCCAGCTGCGGGACCCGTTCTCAGGGAGCAGCGCGGCCG
 CCGCCCTCGGGACCGCCGCCCGCCTACCGGCCTCTCAGCAGCCGGCTGCTGACGGGGCCACCG
 15 CCGGCTTCCTCCTCTGGCTCGCAATCCACTTCCGGATCCGGTCAGCCTGGTTGAGGGTTCTCA
 TACTCCGGATGCAGAAATGTGAGCCCGGAAGTACAATGCAGCGAGGGGCGGGATGCCACGCC
 TCGCGTAAGCTTGGCCCTCCCTGCTCGCCAGGTGGAGTCGGGCGCGCGGGCGGGATACCGTAC
 TGTCTTGTGCTGGGTGGTGCTGGGCCTCCCACAGCGGCCTGAACCTTCTTTTTTTTTTTTTCT
 TTTCTTTCTTTTTTTAAAGTAAGCATTTTTTTTATTATTATACTTTAAGTTTTAGGGTACATGTG
 20 CACAACGTGCAGGTTTGTACATATGTATACATGTGCCATGTTGGTGTGCTGCACCCATTAAC
 CGTCATTTAGCATTAAAGTATATCTCCTAATGCTATCCCTCCCCCTCCCCCACCCACAACAG
 TCCCCGGTGTGTGATGTTTCGCTTCCCTGTGTCCATGTGTTCTTATTGTTCAATTCCCACCTATGA
 GTGAGAACATGCGGTGTTTGGTTTTTTGTCCTTGCAATAGTTTGCTGAGAATGATGGTTTCCAG
 CTTATCCATGTCCCTACAAAGGACATGAACTCATTTTTTTATGGCTGCATAGTATCCATG
 25 GTGTATATGTGCCACATTTTAGGAGGAGCTTGTACCATTCCTTCTGAACTATTCCAATCAAAA
 GAAAAAGAGAGAATCCTCCCTAACTCATTTTATGAGGCCAGCATCATCCTGATACCAAAGGGT
 GGCAGAGAGAGACACAACAAAAAAGAATTTTAGACCAATATCCTTGATGAACATTGAAGCA
 AAAATCCTCAGTAAATACTGGCAAACCGAATCCAGCAACACATCAAAAAGCTTATCCACCA
 TGATCAAGTGGGCTTCATCCCTGGGATGCAAGGCTGGTTCAACATACGAAAATCAGTAAACGT
 30 AATCCAGCATATAAACAGAACCAAAGACAAAAACCACATGATTATCTCAATAGATGCAGAAA
 AGGCCTTTGACAAAATTCAACAACCTCATGCTAAAAACTCTCAATAAATTAGGTATTGATGG
 GACGTATCTCAAAATAATAAGAGCTATCTATGACAAACCCACAGCCAATATCATACTGAATGG
 AAAAAAAGTGAAGCATTCCCTTTGAAAAGTGGCACAAGACTGGGATGCCCTCTCTCACCCT
 CCTTTTCAACATAGTGTTGGAAGTTCTGGCCAGGGCAATCAGGTAGGAGAAGGAAATAAAGG
 35 GTATTCAATTAAGAAAAGAGGAAGTCAAATTGTCCTGTTTGCAGATGACATGATTGTATATC

TAGAAAACCCCATCGTCTCAGCCCAAATCTCCTTAAGCTGATAAGCAACTTCAGCAAAGTCT
 CAGGATACAAAATCAATGTGCAAAAATCACAAGCAGTCTTATACACCAATAACAGACAGAGA
 GCCAAATCATGAGTGAAGTCCCATTACAAATTGCTTCAAAGAGAATAAAAATACCTAGGAATCC
 AACTTACAAGGGATGTGAAGGACCTCTTCAAGGAGAACTACAAACGACTGCTCAATGAAATA
 5 AAAGAGGATACAAACAAATGGAAGAACATTCCATGCTCATGGGTAGGAAGAATCAGTATCGT
 GAAAATGGCCATACTGCCCAAGGTAATTTATAGATTCAATGCCATCCCTATCAAGCTACCAAT
 GACTTTCTTCACAGAATTGGAAAAAACTAAAGTTCATATGGAACCAAAAAAGAGCCCGCATT
 GCCAAGTCAATCCTAAGCCAAAAGAACAAGCTGGAGGCATCACACTACCTGACTTCTAACT
 ATACTACAAGGCTACAGTAACCAAAACAGCATGCTACTGGTACCAAAACAGAGATATAGAGC
 10 AATGGAACAGAACAGAGCCCTCAGAAATAATGCCGCATATCTACAAGCATCTGATCTTTGAC
 AAACCTGACAAAAACAAGCAATGGGGAAAGGATTCCCTATTTAATAAATGGTGCTGGGAAAA
 CTGGCTAGCCATATGTAGAAAGCTGAAACTGGATCCCTTCCTTACACCTTATACAAAAATTAA
 TTCAAGATGGATTAAAGACTTACATGTTAGACCTAAAACCATAAAAAACCCTAGAAGAAAACC
 TAGGCAATACCATTCAGGACATAGGCATGGGCAAGGACTTCATGTCTAAAACACCAAAAAGCA
 15 ATGGCAACAAAAGCCAAAATTGACAAATGGGATCTAATTAACTAAAGAGCTTCTGCACAGC
 AAAAGAACTACCATCAGAGTGAACAGGCAACCTACAGAATGGGAGAAAATTTTTGCAACCT
 ACTCATCTGACAAAGGGCTAATATCCAGAATCTACAATGAACTCAAACAAATTTACAAGAAA
 AAAACAAACAACCCCATCAACAAATGGGCGAAGGATATGAACAGACACTTCTCAAAAGAAG
 ACATTTATGTAGCCAAAAAACACATGAAAAAATGCTCATCATCACTGGCCATCAGAGAAATG
 20 CAAATCAAAACCACAATGAGATACCATCTCACACCAGTTAGAATGGTGATCATTA AAAAGTC
 AGGAAACAACAGGTGCTGGAGAGGATGTGGAGAAATAGGAACACTTTTACACTGTTTCGTGGG
 ACTGTAACTAGTTCAACCATTTGTGGAAGTCAGTGTGGCGATTTCCTCAGGGATCTAGA ACTGG
 AAATACCATTTGACCCAGCCATCCCATTA TAGGTATATACCCAAAGGATTATAAATCATGCT
 GCTATAAGGACACATGCACACGTATGTTTATTGTGGCACTGTTCA CAATAGCAAAGACTTGGA
 25 ACCAACCCAAATGAACCTTCTTTTTTGCTTGCGTTGTTGAAAGAAGGCAAGTCTATGGATAGG
 AATGAGTGAGGCACAGCTCCCTGAGGATGCCATATCTTGCCCGTTTCTTGTGTATTAAGTGAC
 ATCACGTGTTACCAAATAAACCGGCTGCATTTGCCTGCGCACAAACATAAAACCAAACACCCA
 AGCATTGGATTTTTGTAGCAAGAAAGATGTATTGCCAAGCAGCCTTGCAAGGGGACAGAAGA
 CGGGCTCAAATCTGTCTCCAATACTTGCTTCGCAGCAGTAGATTTAAGGGAGAGATTTTGGA
 30 AGTGGAGTTTCGGGCTGGACGGTGATTGGCTGAAACGAAGAAGTGTTTAGAAAATCTCTTGGT
 CATGAGCTGTTGCTTCTTCATGCTGCTTCAAGGGTCACATGCAGATT CAGGAGGTGGTATAAA
 ACAAGCTGTGGGAATTTGGGCTGTGACATCAAAGGGCCGCTCCTCGGGCTAGTAAGTCTATTT
 TGCACAGGCTCCAGTCAGCCATATTGGTTCCAACCTGTTCCAGCAAGTTGTATAAGCAGAGGG
 GATTATAGCAA ACTGTTTCCTTATCGGCTGCCCTGCAAGACAAGCTCAAGATTTCTGTTAGTTA
 35 CCAGTTTCTTTAACCTGTGCGGCACAGTTTCACATGTAATCAGAAAGGAACTTGCAAGACAC

ATACAACTGAAAGAACTTGGTCTTTGGAAGTTGTCAGTAAGGTCACAAAGTTGTGATGCTAG
 AAGCAGCCGTATCTGAGATTATGGGAAAGAGATGATATATTGGAAAAACAACAGCATCACTT
 TAAACATTACTCTAAATCAAGGTTTCTCAACCTTGGCACTATTGACATTTTGGGTAGATAGTT
 CTTTCTTGTTGGGAGACTGCCCTGTACATTGTGTAGGCAGCATCTCAGGCCTTTGTAGAAATGT
 5 CAGTACCAACCCACCCCTCCCCACTGCACAATCAAAAACGTCAAAATGTCCTTTGGGAGCAG
 TAGTTTTGAGAAACATTGCTTTGCAGATATATATGTTTTGTTTGTGTTTTGCTTTGTGACAGG
 GTCTTACTCTGTTGCCAGGCAGAAAGTGCAATGGTGTGATCCCACTCACTGCAACCTCTGCCTC
 CCAGGTTCAAGCGATTCTCATGCCTCAGCCTCCCGAGTAGCTGGGATTACAGGAATGCATCCA
 TACACGCGGCTAATTTTTGTATTTTAAATAGAGATGGGATTTACCATGTTGGCCAGGCTGGTC
 10 TGAAACTCCTGGCCTCATGTGATCCACCCACCTCGACCTCCCAAATTGCTGGGATTACAAGCT
 TAAGCCACTGCGCCCAGCTGAGAAACATTGCTTTAAATAATCTGTGGTGAAAGGAAGTTCCCA
 CCACCTGCCCCTCACTCAGTACCTCTGTCAACCAACCTCTTCCCTGGGTGTTTCCAAGTACAG
 AGGGTGGAAGGGCTTTTCCACATTTCCCCTGTTTTGGTAGTAAACATTAGGAACAGCCATTG
 GCCGTGGCTAGGCTCAGCCACCCACAGATATGGACACAGTAGTCTGACAAGCTGGGTGCTG
 15 GGTGCTATCAGTCCAGGCTCAACTGCTTGCACTGACACCATTTCCTATAGGAGGCAGGTGAG
 AGCCATTTCTGAGGAAAGTCTCTGGAGCCCCCTCTTCCTTCCACTGAAAGTTGTGCAAAAAGAT
 CAGGAAGACAGCGCTTGGATGGAATAAATTTCAAGTGTATCCACTTGACACATTATAGTGGCTG
 TCCCAAAGTTTACCTTATGCCAAGTACTTTCCATGTGCCACATCATTTAATCCTCACAAAAACA
 GGGGAAAATATTATTGCCACCCTACAGACATAGAGACTGAGATTCAATTTAAGGAGATGGTT
 20 GGTAAGGGACAGAGTTGGGGTTCAGATGTCAACAGTGAAATGCTTAACAAACTGTCATGCAG
 CCCACTCCTGGCAACTCTTCCTGCTCCTCTCTGGCCTCACTCAGCCTCTACTGTTCCAGGAAGC
 CTCATTATAGTCATGTGGTTGCAGACTTCCCAAGCTCACTGTGTTACCAAAAAGCAAGACCT
 GCCTTCTGCTGCATCGCCCCAGCTGTCACCCAACTTGGATTCAAGTCCCAGCACTGACACATCA
 CAAAATCACAAAAGTGAGCAAACCATTAACCTCCCTGAGTCTCCTTTTGTGTTTTATCTATAAAAC
 25 TAGAAAAATATTCTTTCCATAGGAATGTTGTTGGAAATAATAAAACATTATATTACAAGCTCT
 AGTCATTGTTGATGTTTAAACAGGTAACAGTGATAATTATTTGTCTTCTCATTAAATGAAGAAAA
 GGATTATTAATCATAGAGGGTGGAAAGGCATCTATGGGAAGTAGAGATTTGAAGATAGGCTAA
 AACCCAAGTAAGGCCTCTAGATTAGATAAATAGTATTGTATCTATTTTAATTTCCCTGCTTTCCAT
 CACTGTGCCATGGTTATATAAGAGAAGTCTTTGTTTATAGGAAATATACACAAGAATTTAGAA
 30 GTAAAGGGACATTGTGTCTGCAACTTACTCTTACAGGGTGTGTGTGTGTGTGTGTGTGTGTG
 TGTGAGAGAGAGAGAGAGACAGAGAGAGAGAGAGACAGAGAGAAAGAGAATGATAAAGCA
 AATACAGGAATCAGGATGAAGCGTATCTGTTTGTGTTTGTGTTTTGCTTTGTGATAGGGTCTTGCTCT
 GTTGCCCAGGCAGGAGTGCAATGGTGTGATCCCGCTCACTGCAACCTCTGCCTCCCAGGTTCA
 AGCGATTCTCATGCTTGTATTGTTCTTGCACCTGTTCTGCAAGTACAACATTGTGGGAATGGAA
 35 AATGCAGGAAATGGGCAGTAAGGCTATGAACGAAGCCCGCACAGGAGTGTGGGTAGCAGAG

TTCTCTAGTCCAGGCTCCACCTGAGGTGCTGGGACCTAGAAGAAAAGCCTCTCTGCAGACAG
 AACTGGAGTTAACGCTGTCCACGATAAATGGCCCAGGCCCTGTTAAGTTTGCCCCATTGAGCA
 AAACAAGTACCCACCCGCCTTTGCAGCCTTGCTAGCTCACATAAGGTGCCAGCCCTTGCTGT
 ACAGCAGAACCTTTGGGGAGCTGGACAAAAGCCTATCAAGGAGCATACCCCCAGGAAGCCCA
 5 GTCCAGGTGGGGAGCCCAGCCACACAATGGCCCTTGCCCCACACCTCCTCATTGAGTCAGCT
 AAGGCCATGGCAGCTGAGCTGCCTCCACAGCTCATATAGGAAAAGGGTGTGGAAAGGGGCCA
 CCAATGTGGTCAGGCCTCCATGGCCTGAGTAGGTACCAAGCCTCAGGTGCACAGACTTGATG
 TCATCAATCAGGGTCTGTGTCAGCACACCTAGCCCTCAGGAACACTGCTCCCCACTGCAACCCCA
 CACCAAGGCATCCTGGGCTCCCTCTGGGTTCTCCAGGCCCCAGGGAAGACAGACAGAGTCTGC
 10 CACCAAAGGTTTGAGCTCTGCCACTGGCTACGAAGCAATAGGGGATGTCAGAGCAAGGGAGG
 AACAGGACAGGAGTATACGTGGGCAGGAAGGGATTACAGCCAAGGAAGACAGGAGGCAGGT
 GCCCTGATTTTGAGGCTGTGCCCCAGCAGGGGCTTCCAGAAGCTGTATTTGTCCTAAGACAC
 CCCTCTGCAGCTGAGGGGCTAGAGATGGATATGTAGCTGTGTTAGGCCATTCTTGCAATTGCTA
 TAAAGAAATACCTGAGACCAGGTAATTTATAAAGAAAAGAGGTTTCATTGGTTCACAGTTCTG
 15 CTGGCTTTGCAAGAGGCATGGTGTCTGGCATCTGCTCAGCCTTTGAGGAGGCCTCAGGAACTT
 ACAGTCATGGCGGAAGGCAAAGGGGAAGCAGGCACATCACACAGTGGAAGCAGGAGTGAGA
 GAGAGAGAGGCACTGGGAGGTGCCACACTTTTAAACAACCAGATCTCGTGTGAACTCAGAGC
 AAGAGCTGACTCATCACCAAGGGGATGGCCCAAGCCATTCATGAGGGATCCACCCCCATGAC
 TCAGACACCTCCCACCAGGCCCCACCTCCAATATTGGGGATTACAATTCAGATGAGATTTGGT
 20 GGGGACACATATCCAAACCATATCAGTTATCAGTAGCCATACTGGATGAATGCCAGGAACTTA
 GAATTAGGACACATGGTCAATTTAGGCAAGTGGCTTGTCTGTCAATGGTACCCTGATAGTCGT
 GGGGTTGCCCGTACAAAAAGCGAGAGGAAGTCTACAGAGCTGTCAAAGAGGGGCAGGTGG
 AAAGGCCTGCAGAGGAGTCCCCTGCTCCACAACCAGGCGTGCACCTCCCACATCCTCGGGGCT
 GTAGGCCCCACATGAGAGCAGAAAGAAGGATGCAGAGGAAGGCC
 25 AAGAACACAAGGTGTGCCCTTGGAAGGCTGGGCACACCAAAACACAACCTAATAAACAACAG
 CAATGAGCACACAGGGAAAGTACTCACAGGGAAACCATCATGAACTAGAGGCTGATCCCACA
 CCCTGCCACATGGGGCCCCAGGCCCCAGCCTATCAACCAGTGGTCCTTATTGCCACAGCGATT
 GGTCTTTGGATAGGCACCTGATGCAAGCTTCAGCCAATCAACAGGCCACTCAGCTGGCCATCA
 GTAGGCCATCCAATCAGAGCAAAGCCCAGGACTTTCTTCGACTCTTAAGAAAAGAGAAGCAA
 30 AGTAACTGGCACAGATTGGAGAGGATCAAGGAACCCCGAGCTGGATACATACAACTTTGGG
 TTAACATGGATGATTAAATACATATGTTTATGTGAACCACCTCCCAAATATGCTCCACTATAAT
 GACACAAGACAAAGGGCAGGGGGAGACCAATTGCAAGGTGGCGCAAATGAGAGATGCTACC
 AAGGGTGGCGGGGGAGAGAGGGGAGCAGTTGTCAAGTTAGGAGGCAACAGGCTGAGGGACA
 GGGACCAGCAGACGGGGAGGGAGGGGCTGAAGCAGAAGTGTCCAGTGTCTGGAGGGATGGG
 35 GCCAGAAAGGCAAGGGGCATCCTGAAGAAGCTATACCTGGGGAGGGCAGCTCTCTCCCCACC

TGCTCCCCAATTCATCAGCCAGGAATGCCCCATCCACCCCACCCCAGGGAGGAGGACAGAGG
 ACTTTTCGTTTGGGAGCATTGAATGGTTCAGAGATTCTGCAACTCTGCGGTCCCCAACTAACT
 GCTCATTGTTTCAAGCAGTCCCTGTTGGGTAAATGTCCCCATTGTAACCGGACTCGGATTCCA
 CCGCTTGAAAGCCAAATACAAGAGGAGAGGTTTGGTGGGAGGAAAAGTGGTTTTAACTAGAG
 5 CCAGCAAACCAAGAAGATGGTGAATTGTTGTTTTAAAGCATTCAATTATCTCAAATTTTAAAA
 TTTATCATAGGATTCTGAAAGGAAAACCTTGGTATGGGACATACGTGGGAGCAGTGCAGGGTA
 CAGGGTCTATGTGTCTTGATCCAATGGCTGTCTTGAGTATCACCTATCCTGAGGTCTGGTTGGT
 GTTATCTTTCTTCGGCCAGATGGTGGTGGGTGAATTGTTTCGACTCCCCCTAAGTTGGAGGAT
 TCCGCAGGGGTTCCGTGTCTGGTTTTTGTTCAGATTAGCCCCCTGGAATTCCTCAAATAAGCAT
 10 AGAGTTAGATAAGCGGGCATGGTGCAAAGGAGTGTCTAGTGGGAAAGGGAGAGAAGCAGAG
 TTTCAAAGTACATTTCAAGGTTACATTTTAAGACTAAAGAAAAAGCCTTAAAATGCATTTTA
 AAGCTGATTTAATGCTTGGCTACACTAGGCTGTGGCCAGTGTGCAGTGTGGCTGCTCTTGAT
 CAGGTGATGTTTCATCAGCTGTGTCCAGGGAGGGCAGGGCCATGTGGCAGAACCTGGGACCT
 CTGTGTGAGGGACTACCTTGGCCCCTGTCCTTAGCAGGAAGCTATGGTAAGGAACCTTAGGG
 15 AGACATTAAATTGGGGAGACCGTCCCTGCCAATCCTTTAACCTCCCCAGCCTCAGCGACCTCA
 GTTGGAAAGTGGTGGTAATAATACTACCACTGACCAGGTGTGGTGGCCAGACATTCCACACTT
 TGGCTTCAGCCGCTCCCTCCCCACTCTACTGTAATCCCAGCACTTTGGGAGGAAGAGGTAGGC
 GGAACCTGAGGTCTGGAGTTGAGACCAGCCTGGTCAACATGGTGAACCCCATATCTACTAA
 AAAGAAAGTACAAAAAATTAGCCAGGTGCAGTGGCACACGTGTGTGGTCCCAGCTACTCGTG
 20 GGTCTGAGGCATGAAAATTGTTTGAGCCTGGGAGGCAGAGGTTCCATTGAGTGGAGATCGAG
 CCACTGCACTCCAGCCTGGGTGATAGAACGAGATTCTGTCTCAAAAAAATAAAAAATAAATA
 ATAATAATAATACCACTGCCTGCCACACTAAGATTGTCTGATTAGATGACAGAATGAATGCAA
 AAGTACTTTGTGAATCATAAATGTTTTTCATCAATATTAGTTATAATGACAATTGCTCCTTCTCC
 TAATAAATGTATTGCCTTTCTTTAGGAATAAATATAACAAGAAATGTGTAAGATATATATGAG
 25 AAAAAATAAAATTACCTGAAGGACATAAAAGAAGACCAAAATAAATGAAACAACACAT
 ACTTCTAGATGAGAAAACCTCAATATTATAAAGAGGTTAGTTCTCTAAAATGAATCCCTAAACC
 CACAAAGTCAATGTATTTCCAATGAAATTGTCAACAGCATTATTTTCCGAAGTGGGATGAGTA
 GTGCTAAGATTTATAAGAAAGCCAACATTCCAGAGCAGTGGGGAAGGGATTGCTTCACCACC
 AAATAGCCATATTAGAGATTCCCTTGCACCATACCCAAACCACCATCTCCCAGGACCCGGGAG
 30 AGCAGAAAAGAGGAATGAGAAGAAAGGCGAGGATGTGAGGTGTGCCCTCATAATGGCGGTG
 CACGCAGCACAAGCAATTGCAGAAAGACTAAAGTACTGAACAAATAGAAAACCTTGGA AAAAT
 ATTAGAAGGAAATGTGGGAGAACATTTTTGCAATTTGGGGATTGGAAACGGTTTTCTTAACAA
 GATATAAAAACCCCAAAACAAGAAAACAAAGGTTGAAATTCATAAAAACCTAGATACTTCTGT
 ATGATGAAAGACACGATTAATCAAGTTGTTAAGTTTAGCAATAGACTAGGGGAGATATCATA
 35 GTATATTTAACAGACAAAGGATTAATAGATACTACAGATGAAATATAAAATAGTTTCTCCAAG

TCCATAGGCAGAAGATAATCCAATAGCAACATAGTTAAGTAATGTAAACAAATCATCCTTAG
AAGAAGAAATGCAATCACCAAGAAACACATGAAAAGGTGTCCAGCATTTTGCAATTCAAGCA
ACAATGAGGTGACAGATCGGCAAAAAAATCATAAAGATTTATCATCTGAAGGATTGGCCAAG
ATAAAGCCAACTTCTCGTGTTGGCAGAAGAACTGGTGAAGCCATGTGAAGAGGCCACGTG
5 GTCCTGCCTACCAAGATGTAAAATGTGTACAGCATTTGAACTAGCAATTCAGCCTCCAGGAGC
CATCCAGAAGAAACACTGACACACACTTAGACTCCGGTGAAATTCAAGGACTTCTGCCACAG
CCTGCTTCGTAATAGTGAAAATCTGAAACTGCCTCAATGACCGTCAATAGGAAGTTGATTTTA
AAGTGTTACAGCACATCTGTCTGGAGAGATCGCACTGGCCACTCCTCCTCACCCCCTCTGCTG
GACCTCTGAGCGTAGGTGGCCTGGAGCTGGGTCTGAGCCCTCTTTGGTCTATACCGACACTA
10 CCAATATGGTAGCCACCAGTCACGCTGGACACTTGAAAAGTGGCCGATCCTGACTGAGAAG
GGCCACGAGTGGGAAAAACACACCAGACCTCAGTGACTIONAGGCAGAAGTATGTTTTGTTCCA
GACTATTGACTGAGCCCGCAGCTGAGTTGGCTCCAGCACCCCTGGCCCCCTGCTCCATCCACTC
ACTGGGACTCCCCACTGCACAGGGCAACCTCTCCAGGGGCACTTGGGCTGCGAAGGGGAGAG
TGGGTGGCATCCCAGGCTGAAGCTTCCTGAGCAGGGCCAGAGGAGGAGCCAGTCCCTGTGGG
15 CCTCTGTTCTGACAGTGTCAACCTCAGCCAGGCTTGTGTGGGCCAGGTGTACTGTTCTGGTTCA
GATTTCAAGGAGATAGTCAGGGCAGGCCGCGCCAAAGCCCTCCGATGGGCTCCCCTACTGCCT
GGCAGACCTGTCCAGCTTTGGACTCTGGCCCTGCGACCTGGAAGTCAGGCTGCCAAGAGGTCC
AGGCAGTGGCCTCCACTGTGGAGGGTCTCTGGAGAGTTTACAGCCCTAGATAGGGGGGTTAG
GGATGTGAGATGGTCCCAGGGGCCTGCTCCTGAGCCACGCCAAGCTGCCTGCTCCCTTTCCCTC
20 TGCTTCCAGACTCACGGGATCCTCTGCTCATCAGAACAGGAGTGTGGGAGACCCTGAGACACT
GCCCCAGGATCTGAACAGGTGGCAAAGGCTTAACAGGCTAGCGGTCACTGTAGTGACAAGGC
GATTGAGTGGTCACCATGGTGATGGGGATGGAGGCTCTTTGCCACCAGTCCCAGTTTTATGCA
TGGCAGCTCTAATGACAGGATGGTCAGCCCTGCTGAGGCCACTCCTGGTCACCATGACAACCA
CAGGCCCTCTCAGGAGCACAGTAAGCCCTGGCAGGAGAATCCCCCACTCCACACCTGGCTGG
25 AGCAGGAAATGCCGAGCGGCGCCTGAGCCCCAGGGAAGCAGGCTAGGATGTGAGAGACACA
GTCACCTGCAGCCTAATTACTCAAAAGCTGTCCCCAGGTACAGAAAGGAGAGGACATTTCCC
ACTGAATCTGTCTGAAGGACACTAAGCCCCACAGCTCAACACAACCAGGAGAGAAAGCGCTG
AGGACGCCACCCAAGCGCCCAGCAATGGCCCTGCCTGGAGAACATCCAGGCTCAGTGAGGAA
GGGTCCAGAAGGGAATGCTTGCCGACTCGTTGGAGAACAAATGAAAAGGAGGAACTGTGACT
30 GAACCTCAAACCCCAAACCAGCCGAGGAGAACCACATTCTCCCAGGGACCCAGGGCGGGCC
GTGACCCCTGCGGCGGAGAAGCCTTGGATATTTCCACTTCAGAAGCCTACTGGGGAAGGCTGA
GGGGTCCCAGCTCCCCACGCTGGCTGCTGTGCAGATGCTGGACGACAGAGCCAGGATGGAGG
CCGCCAAGAAGGAGAAGGTATCTCGCCCTCCATTGGGCATTCTGGGAGTGTTTGCTTGCCTGT
CCCCAACATTCCATGGTTTTGTTTGGCCTCAGAATCTGATTTTATGCACAGGCTCTTTGAGAAG
35 GGTCTTGCCAGGGGTGCCTTCTGGGGCAGGAAGGCCCTACTGCCTGGCAGACCCATCCAGCT

TTGGA CTCTGGT CCTGCGACCCGGAAGTCAGGCTGCCAAGAGGTCCAGGCAGTGGCCTCCACT
 GGGGAGGGGCTCTGGAGAGTTT TAGAGCCCTAGATGTGGGGGTTAGGGACATGAGGTCTTGTG
 GACAAAGCCCACTACCTGATTTTGAGACAACACTCACTAGACATGGTGACAAGTCAAAGATG
 CCTTGCCTCCTACCAGGAATCACTTCGCAGGGAGCCCGAGGGCTGCTGTGGCCTGCTGAGGAG
 5 TGCAGGGCAGTTACTTTTTCCAAAAACAAAGAGAAATCCAGGCATGCTCTGAGCCAGCCCTGA
 GCCCAGCAGTGAGCAAGGAGAGAGCTGGAGACAGGGGACTTTGCTGTGAAACACTGGGGGG
 AATGTGCCTGCATCACCCAGCTGGGGGCCAGGCAGAGTGGGGGAGAAGGGGTAAGTGGGC
 AGAGCCAGTCACTTTGGGCATGCTTCCCTCTCGCCTCTGTGTGAAATGACCAGGTCAGCATAA
 ACCCCGGGCTGGCTGTGCTTCTGGCAGAGCTAATGATGTTAGGAGGAAAACAACCAACCCAA
 10 GTGAGAGGGTGCAGCAGCCAGACAGCTGGACCGGCCGAGGCCCAACCAAGTCCCAGATCTGC
 CTGTCACTGGTGCTATGGCAGCAATTTGGATGAGAAATCCTGCCCAAAGGGCCCCCTCAGGCC
 ACCCGGGGAGAAGGAAGCGGCTGTCTTTGGCATGACCAGAAAGATGGCTCGGAGCTAGGGAG
 AGGTGGACATGTGGGCTGTGGAGATCTGGCACTTTCCCCAAACAAGGAGAGAAAGCATAGTG
 TGCCTATGTGTGAATGTGCTATGTGTGCATGTTTGTGCCTGTGCATACCTGCATGTGTACATGC
 15 ATGTGCACATATGTGTGCACAGGGAATCACTTTAATAAAGGCCACAGCAGAGCTGTCCCTGAG
 CCCCTTGCA TTCACAGTGGCATGTGAGTGAACCACCTTCTTAGGCTGGGCATCCAGTCTCAGA
 CTCTGGGGCTGCCCATGCCCCATCCTTTATCTGCTCCACGTGTGAGGGGTTGCTGGTCTGACC
 AGGGCCAGCTGTGAACCCAGAAATCCTGGGAAGTCACTGACATTCTTGTGAGGGCCAAGAGT
 GGAGCAAGGCAATGCCTCGGGCACAACTTTAAGGGGTACCAGAAACATCAATCATCAAGA
 20 TATATGCTATTTTAAATAATCAAAATGAATGCAAAAAAATTTATGATGGACAACATACCAAA
 TTCTAAACAAAGGCAGGATGAGTATCACTGGCTTCTGCACTTTTCTCCACCCAGTCTACCCCTC
 TTCTAGTGCCTGGATCGCAGGGTGCCAAGGCCTGGATGAGGGAAGCGTGGAGCTGCAATGGC
 CACTCCTGTCTGCC TGTCTGGCTGCACAGAGGACTCAGTCCTTGTCTTGGGGGAACCTATCTT
 GGTTTTAGGGTCATCCTAAGGATCTGATGTTTTCCAAGTGAGCTGGCTGTCCAGGCCACCCA
 25 GGTTCAAGTCCAGTCTGTGTCTCTGGGAAGTGCTGCCCCACCCCAAGCCAGTGTTTGACCTTG
 GAGCAATGAGCAATGCCCTCCTTCCACTTTCAAAGTTGTCCCCAAGACGTCAGCTGTGGTTGT
 CTCTGTGCAGACACCGAGGAGGAAGTGTCTTCTTTCTCCTTTTGGTTGCTTTGGAGGAAAGTAA
 AGTGTGCTGGTTTCCCTCTTTCTACTTCTTTGATTGAGAGCAGCCGTCTTGCCGGTACCAACC
 TTCCAGATCTTACCTGTGGTTGCAGGAGCCTGTGGCCTCAGTCCTGTGCCAGTGACTTCTCCA
 30 TGTGGATGTCAGCTCCTTAGGGGCAAGCCTGATTCCACTGACACTACTCCACCCCTCATAAG
 CCCCTTCTTACCAGCTGCAGTTGCCTGGTACCCACCATCGCTGACTCATTCCTTTGGCATCAA
 GGTTCACTCCCTTACTGGGCCACCACTTCTGGGTGGCCTGAAATAGGGCCCTGGGCATCCCTCTT
 GGGGACCTTTTGGTCTATATTTTCACTCTCACCTCACTAAAGGACAGATGAGTAAATCTGGTTAA
 CTTTGCCTGATAGATTTGGTGACCTTTTTTTCAGGAAGGAGCCTGGAAAGATGAGATTCAGGTG
 35 TATTGGTCAGCTTAGACTGCCATAAGAGAATACCATCCACTGATGGCTTAGAAACAACAGAA

ATCTATTTCTCACTATTCTAGAGGCTGGACGTCCAAGATCAGATGCCAGCATGGTCAGGTTGC
 AGGGAGGGGCTCTCTTCCTGACTTGCAGACCGCCACCTTCTTGCTGTGTCCTCACATCGTGGAG
 AGAGAGTGAAAACAAGCTCTCTGGTGTCTCTTCTTATAAGAATGCTAATCCTATGATGGGGGC
 TCCCCCTCCTTACCTCATCTAAACCTAATTATCTCCCAAAGGTCTCATCTCCAGATACCATCAC
 5 ACTGGGGTTAGGGCTTTGACATATGAATCTGGGGGGACACAATTCAATCTGTAACACCAGGA
 GGGCATGCCGGGAGGAACTGACCTTCCTCCCTCCAGCTGCCCTGGACACCTTTGCCCCATTGA
 AGGAGCAGGCTCAGAAGTGGAATGAGGATGGAATAAGGTGCACTCCATCATGCTTACCCACA
 TCCCTGGCAGGAATTGTCTGGGCCCCAGCAGGAGAGATGCCCCCCCATACTGCCATGGCACC
 TGCTCTGAGACAGGTGTGCAGAGTGCAAAGCTCCAGGTGGCCCCCAAGCAGGTGTGCTGGGA
 10 GGAGGGGGCCCGTGTGGGAGGAGCAGGCAGCGCCAAGGCCTAGCGGAGCAGTGACAGGTCCC
 TGACTTCAGGGAATGGGCACGCTGTGGGCAGGCAGCTGGTGTGGGGGTGAGGGCTGGGGCTG
 CATCTGTGGGACCAGGGCTGGGCCATCCTCATATGCCGTGTCACAACCCCAAGTGCCCTGCTG
 TAGCCAGGACAGGAGGCTGGGCCAGGCTGGGAGGTGACAAGAGTGGGGGCTGTCCCCAGGA
 GAAGCACTCTGCTGCCTGTGCCAGGCCTCTGGGGATGAGGACCCCTCAGAAGGAGTAGCTAT
 15 GTCTAGGAAGCCCCAGGGCAGGAGCAAGCCAAAGGGGACATCATTAGTGAGATCCAGGGGAT
 CAGTGGGCCACAGAAGCCCCAGCGTGAGCCCCTCTGACTGATGCAGCTAGGCCACACCTGC
 ACCTGCCCACAGCAAGACCCCAAGGAGGAGAGGGGACAGATGGAGAGAGGCACAAAGTGCC
 CCTGGCCTCTGCCTTGAAGCCACCCCAAGGCAAGAGAGATTTGAGCCCCTGTTTAGTGACCTC
 CAGGGGAACATTCTGGCCCATCTGATGTGGGAAGCCCTTGTGGAGTCTGTATTCCTCAGCT
 20 GAGCCAGGCCTTTGGAGGCAGCCAGGCATGTCCCCTGTGTGCTCCTATCCCTGTGTTGGGAC
 ACCTGGCCCAGCCCCTCCTTCTGCCTTTCTCTTCCCTTCCCTTCTCAGGAGTGGACACTTCCTCC
 TTTAGCCCCCTCACAGCTGTGTGAACCTTCTCTGTATCTCTCTCTTTCTGTCTCTTTCTCCCCCTCT
 CTCTCTGTCTCATTGTCTCTCTGTGTGTCTGTCTGTAGTATTCTCTCTGTCTCTGTCACTCTGT
 CTCTCTCTCTCTGTGTCTACCTTTCTGTATTTTCGCTTTGTTTCTTTTCTCTGTGTGTGTGTGT
 25 GTGTATCTGTTTTTCTCACTCTCTCTGTGTCTATCTTTCTGTATTTTCGCTTTGTTTCTTTTCT
 GTGTGTGTGTGTGTGTATATCTGTTTTTCTCACTCTCTCAATCTCTCTCTCTTTCTGTCTCTCT
 TTTGCTGGCCTGAGCAAAGAGGGAGCCCCATCCTGATGCTACATAACCG
 TGAACCAGCACAGACAGAATTGTAGGAAAGTCCTGCAAGTAGAAGGATAGAAGGATGAGGG
 AAGAAACGCCATGTGAGTCATGACAGATCCCTTTCCAGGAGCCACTGACTCACCTGCCTCCT
 30 GCCCTCCCACTGTGACACTATTACTCACAGACAGGCCCGGATTAAACCTATGTTCCAGGTGCC
 CTGTGGTTCCACAGTGTGGCTCCCTGGGTCTGGCCTCAGGCTCCACAGGTGCCAGCCCTGC
 CAAAGTCTCCAGAGCAGCTGTCCAGCTGGGGAGCTGCGGGGCCCCTTCACAGAGCGCATGGG
 AAGAAGTTCCATCCTACACATTACATCGAGAGGGACGTGCCTGAGAAGGGGAGCTGGAGCCC
 GTGCAGCCCCCTGCTTGCGTGCAGAACATAGTGTACCCTGAGCATGCCATGAAAAACACAAA
 35 CGCACAAAGTTGTAAAGAAAAAAGAAATGACAGGTGGCTGTAAAATCAGTTATAGCCACGA

GAGGCCCACTAATGAGTGGTGATTTTCAGCTGATTACAAAGAAATGATGGTGTTTCTGTAATGA
 ACTAAACATGCACTCGTGCGTGACACACGCGCACGTATAGTCACATAACTGACCAGCCCTAT
 GCATCACTTGTTAATTACTTAGTAACTGTAACAATAATAGTTTCCAATAAGTGAGCCTTAGTCT
 CTGCGCAAGGGTCAGTTTATTGAGCACACGGGGGCCTTGCAGTGGGGGCAGGTGATCTGCTCC
 5 TGGGAGCCGCCAGCCTCTCCTCTCCTGCTCTTCATCTTCCTCCGTGGTGGGAAATTGTCTCACT
 GCTTCTACACCTGAGGCTGAACATCTCCCTTTATTTTCAGTCTGAAACACATGTAAAAATATACT
 GGAATGAATTAAGGTTGCAATTATTGATATCAGGCAGTGAGTACATCAGGGTTTATTATACTA
 TCTCCTTTACTTACTTCGAAGTTCTCTATTACCAAAAAATTA AAAA ACTATAAAAGAAAGAAAA
 AGGAAATGAGGCTAGATTCAACACAGATTACTCTTACCAAACCCTTCGTAGTCCCAGGAGTCC
 10 CCTAACACAAGCACTTGTGACCTGGAGTGATATTCACAGCATTCTTACCTGGCAATACCTGA
 GTATTAGCCCCCCCAGTGGGATCTTTGTTGTAGACAACCAGCAACTATCAGCCCAGCCAATAA
 ACAAGTAGGAAAGGGGAGTGCTGGAGAGGCCAAGAAGTGGGATTTTCCATGCTCCTGGGCTG
 TGATCCAGAGGGCACGGCTGTGAGGCTGATCTCAATGAACACTCTGTCTTGGAAGTACAGGG
 ATCCTCTGCTACCTGAAAACGTTCTGAGTATTCATTTTCATGGATTGCAAAGTCATTTACCCAA
 15 AATTCACTCTCCAAATGAAAAGTGAGTATGATGAATCAGTATTCAAGTTCCACCTGGGTCCTG
 GGAGAGGGCATGGACATCATATCCCAGCTGTTCCGACAGGAGGACCCAATCTGAGTCTCACT
 GCCTGCCTGCATCGTTTGTCTGCTGCCAGCCTGCACAGTAGGAAGGGAAAACATGATTTGTAT
 CTGTTTTAGGTCAGGTTCCCAAGAAGTAGAGCCTGAGATTGGAATTCTTGGA AAAATGGTGTTT
 GCGGGAGCGCTGTCAGCAGAAGCTATAAGGAAGTTGGGGGGACAGAAAACGAGAGGTAAGA
 20 AGCCAGTCAAAAAGGCAGGTCCAGCTTAAGTCCGCCTCAGTCTGGTTCCACAAGGGCTCTGAT
 GCATGAAGAATATCACAGGGTTGTCCCTCCTGGGAGAGGGGCCAGCCTATTGTACCTGTATCA
 AAGCCACCAGCTGAGGGCCAGTGGGGAGGGAAGATCTTCCAGGCATTTCCAGGAAACTCTCA
 GGAGAAGGGTGTAGCTGTGAGCAGTCTGCAGCTGCTGCTCACTGCGGCTAAAGGCTGGGTGT
 GCAGGCCAGTCAGCCAGTGAGGTGCCAACAGCAGGCACTACAGTCCACCCCTTGACTGCTCA
 25 GACCTACTGCTTTCCACTTTAAGCTCTCTCCATCCAGGCACAGCTTCAGGGAAAAC TTACAATT
 GGAGAAACAGAGGGATGAACTACAATGCCCACTTCTGCATGTGATTGTAAGACTGTCACTGAT
 ACTCACCATCATGCCCCATCCCCACCATCCATTCTAGTGTCCCTTCCCCTTGGCTAACACTGC
 TGGTCTAGGTGACTTCCCTAGAGCAGGAGCCAAACCCTTATCCCTGAGGCATCTGAATCCTGG
 ATTCCTTTATCAGGCTATTGTTGTTGTAAGTTGTCCATTCCCAATTACAACTGGACATGAGACT
 30 ACCAAGAAACACCCTGGCAAATCATCTGAGTGCAAGCCATATTCTTCCTGCTCCATTATGTAG
 CGGTAGTCCTACCTCCTAATGACAAGGGTAAATTGCCACATTTTGCTCCTTGTGCCAGGATGG
 TAATACCTTTCTCTACCTGCTTGGCTACTGGCACAAGGAAGCACAGCATGACCAGGAGGCAAT
 TGTAGCTGTACATTTAGTGAATGTGTTAATGTATCACCTGGTGGGAAGGACCCCTCTGAGAAC
 CAGGACTTCTAGACCCACAAAACCTAAAGTTGTGAATGGCGGAAGCACAAATTTCCCAAGTG
 35 GATCATGGAGAGTGATGAAGAGTTCTTGGTTCCCAAACCCACATATTTTACCTTTCAGGAACA

TGGCCTCATCCCATAGCCATTAGAGTGCATATTGCATTCTGGAGGAGACTGGGCCCTCCTCAT
 GGGTGTATCTTTCAAGATGACAGCTCCACTGTGCCTCCAAGAGGATGCTCCACCACCCTATCT
 GTGATTCCTTGGTTAGCAGGACAGGCTGCTGCACTGAGGGTAGGAAAGGCAAGTCCATTGAT
 GGCTGGAATACATGTCAATCCAAGTCAAGAGAAAAATGCCGCCCTTTCCAGGTTGGAAGGGGC
 5 CCGATTTAGCCAACTTGTCAACCAGTAGTGGCTGGTTGGTCTCCTCCAGGAGCAGTGTTATAC
 CAGGAATTCAGCACCAGTCGCTATTGCTGGCAGTTCTTACATTCAACAGCAGCAAACTAGGT
 CAGCCTTGATGAGAGGGAATGTATGCTTCTGGGCACAGGCATGGCTTCCTTCTCTGACTCCAT
 GACTATCTATTTCTGAGTGCATGGTGGCCGACATTCAGCTGCCTGCCCATCCTATCCACTTGGT
 TATTATTGCCTCTTCCACAAGAAGTGGTTTCTGGCTGTCATTAATGTCTCATACTTTGTGCCCA
 10 CTCACACAGGTTTAGCTCTACAACTTTTCCCATGCCACCCTTTTCCACAATCTTCTAATGTT
 GCTCCTTCCAAGCTACTGAAGAACGAGCTAAGCTATTCACCAATGTCCATGAGTCTATATTTA
 CCTTAGGCCACATCTCTCTCCACACAAAGTGAATAAGCAGGTGCACCCTCCAAACTCTACTA
 AGAGGATTTCTTCTCCCCAGTGTCTTTCAGGGCCACCTTGAGTGGGGCTGAAGTACAGCAGAA
 GTCCATTTCCAGCTTGCATCAACATTCCAACTAACCTATCCATGATCAATGCATAGATGGGTT
 15 TTTCCCTCCTCCAGCAGCTAGACAAAAGACACCCCCACCAGGAGGCCATATTTGCATGTGGG
 TGAAAGAGAGGCACAGGGGCCAATATTCGTGCAACAGTGGTAGATGGCAGGTGGGTCTGGGC
 CACCTGTCCCTGCAGCTTATCTGTGCCATCTGGACCTGCTCAAGCCTGATTCCAGATATACCAT
 TTCCATCTTATGATGGATGGCTTATGACCTAGTGGGTCTGACAGCACCAAACTCATAATGGGC
 AGTTATGGCCACATGGTCACTTAATGTCCTATGGTCAGACACTCTGCTGAGTGGCATGCCAGG
 20 AAATGCTTTACAAGTGGTGTGTTGGTTCTCTGCTGCAGATGGCATGACCTTGGTCCGGAGCCCT
 AGGGGTTTGGACAGTGAATCCTGTTGGGGCCTAATCTCACATTCCATGCAGAGTATCATCAGA
 TTTGCCAATCACATAGCCTAAGGGTCAGGACTGATCCAACAGTTTTTGCAGAGATCAAAGTGA
 GAGAATGAAAGGTTGATATGATGTGACCATCATATCACGTTTTTCTCTTTGAAAAGTATGCA
 GATGTCTGAAAGAGACAAGTGGCCAGGAGAAAATGCATGCCTTCCTCAGGATCGGCCCCCA
 25 CCTCCCCTCCTGGCCACAAGGAGGGTCAAATCTCAGCATGGCCCAACTTGGACCTGTCAAGGA
 AGAAGAAAAAATTTGTATGCCAAAGGAACTCAGTCTTTGGCTAACAAGTACTAGACATCCTTT
 AAGTCTTTGAGAATGGTAATAATTTCTGCCATCCCTCCAGATTTGTGTTTTTCTGTTTTGGCTG
 GGTGGGAATGCAGCATTTTCACTTTGCCTTTGTTATTACAAATGTTGCTTATTCTATAAATCAA
 GGAACCATTTGTAAGGGCTCTTCTGATGGTTAAGTATATCCATTCCAATGATTTATTCGGGATCC
 30 AAGGAAATGATTTCTGGGTGAATACACAGAACTAGTGGATCCAATTTGAGACATACCTGGGC
 CAGAACTATATTTGTCGTCTTACCCCAATAAGCCTGCACTCTACTAGGACAGCCATGACAGCA
 CTTTGGGACCCTAGATATAAGTGTGAATTGCTGGCTGGGCATGGTGGCTCACGCCTGTAATCC
 CAGCATTTTGGGAGGCTGAGGCAGGTAGATCACCTGAGGTCAGGAGTTGAAGACCAGCCTGG
 CCAACACGGTGAAACCCCATCTCTACTAAAAAATACAAAAATTAGCTGGGCGTGGTGGTGGG
 35 TGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGGAGAATTGCTTGAACCCAGGAGGCG

GAGGTTGCAGTGAGCCAAAATCACACCACTGCACTCCAGCCTGGGTGACAGAGCGAGATTCC
 ATCTCAAAAAAAGAAAAAAGTGTGAATTGCTATGAAATCACTATCAAAAGATCTGAGT
 GTTACCCTTACTCAGTGTGGTCGAATATAAATAGCCATAGGTTCTGTTATACACACTTGCTGT
 GGTGCTACAGAGTCTTTCCTCATGGGAACCCAGTCCCTCTTTCAGTCAATGGGTTCTGGTTCGA
 5 GAACTGGCTGAGGTTTGGAACTGTGCCTTTCATCATAACTTTCCTACTGGGGTGACTGACCTT
 GGCCTTCTGTTTCATCCTTCTAGCCCCTAAGAATCCAACACTCTATTAGCCTTCTCCTTAGACC
 CCTATAAGCTAATCCCTTCTAGTTGTTAGTCTGACCTTGGTGCCCAATATGATAATTATTCCCA
 CTTTGCTTCTGATATGCTTCTAAGTGCTGCCCCTGGTCTCTGCCCTTAAGTGATCTATCATCCCC
 ACTGCCATTAGGGGGAGAAGCTCTGAAAAAGAGTTGTCTCCCATCAACTCTGGTCTACAAAGG
 10 ACAGCCCTACTGAGCCTCAGCCATGTGCCCCGACACCAGCAGATTCTTTACAGCCTGGGAAGCA
 GAGTGTCTTCCCTGCCTTTCAGGGAACATAGCCAGCTTACAGGCTTTTTGATCTTATAGAGTA
 GGTCAAGTATATTTTGGCCCATTTCTTTTATCCTTTTGATCACTTCCTCTTGGCCCACCATGTAA
 ACTCAAGCATCCCTGCTTCATTTAATCGAGCTGTTGCTTTTTCTAAGCTACCAAGAGCAACCCC
 AGCAATATATCAGAGCCCTCTCTTGGGACCCTTGCTAGGGTGTTAAATCCTGCATCATAGGAG
 15 AATGCCCCCACATCAGCAAAGTCCCCTTATCCTCTTGATATCCACCTGCCCCAGTCCAGCACC
 TTCAGGATCTGGTCTCAATCACAGGATCCAGCACCTTTGGGACTGTTGCAAGCATAAGATCCA
 GCACTTTTGGGATCTAGTCTCCCACTTCCTGCTAGTACTTGTTAGCCAAAGACTGAGTTCCTTT
 GGCATACAATTTTTTTCTTCTTCTTGACAGGTCCAAGTTGGGCCATGCTGAGATTTGACCCTC
 CTTGTGGCCAGGAGGGGAGGTAGGGGCCGATCCTGAGGAAGGCACTCATTTTCTCCTGGGGC
 20 ACTTGTCTCTTTCAGACATCTGCATACTTTTCAAGAGAGAAAAGGCCTCCTTCTCACAGCAAG
 ACTACTTCTGTAGATGCAGGTGGCTCGTGGGAATCTGGCAATTCAAATTTCTCAAGTGTACTC
 ACTAGCACATTAGAAAACCAGTAGTACACATCTCTTTCCAAATCTTCATTCAAGTGACACTATG
 TCAGTAGCTGGAAATGGGCCATGGTGGGTGTATTTAAACCATGAAAATCAGAAAATGCTACA
 AACCAGGGCATCCCGCATCTCTAGACAGCAGATTGTTGGCCATTTCCCAGCATACCATTTGTGT
 25 ATACTCCTTCCCATCAGGGCCGTGGCTTGCCTTGGTGGAGGACTCAGCCCTTGCTGAAGTTCTG
 CTACTGCTCTTACAATTGAGTCCTATGCCTGGTCTCCAGCTCTGCCTGCCTCACTACAGGAGAC
 AAGCATCTCTTTGAACACTGCCGAGAAGACCCTCTGGCTCTCAGGCTTGGCTTTAAATCGATA
 GACCTGAGCCTGCCATTTTCTCTTTTCCATGCATCACTCCACTGATCCACAGGTCTCAGTGGCA
 TAGTCCTTCGGGTTAGCATCTCCCCACACCCTCGGTGCCAGAGACACTGAGTAAGAAAGTAC
 30 CTCCTGTCTACCCCCATCCCCGCTCCCCACAGGCAGGGCCTTGGCGATCCACTGCTGCAATGT
 GCCAGAGACTGTCAGTACTCCTACCACCAGTGAGGTGGCAACCAGCTGGGAAGTGATCCAAC
 TCCAGAGTCCCGCCCTCATAGGCTGATTTCTAGGACCACCCCTGGTATACTGTGTTAGGTTCTT
 GAAGCAGAGCCTGAGATAAGGATTCTGGCACCTGTGATTGAGTGGGAGGGTGCTCTCAGGAT
 GAGATGGGGTAGAAATAGGCAAAGGTACAGATTACAGCAGCAGTTGAGCCTCAGTCTGACCCA
 35 GCAGGGAGCTCTCAAATGTGAATGACATCACAGAGTTGTCCCTCTGAGGCAGGGGCCAGCCTT

TGTGCTCCTACATGAGTCAGTCACTGGCTGGAGGCCCTGGGGAAAGGCTAGGGCTGCCAGCT
TTAGCAAATAAAAAATTAGGGCACTCAGTTAAATTGAATTCAGATAACAACA

The genomic DNA or YKT6 SNARE gene is 39,000 base pairs in length and contains seven exons
5 (see Table 1 below for location of exons). As will be discussed in further detail below, the YKT6 SNARE
gene is situated in genomic clone AC006454 at nucleotides 36,001-75,000.

The human liver glucokinase is depicted in SEQ ID NO:2:

MPRPRSQLPQPNSQVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTP
EGSEVGDFLSLDLGGTNFRVMLVKVGEEGEQWSVKTKHQYTSIPEDAMTGTAEMLFDYISECIS
10 DFLDKHQMKGKHLPLGFTFSFPVRHEDIDKGILLNWTGFKASGAEGNNVVGLLRDAIKRRGDFE
MDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEW
GAFGDSGELDEFLELDRLVDESSANPGQQLYEKLIGGKYMGEVLRLVLLRLVDENLLFHGEASE
QLRTRGAFETRFSVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAG
VINRMRESRSEDVMRITVGVGDSVYKLPSPKFERFHASVRRLTPSCEITFIESEEGSGRGAALVSAV
15 ACKKACMLGQ

and is encoded by the genomic DNA sequence shown in SEQ ID NO:6:

ACTAGCACATTAGAAAACAGTAGTACACATCTCTTTCCAAATCTTCATTCAGTGACACTATG
TCAGTAGCTGGAAATGGGCCATGGTGGGTGTATTTAAACCATGAAATCAGAAAATGCTACA
20 AACCAGGGCATCCCGCATCTCTAGA
AGCAGATTGTTGGCCATTTCCCAGCATACCATTTGTGTATACTCCTTCCCATCAGGGCCGTGGCT
TGCCTTGGTGGAGGACTCAGCCCTTGCTGAAGTTCTGCTACTGCTCTTACAATTGAGTCCTATG
CCTGGTCTCCAGCTCTGCCTGCCTCACTACAGGAGACAAGCATCTCTTTGAACACTGCCGAGA
AGACCCTC TGGCTCTCAGGCTTGGCTTTAAATCGATAGACCTGAGCCTGCCATTTTCT
25 CTTTTCCATGCATCACTCCACTGATCCACAGGTCTCAGTGGCATAAGTCCCTCGGGTTAGCATCT
CCCCACACCCTCGGTGCCAGAGACTGAGTAAGAAAGTACCTCCCTGTCTACCCCCATCCC
CGCTCCCCACAGGCAGGGCCTTGGCGATCCACTGCTGCAATGTGCCAGAGACTGTCAGTACTC
CTACCACCAGTGAGGTGGCAACCAGCTGGGAAGTGATCCAACCTCCAGAGTCCCGCCCTCATA
GGCTGATTTCTAGGACCACCCCTGGTATACTGTGTAGGTTCTTGAAGCAGAGCCTGAGATAA
30 GGATTCTGGCACCTGTGATTGAGTGGGAGGGTGCTCTCAGGATGAGATGGGGTAGAAATAGG
CAAAGGTACAGATTCAGCAGCAGTTGAGCCTCAGTCTGACCCAGCAGGGAGCTCTCAAATGT
GAATGACATCACAGAGTTGTCCCTCTGAGGCAGGGGCCAGCCTTTGTGCTCCTACATGAGTCA
GTCACTGGCTGGAGGCCCTGGGGAAAGGCTAGGGCTGCCAGCTTTAGCAAATAAAAAATTA
GGGCACTCAGTTAAATTGAATTTTCAGATAACAACAAATTATTTTTTAGTATATGTCCCAAATT
35 GTGCATAACATAATGTGTTTTCTCCGCCAGCCCTGGGAAGGGCGTAACTTCCCAGGTATTTCT

AGGTGAAGTAACTTTGTAGATCAGGAGTAAGTCCCAGGAAAGAAGTCCAGCTCTTCTCT
 TCAGCCCTGGGCAGCTGGGGGTAGGCACAGGGGCCAGCAGGCACCCATA
 GCATCTCCTACAGCATCTGAAATGAACAGGGTCATCACGTACTACATACAAATGTACCCACTG
 CTGAGTTCTTCAGGGATTATATCATTAGGTACTTGGTATTTTAAATACATTACATTATGCAGAA
 5 GTCCTTTGTGGATTGCTATATTTGGAGAGTTTTGTGATATTGGGGGGATTAGATGGAGTTTTCA
 GATGGGCAT CACACGGTTTTTTCATTTAAAACCCTAGAGTATTGTAATCCTAGGGAGTGA
 TCCTGCGATTAGTAAATTAGCTCTCCAATAGATTTTCAATGTGGTTGCAAAGGACATGCATGT
 GGTTACCCCTCCCAGGAAATCCAGAAGGGCAGCATTGGCCTGAGTGGCCTGAGTTTGGCTGGT
 TGGGCTGGTAATGCTGGACAAAGA
 10 CAATGGGTGGAATGGTTTGCTTCCCTCAGTCCTTTCAGACACAGCCCAGC
 CCACCACGTCAAGCCAGTGGGTGCATCTGCAACCAATCCCCATGAGAACT
 GCAGCCTCTCAGAGGTGGGCAAGTTGGCCCGGGTGGGTCAGGAGGATCAG
 ATGTTGAGGAAATCTTTGGATTGGAGGCAGGCAGAGCAGGGAAGCATCGG
 GTGATTCTATGACAGACCCAGGGCTCCAAGCTGCAGTTCAGGAGGGGGCAC
 15 TGGCACGGCCTCTGCTCAACTCCCCCTTGAGTGACATCAGGTGAAGTGCC
 GACAACACAGAAGGCAGCAAATGCTGCCAGTCAGGTCTGCTTCCCAGGAC
 AGCCAGTTGCTAACCCTTCTCCAGCACAGCACTGGATTTTGGTCACTGG
 CTGGGAGCTCCACCTCCCCAGCTGCTGCCTCACCTGCTTTTCCAAACCCC
 ACCCTGTAAACGGTAACTACATTTTGTGCCCACTACGCCTCGTTTCCATC
 20 TCTTTGGAGCACCTCTCACGTGGAGCTGAACAGAACGACCTGTAAAGCCC
 ACCGTGTCTGTTAGGGTTGTCTAGGCTGTATCAGATACCCAATAAACT
 GGATTCACCAACAGGTATTGTCAAAGCACATAAGAAAGAGTCCAGAGGCA
 GGCAGCTCTCAGCCTGGTGTGTCAGGCTCTGGGTCAGCTTTCCAGATTCTCT
 TAACCTTCCCCACATCTGCCAGATGCCGCCACAGGCACAGGAGGTACAAA
 25 CAAACCCAAAAATGTTCTGGAACAAGAAGGGAAGGGGATCCCCACCATA
 TCTCCCCAGAGGCCTTCCTTCTCACATCTCACTGTACTGAAGCCAGCTCT
 AGCAGAAGACAGCAGGGTGAATTTGTCCAGGGTATTCAGCCCCCAGTGCT
 GGGTCCATTACTACTTGACCCCTGAATAAAACAGAGGTTCATGAGCAAG
 AAGGAAGGGGAAGTGGATGTTAGAGGGCAAGAATGTATCCATCCCACCCC
 30 TAGGAGCACGCATGGACAACTGCCCCATTTTTGCTCCTATTGCAGCCCAG
 GGGCTAGCCCAGAGACCTTGCCAGTGCTGAGTCACAAGATGCTGGGAAAG
 TGAGACCAGAGCCTGGTCTTGGGGAACAGCTCAAGGCCGCATTGGTCTGC
 AGGTCATAGAGCAGCTGCTGAGCAGTGAGAGCCCACGATGGGCCAGGCCC
 TGGGTCTTGGAGACCTGAATGAGATAGACTGGGTTCCTGTTCTCCTGGGC
 35 ATTGCCTCTTAGAGGGCAAAGACAATTAACAATAAACAAATAGAACATGA

AGTGTTTTCCGATAGTGACTGATATACTTTGGATATTTGTCCTCTCCAAA
 TCTCATGTTGAAATGTAATTCCTTATGTTGGAGGTGGGGCCTGGAAGGAG
 GTGTCTGGGTCATGGGGGCAGATCCCTCATGAATGGTTTAGTGCCATCCC
 CTTGGTGATGAGTGAGTTCACGTGAGAGCTGGTTGTTTGAAAGAGCCTGG
 5 CCCCCTCTCATTCTCCTGCTCCCACTCTTGCATGAGACACCTGCTCCCC
 TTCTCCTTCTGCCATGATTTTAAGATTCCAGGGACTTCACAAGAAGCAAA
 TGCTAACGCCATGCTTCTTGTCTGTCTGCAAACTGTAAGCCAATTAAA
 CCTCTTTTCTTTGTAATTTATCCAGTCTTGGGTATTTCTTTATAACAGCA
 CAAGAACAGCCTAATACAGTGATGCTCTCCAAGTGACCTTTGGGCTGAGA
 10 CCTGAAGAAGAAGGGGAAGCAGTTAGGTCTGATAGCTCATGCCTGTAATC
 CCAGCTCTTTAGGAGGCTGAAGTGGGAGGACTGCTTGAGCCTAGGAGTTG
 AAGACCAGCTTGGAACACATAGCAAGACCCTGGCTCTACAAAAATATTTT
 TTAATTGGCCAGGTGTGGTGGTGCACACCTGTAGTCCCACCTACTTGGA
 GGCTGAGGCAGGAGCATCTCTTGAGCCCAGGAGGTTGAGACTGCAGTGAG
 15 TCATGTTACACCACTGCACTCCAGCTTGGGTGACAGAGCAAGACCTGTC
 TCGAAAAAGAAGAAAGAAGAAAGTAGGAAGAAGAAGAAGAAGAAGAA
 GAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAGGAAGA
 GGAACAAGAACAAGAAGAACAAGAACAAGAAGAAGAACAAGGAG
 AACAAGAAGAAGAAATAAGAAGAAGAAGGAGAAGAAGAAGAAGGAGAGGAA
 20 GAAGAAGAAGAGGAAGAGGAGGAAGAGGAGGAGGAGGAAGATGAGGAGGA
 GGAAGCAGAAGCAGAAGAAAAAGAAAGAAAGAAAGAGAAAGAAAG
 AAAAGGGAAGGAGGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGGAAGGGA
 AGGAGAGGGAGAGGGAGAAGGAAGAACAAAGAAGAAAGAAGGAGAAGCAG
 AGGCTTGTGCTGGATAGCCTTGCTTTTGCCAATGACCTTGCTGATTTTCA
 25 GGGGGTCCTGGTGTCTTAGTCCATTTGTGTTGCTGTAAAGGCATACCTGA
 GGCTGGATAATTTACAGAGAAAAGAGGTTTATTTGGCTGAGAGTTCTGCA
 GGCTCTACAAGAAGCATGGCACCAATGCCTACTTCTGATGAGGGCCTCAG
 TCTGCTTCCACTCATGGCAGAAGGTGAAGCAGAGCCTGCATGTGCAGATA
 TCACATGGTGAGAGAGGAAGCACGAGGGGGCAGGGAGGTGCCAGCCTCTT
 30 CCTAATAGTAAGCTGTCTTGAGAACTAATAGAGTAAGAAATAACTCACAC
 CCTGCCCCCAAGGAAGGGCATTAACTATTTCATGAAGTATCTGCCCCCAT
 GACCCAAACATCTCCCATTAGGCCCCCACCTCCAACATTGAGGATCAAA
 TTTCAACATGAGGTTCCGGTGGGCAAACATCCAGCTATAATACTGGGCAA
 TGCTGACCAGACTCTTCCCCTCTCAGGCCAGAGCTCCTTGGCCCTGTAA
 35 CAACAGAAAATTGCGTTTGAGTGTCAAGATTTTTCTTTAGTCCCCATGC

AGCTCCTTAGAATGAGGTGGCATCTTCTCCCTTTTCATAGGTGAAGAAAC
 AGAAGCTCTGGAGGAACGAATCATTTCATCCAAGGTCAGGTAGCTAGTAAG
 CGTCCCACCAGCTCCCCAGATCTCCTGTTTCTGTCCCAAGTCCCCTGA
 GTGAGCTGGAACAATGGCTTCACTGGCACCTGCCGGGAATGGTGGCAGGT
 5 GCCTATAATCCCAGCTACTCGGGAGGCTGAGGCATGAGAATCACTTGAAC
 CCGGGAGGCAGAGGTTGCAGCGAGCCAAGATCACACCACTGCACTCCAGC
 CTGGATAACAAACGGAGATTCCATTTAAAAAATTAACATATAATATACA
 TACAGTAACATTCACTTTTTAAGTGTACAGTTTGATGAGTTTTATCAAAT
 GTATATGGTTATATAACCACCATCACCATTAAGGCAGAATCTTCCCATCA
 10 CTCAAATAATTCCCTCAGCCCCACCTCTTGCTGTCAATCACTTCTCCCAC
 CCTAGCCACTGGAAATCATTTCATCTGTTTTCTGTCCCCTTGTTTTGCCT
 TTTCTAGAATGTTCTATACATGAGACCACTGAGAATATAGTCTTCTGTGT
 CTGGCTTCTTTCACCTAACATAATGCCTAGCTCAGCAGTGTGTCAATCCT
 CCCTCCCTTGCCATTGCTGAGCAGTGAGTATTCCACTGTATGGCTGTGCT
 15 ACGGTGTGTTTCATCCATTTATTCATTCACCAGCTAATGGGCATTTGGATT
 GTTTCAGGCTTTGGCTATGATGAGTGAAGCTGCTGTGAATGTTCAAGTA
 CAAGTCTTTGTGTAGACAGGGGTTTTCAATTGGCGGGATAAATACCTAGG
 AGTAGTATCGTGTGGTTAAGCGTACGTTTTAACTTAGAAAACTGTCAAA
 CTGTTTTCCAATGTGGCCTGTACCATGTTGCATTTCCATCAGCAGTGTTT
 20 GAGAATTCCAATTGCTCCACATCCTCCTCCCGACACTTGGTTTCACCCAT
 CTTTTAAATATTAGCCACTCTGGTGACTGTGTAGTGATATGTCAGTGTGG
 TTGTAATTTGCATTTCTATGATTGACTAATAATAATGTTGCAGATATTTCT
 TGTATGCTTAGTGGGCATTTTTGGTGAGTTTTTAAAAATTGGGTGTTGT
 CACCGTCTTATTGAGTTGGAAGAATTCTTTATATGTTCTGGATGTTTATT
 25 CATGTGTGTGTCTGCTAAGAGGTGAGACTGGTTCTACCCTGGTCCTAACA
 AGCACCTGGGCCTGCATCCCTTTTTGTGTCTGTGAGCTGGGTCTGCAGC
 CCTCTCCTCCCACTACCTACTGCCAGCAGTACCCCTCACCCATCACTGT
 GGCTCCTGCAATGACATCTCAGCCTGTCTCTCCCTCCCTCCAGCTAGCCA
 GAGGCAGGATGGCTCAGTGACACAGGGTGGGCCCTGAAGACAGAGTGCCA
 30 GGGTTTGGACCTTGTATTAGCAAGAGTCACAAGGGAACTTACTTTATCT
 CTCCATAGCTCTGTTGTGAGGATCCAATAAATTAATCCATAGAAGAGCTT
 AGGACAGCACCTGGCACAAAGTATACATGAGCTATTATGATGTTATTCTT
 CCAACCCATTGTTTCTGTGTTGTCATAAACATGAATGCAGGACTCAGTGT
 CCCAGCTCTGTGTCCCTCGCATACATTCCCTAACAGCCCACAGGTCTTGC
 35 CTGTCACCGCCTCATTCAATAAGTGATGACTCTGCCTCTTCTTGGCTGG

GGCCTTGCATTGGACATTTCTGTATCCATATTTGTTTTTTAAAACTAGC
 TGTGGCCGGGCGCGGTGGCTCACATCTCTAATCCCAGCACTTGGGAGGC
 AGAGACAGGTGGATCATGAGGTCAGGAGTTCAAGGCCAGCCTGGCCAACA
 TGGTGAAACCCCATCTGTACAAAAAATACGAAAATTAGCTGGGCGTGGTG
 5 GCATGCACCTGTAATCCCAGCTACTTGGGAGGCTGAAGCAGGAGAATCGC
 TTGAACCTGGGAGGCAGAGGTTGTAGTGAGCCAATATAGCGCCACTGCAC
 TCCAGCCTGGGCAACACAGCAAACTCCATCTCAAAAAAAAAAAAAACAA
 AAAACAACCTAGCTGGACTTGACACTCTTGTTAGAGGAAGATTTTTCCAC
 ATCTGTAACTTTTCTTCTATTGTTATCCATCTGTGCAGGTTTTTCTGTC
 10 CTCCTGAGTCATTTTGATAATTTATATTATTTTTGAAAATCATCCATTT
 CCTATAGTTGTTTATTAGTGTCTTCTCTGTTATATTTGATCAGATTACCA
 AATCTTGCTCATTGATTGCCCATTTATTTTATTGTGTTTATTTTTTTGAG
 ACAGGGTCTCACTCGACAGCCCAGGCTGAAGTGCAGTGGTGCAATCATGG
 CTCACTGCAGCCTTGACCTCCTGGGCTCAAGCAATTCTCCCACCTCAGCC
 15 TCCTGAGTAGCTGGGACCTCAGGCACACGCCACCACAGCTGGCTAATATT
 TTATTTATTTATTTATTTATTTATTTTTGTAGAGATGGGGTCTCACTATG
 TTGCCCAGGCTGGTTTCAAACCTCCTTGTTCAAGTGATCCTCCTGCCTCA
 GCTTCCCAAAGTACTGGGATTACAGGAGTGAGCCACCATGCCAGCCCCT
 ATTTACTTTATAGTAAGTGCCTTCATGGGCATAAATGTTCTCTGAGACA
 20 GCTTTGGCTATTAGCCATACTTTTAATATTTTGTACATTCATGGTTATTC
 ATTTATAAATGGTCTGTAATGCAATGCAGATTTCCCCTTTGGCCCAAATG
 CCATTTACAGCAGCACTTTTCTCTTCTGAGCAGACAGAATATTTTGGTT
 TCCCCTCTGTTGTTTATTTCTCGTCTGCCTCGCCTCATTTGCTAGGTGTT
 CCCTTGGTGTGCCTTAAGTATGAGCCACTCAAATATTTGTGTTTCTCTAA
 25 ACACCCCTGACACTGTCCTGCTGGTTTCTCTATCTGGAATATCCTTCCCT
 TCTTGGCCAGTTCCCCCTAGTGCATCAAAGAAATCCTGCTCTTTTGCCTT
 CAGAAAACAAAACAAAACGAAACCTATCAGTCTCCTTATGTCCCCAAAGA
 CATAGCTTTGCTGGTATCTGGTTGTATTGAGCTGTTCAATTTGTCTCTTCT
 GCTAGATGGTAAGCTCCTTGGAACATAAAACTAATCACTTTTCTAACTT
 30 CAGACTGAGCACAAATTAGGTTCTCAAGAAACATTGAATAATGAGTGATC
 CGGTATCCCCTTCCAACATATTTTTGGTCATTGATACCATCATTCTGAGT
 AGTTACTAGGGAACACTTCACTGCAGTAACCAATACAGCAAAACGTGAAA
 TACAGTTACATAGTAGAATTGTATTTCTTGCCCATATAATAGTCAAGTGC
 AGTTCTTCATCAGCTGGGAGGTTCTCCTCCACACAGTCATTTAGGAATCC
 35 AGGGAACATAGCAGAGGTTGCTAGCTCTAGACCCAAACCCATGTCCTCTT

TGTCCACAGTGAGGACAATGCCAGCAACAGCTGGCCAGCTGTTCTGTAGT
 TCTCAGCCTCCCTCGCAGTGAGATGTCTCCATGCAATTTTCAGTGGAGCAA
 CATATACCATTTCCATTTCCAGGTGTAGGCTCCTAAGAAGAGGGTGGCTT
 CTTTCATGTTCTTTCTCACCTTTCCGTAGGCTAGCTGCAGATAATGATGAG
 5 GCTTTAGGGAGTGGGTGGAGCCATAAAGTAGAAGCCTGGATTCCTAAATG
 ACGGTGTGAAGTGTTCCCTAATTTTCACGTAATTGTTTCTTAATTTCTGT
 TTGGGTTATTTGTTGCTAAGGTATAAAAAAACCTGATTTTTGTGTGTTG
 ATATTTGTGTGCTGCAACTTTGCTGAATTAGCTTATTAGCTCAATTTGAT
 CTCAGATATTAGCTCAAATATTTTGGGAGATTATTTATGGTTATCTACAT
 10 AAGATCATGTCATCTGAAATAAAGATAGTTCTATTTCTTCTTTCTATCT
 TAGTCCATTTGGGCTGCTGTAACAAAATGCCATAAATTGGAGGCTGAGAA
 GTCCAAGATCAAGGCCCAAGCTAATTCAGTGTCTGATGAAGGCCTGCTTT
 CTGGTTCATACATGGCACCTTCTAGCTGTGTCTCACATGGTGGAAGG
 CAAGGTAGCTCTCTGGGATTCTTTTTGTTTGTGTTGTTTGTGTTGTT
 15 TTTGTTTGATTTTTTGAGACAGAGTCTCACTCTGTCACCAGGCTGGAGTG
 CAGTGGCACAATCTCGGCTCATTGCAACCTCTGACTCCCTGGTTCAAACG
 ATTCTCCTGCCTCAGCCTCCTGAGTAGCTGGGATTACAGGTACCCATCAC
 CATGTCCAGCTACTTTTTGTATTTTTAGTAGAGACAGGGTTTCACCATGT
 TGGCCAGGATGGTCTCGATCTCTTGACCTCGTGATCTGCCCACCTTGGCC
 20 TCCCAAAGTGCTGGGATTACAGGCATGAGCCACCGTGCCTGTCCTCCGGT
 ATTCTTTTTATAAGGGCTCTTTTTCTTTTTATGTGGGCTCTACCCTCATG
 ACCTAGCACCTTCTAAGGCCCCACCTCTTAATATCATCACACAGCAGATT
 TAATATATGAATTTTGAGGGGACACATTCTTTCCATAGCACTTTCCAGTA
 TGGATACCTTTTATTTATTTTTCTTCCCTAATTGCTTTGGTTAGAAATGT
 25 CTTCCCTAATTGCTCCACTACTATGTTGAAAAGAAGTGGCAAAGTGGGT
 ATTCTTGCTCTGCTCCTCTCTTAGGAAGAAAGTTTAAGTCTTTTGCCATT
 AAATATGACGTTAGCTATGGGGTTTTTCATATATGACATTTATCATGTTGA
 GGAAATTTTCTTCTTGTTTCAATGATGACAGGGTGTGAGTTTTGTCAGA
 TGCTTTTTCTGCATCAATCAATATGACCATGTAGTTTCTTTGTTTTATT
 30 CATTATTGTAGTACATTACATTAATTTTTGCATGTTGAACTATTCTTG
 TTCCTGGGATAAATTTCACTTGGTTATGGTGTATAATCCATAACCATAAC
 CTGAAGATATGCTGAAGAGGCTAAGTGCCATGGCTCATGCCTGTAATTCC
 AACACTTTGGGAGGCTGGTGTGGGAGGATCACCTGAAATCAGGAGTTTTA
 GAAGAGCCTGGGCAAGTAAACAAGATCCCATCTCTACAAAAAATTGAAAA
 35 TTACCGCTGGGCATGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGTGG

CCGAGGCAGGCAGATCACCTGAGGTCGGGAGTTCTAGACCAGCCTGACCA
 ACATAGAAAAACCCCGTCTCTACTGAAAATACAGAATTAGCCAGGCGTGG
 TGGCACATGCCTGTAATCCCAGCTACTCAGGAGGCTGAGGCAGGAAAATC
 ACTTGAACCTGGGAGACGGAGGTTGCAGCGAGCCAAGATCATGCCATTGC
 5 ACTCCAGCCTGGGCAACAAGAGCAAATCTCCGTCTCAAAAAAAAAAAAAA
 GAAAAGAAAGAAAGAAAGAAAAGAAAAGAAAGAAAATTAGCTTGATGTGG
 TGGTTGTGCACCTTTAGTCCTAGCTACTCAGGAGGCTGAGGCAGGAGGAT
 TGTTTGAGCCCAGGAGGTTGAGGCTGCAGTGAGCCATGATTGCACCACTG
 CACTCCAGCCTGAGCAACAAAGTAAGACCTCATCACTAAAAACAAATTTT
 10 TTAATACTGAAGAATTTTATTTGCTGGTATTTTGTGAGGATTTTGCATC
 TATATTCACAAGAAATATTACTCTGTAGTTTTTCTTCTTGTAGTATCTTT
 GTCTGGTTTTAGTATCAAGGCAATGCTGGCCTCATGAGATCAATCAGGAA
 GTGTTACTTCCTCTTTTATTTTTTGAAGAATTTGAGAGAATTGGTGTTA
 ATTCTTCTTTAAATGGTTGGTAGAATTACCAGTGTAGACATCTGGTCTTG
 15 GGATTTTCTTTGTTGGGAGGTTTTTTAGTACTAATTCCATTTCTTACTT
 GTTATTAGTCTAATGAGATTTTCTGTTTCTTCTTGAGCTAGTTGTAGTAG
 CTCATGTGTGGAATTTTTCTATTTTCATCTAAGTTATCCAAGTTTACCTAA
 GTTAAAGTTCCATTTTATCTAACTTGGGTAAGCCAACAACAATACTAAA
 TTGTTTCATAGTATTCTCTCATAGTCCTTTTTTTCTCTAAAGTCAGTAATA
 20 ACGTTCACCTCTTTCATTTTTTCATTCTGATTTTAATAATCTGAGTTCTT
 TCTCTCCCCCTCCCTGCAATTGAGAGTCATTTAAAAGTGTCTTGATTAAA
 TTTTATATATCTGTGAGTTTTCCAGTTTTCCCTCTGTTATTCTCTCTAG
 TTTTATTTTCATGTGATCCAAAAAGATACTTTATATGATTTCAATTTTTTT
 ACATTTACTAAGACTTGTTTTGTGACTAAAATATCCTTGAGAATTTCCAT
 25 GCACATTTGAGAAAAATGCACATTCTGCTGTTGTTGGACAGAGTGTTCGT
 TATATGTCTGTTAGGTCTAATTGGTTTAGAGTATTGTTCTAGTCCTCTCT
 TTCCTTATTGATCTTCTGTCTAGTTGTTAATCCATTATTCAAAGTAGTG
 GCCGGGCACGGTGGCTCACACCTGTAATCCCAGCACTTTGGGAGGCCGAG
 GAGGGTGGATCACAATGTCAGGAGGTTGAGACCAGCCTGGCCAACATGGT
 30 GAAACTCCGTCTCTACTGAAAATACAAAAAATTTGCTGGACATGGTGGCA
 CACGCCTGTAATCCCAGCTACTCAGGAGGCCAAGGCAGGAGAATCACTTG
 AACCCAGGAGGCAGAAGTTGCAGTGAGCTGAGATCGCACCATTGCACTGC
 AGCCTGGGCAACAGAGCAAGACTCTGTCTCGAGAAACAACAAAAACAAAA
 ACAAAAAACAAAGTAGTGTACTAAAGTCTCCAACACTATTGTAGAACTC
 35 TATTTCTCCCTTCAATGTTGCAAAATTTTGTTCATGTATTTGGTGTTT

TGTTCCTTTATAATTTTTATATCTTCTTAATGGATGAAAACCTTTTATCAAC
 ATATAATGTTCTTTGTCTCTTGAGACTTTTTTTTTTAACCTAAAATCTAT
 TTGGGCTGATAATACAGCCACCACAACCTCTCATATTGGTTGTTATTTTCA
 TAGAATATCTTCTTCCATCCTTCTACTTTAAAATTCTTCTATCTTTATAT
 5 CTAAAGTGAGCCTCTTGTAGATAGCATATAGGTGGATAATGTTCTCTTTA
 TTCACTCTGCCAATATCTGCCTTTTAACTGGAGTTTAATCTATTTATATA
 TAAAATAATTACTGATTAGGAAGGACTTACTTCTACCACTCAGCTATTTT
 TTTTCTGTGTGTCTTATACATTTTTTAAGTTTCTCAATTCCTCCATTACTG
 GATTTTTTTTTTTACTTCTTGATTTTGTGTCTGTGTTGTTACATTTTGAT
 10 TATTTTCTCCTTTTGATAGCGGCAGGAGGCAGCCAAATGCCTGGCAGATA
 GAAGCTTGTCCCCCATGAAACCCACCTTCAAGCCAAAAAATAGCCTGAA
 GGCTGAAAGACCGGACTGCTGGTCCCAGATGAAACCCATGATCCAGAGTG
 AGAACTTCCATTCCCTGTTTGCCTGCCCTCTAAATAATCCCTTTTAACCAA
 TCGAATGTTGCCTTTTCCAATACTACCTATGGCCTGCCCTCCCCCATTC
 15 TGAGCCCATAAAAGCCCTGGAATCAGCCACATTGGGGGCACTTTGCCAAC
 TTCAGGTAGGGGGACCACCTCTGTATCCCTTCTCTGCTGAAAGCTGTTTT
 CATCACTCAATGAAACTCTCACCTTGCTCCCTCTTTGATTGTCAGCGTAT
 CCTCATTTTTCTTGGGTGTGGTACAAGAACTCGGGAACCAGTGCACAAGC
 CAGACTTGGTCTGGGCAGCACGGGTTAGTGGGCCATCTCCACAGCAGGT
 20 AGCATGGCCAAGTGAGGCCTGGGCAGGGCATCACCAAGGTCCCTGGCTTG
 CAAAGTGACCAAGGAAAAAATCCTGTGTCACTTTCTTTCTCATATTTT
 TTAGTTATTTTCCTAATGATTGCCTTGAGGATGGCAATTAACATCTTACA
 CTTATAAGAAGCTAGTTTGAATAATAGTTCCAATAGTACATGAACACTCT
 ACTCCTATATATCTCCATCCTTCTTCTTTATATTGTTATTCCCACAAAT
 25 TATGTTTTTATACATTATATCCTCACTAACATAAACTTATTATTATTTT
 TGCATTTGCCTTTTAAATCATAACAGGAAAAACAAGAATCACAAAGAAAAAC
 TACATTAATATTTGCTGTTATATTTACCTATATAGTGACATTTAACAGTG
 TATTTTTATGTCTTCAGATGTCTTTGAATTACTACTTAGTGTCTTTTCAT
 TTTAGCCTCAATGTTTCCCTTTAGCATTTTCTATAGGGCAGGCCTGCCGG
 30 TAAATTAATCCCTTTGGTTTTCTTTATCTGAAATGTCTAATTTCTTTTTT
 ATTCTTGAAGAATAGTTTTGCTGGCTATAAGATTCTTAGTTAATAGTTTT
 TTTCCCAGCACTTCAATTATTATTAAGTGTTATTATTATTATTATTATT
 ATTTTGAGATGGAGTCTCCCTCTGTCACTCAGGCTGGAGTGCAGTGGCGC
 AATCTCTGCTCACTGCAACCTCCGCCTCCCAGGTTCAAGCAATTCTCCTG
 35 CCTCAGCCTCCCGAGTTAGCTGGGATTACAGGTGCCCCGCCACCATGCCCA

GCTAATTTTTGTATTTTTAGTAGAGACGGGGTTTCACCATGTTGGTCAGG
 CTGATCTTGAACCTCCTGACCTCAAGTGATACACCCACCTTGGCCTCCCAA
 AGTGCTGGGATTAGAGGCATGAGCCACCATGCCTGGTCTAAAGTGTAATT
 ATTATTACAGCTGCCATTTGGCCTCCTTGGTTTCTAATGAGAAATCATCT
 5 GTTAAACTTATTGCAAATCCTTGGTATGTATGCTATGTGTCATTTCTCTC
 TTGCTGCTTCCAAGATTCTCTCTCTGTCTTTGTCTTTTGACAATTTGACT
 ATAATGTGTTTCAGTGTGAATTTCTTAGAGTTTATCCCACTTGGATTTC
 TTGAGCTTCTTGGATGTGTACGTTTGTCTTTACCAAATCTGGGAAATTA
 TTTCACCATTTCTCAAATATCTTTTTCTTCCCCTTTCCATCTCTCTTCTT
 10 CTGGAGCTCCCGTATACTTAGTTGGCATGACTGATGGTATCCTACTGGTC
 CCTCAGGTTCTGTTCATTTTCTTCTTTCTTTTTTCTGCTCTGCAGACT
 GGATAACTTCAATCGCCTTTTCTTCAAGTTCAATGATTATTTCTTCTGCC
 TGCTCAAATTGGCCATTTAACCCCTCCAGTGACTTTTTTCATTTCAGTATT
 GTACTTTTCAGATCCAGAATTTCTATTTGGTTCCTCTTTAATAAATTCTT
 15 TTTATTGTCATTCCCCATCTGTTTACATGCTCTCCCAATTTTCTGTA
 GTTCTTTGTCCATGGTTTTCTTTAGTTAATTAAGCATATTTAAGACAGTT
 GACTTAATGTCTTTGACTAGTAATTTCAATGTCTAAAATTCCTTATGGAT
 AGCTTCTTTTAAATTATTTTGTCTGTTAGAGAGTCATATCTTCCTCTT
 TATTTGCTTTGTAATACTTTGTTGAAAACCTAACATTTTGAGTAGTAAAA
 20 TGTGGTAATTCTGAAGCCAGATTCTCCCCCTCCTTTGAGATTGGTTTTGT
 TGTTTGTGAGGGCTGCAGTTGTCCATTTGTATAGTGACTTTTCCAAACG
 ATTTTGTCAAAGTATGTATTCTCTCTTGTGTCTGGTCACTGACGTTTCTG
 TTCTGGTGCCTCTGCAGTCAGCCTATGACCTGGAAGAGCATTCCTTAAAT
 GCATAGATTTTTTTTAAAACCCAAGAAACAAAAACCTAGCATGTATGTAC
 25 CTTTTTAAAAATCTTCTGATAGATGCCACCTGGAAGGCTGCTGCTGCCTG
 AAGGGGCAGAAACAAAGGCAAGCTCTACTCTGAGCCCTCAGGGAACCACC
 AGATAAACAAAAGAAATTTGATTCTCCAAATTTCTGGAAGACAAGGTCCT
 TTCTGCCCCTCCTGCTCCAGCCAGCTGCTCTAGGAACACAATTACTGTC
 CACATGGCCACAGGAATGTTGAAGAATGCAGGATGGTAGCTGGTTTGGCC
 30 ACACCACTCACTTATGAGCCATCAGCATGCCTCTCCCTTCATCGAGCACT
 CCCATGGTTGCTGTAAGTGTCCAATCAGGTTCCAGAATTCTGAAAGAGTT
 GACTCTTACAGGATTTTTTTCTTTTCTAACTTGCTGGTTGTTTAGATAGA
 GGAACCAATTCCTGAAGTTTCTTACGTTGCCAGCTTCATGAGGATCATTC
 CCTAGTAACTCTTTTTCAGACAAAAAGCTTCATTGATTTACTGTAGGACTA
 35 GCATCAAAGAGTCTATGCCACCTAGTCTGTCTCCTTAAAACACAGAAATA

ATCAGTATGCATTGGGGTAGGAGTTTGGCATTAGATCTGCCGTAAATCAA
 GAGCTGGGGACAGCCCATGTCTTAACTCTGACCCAAGGGCTAAAATATC
 CTTTGGTAGCAACAACAGCTACAACTATTGAACAACCTTGATGTGCCAA
 GAGCCTTACCTGCATTATCCCATTGAATCCTCTCAACAGCCCTGTGAGGT
 5 AGTAGAATTGTTGCCTGCCCCCTTACTGAGGCCTAGAAACATTAAGGAATT
 TGCCCGAGGCCCTAGAGCCAGTGAGTGCCAAAGCCAGTCTCCAGACTCAG
 GCTGGAGATCCTACAGTTCTGTGTTACCCCAGTGTTATCCTGCCTCTCAG
 CACAGAGTCTTGGATGATTCTCCTAACCCCTCCCTAGGCAATGCACAGGG
 CTGCTCCCTGCACCCTTACTCATGCTCTGCTCTTCAACCCCAACAGTGCT
 10 GGCCTTAGGCTTTATCCCTGACACCCAGCCCCAGGCTCCATTCCATCTGT
 TGACAGAGGCCAAACACTGGGGCAAACTGACCTCTGTGGATAACCACTGTG
 TCCACCTCCACCAGCTTCAGCTGAAGCCTCTGAACATCTCCAGCATGGAA
 GAAGCCCCAAAGGATATTTCTGTCCCCCAGCATATGCTTGACCCTGAAG
 CCCTCCCCATCTAGTCAAGAAGACCAAACCTGTTAACAATCCTGGAGTCAG
 15 AGTGACCCATGGGTGAATCTTAGCCAAGTCACTCATAGCTGTTGCATCCT
 AGTAAATCCCTTAACTCCCATAGGCTTCAGTTTCCCTGCATATAAAATGA
 CAGCCTTCAGCTCATCGGCCAGTTTCAATCCATCTAAAGGGTCTAGCACA
 TCCCCTGGCATGTGGAAGCCACAGGGCACACACTAGTTGTGGTCATTTGA
 TCCTGGCATGCTCTGCTGTCTCTCGGCTCTCCCCTTGCCTCTTCCCTGA
 20 TGTCTTGGCCATCAGCCACTGCCTAACACCCTCCCACTCACCAGGCCCTT
 AGCCTGCCCCTTAGCACAAAGAGCACAGCCGGTCTCAAGTCTACCCTGCTG
 TAAGCAAACACTTGCAACATCATGCTGACCTCCAGGCCCTGTTGCATCAG
 CGTGCCACACTTGGTGCCAGCTGGTACTGAGGGTATCAGGGAACAGGC
 CAGTGGTGGAAGGGCGGACACTTTGGGTTCCCTGGTTTCCTGGCTCCCAA
 25 TATCTTTCCCAATGGCATATGGGGTCTAGCAGCTTGGCTCATTTAACTGT
 GAACCTCTACCCTTTAGAATCTGGGCCTCCAGGCTTGCTTCTGTGCAAAA
 TGGCAGATAAGGCTCAACCTTTCTTTTTTTAACTTCATTGTTAAATATTA
 CTCCATTAATACCCATTTACTGCAGAAAAGGTAGGAAATACAGATAAGCA
 AAAAGGAAAATAAATTAATAATCCTCATACCACCATCATCAAGATAATTAC
 30 TGTCACCATTTTGGTATATTTCTCCCAATACATATATTATCTATATCGT
 ATATACGACAAAAATGGATCATACTATGTTTCCTGTTCTTCCCCTGTGTT
 AGTCATCTATTGCTGTATAACAACTGCCTCAAACTTAGTGGCTTCACC
 TTTCCGTGTATTATGATGACAAGAATGTGGTATGACACTGTCTTATATCT
 GGATCATATGCTAAAAGATAGAAAATGGTTTCTAACTTATTTGTTCTGT
 35 AATAACAAAATTTTATTTTATAAAGTGTTTTTAAAAAAACCATAGTAGC

TTGAAACAACAAACCTTTGTTATCTCACACAGTTTCTGTAGGTCAAGAATTCAGAAGCAGCTT
 AGCTGGGTGGTCTGGCTTGGTGTCTCTCCTGAGGTCAGGGTTTTGGCTGGGGCTGCATCACCT
 GAAGGCTTGACTGGGGCCAGAGGA
 CTGCTTCCAAAGTGGTCCACTCACATGGCTGGCAAGTTGGAGTTGCGTATTGGCAAGAGACTT
 5 CGCTTCTTCTCAATGGATCTTCCCAGAGTTCTTGTAGGCAACCTCATAGCATAGCAGTTGGCTT
 CCCCCAGAGGGAACAGTCCAGGAGAGAAACAAGGCAGAAACCACAGGGTCTTTTCTGGCTTAG
 GCTCCAAAGT CATACTCCACCATTTCTGCATTATCATATTAGTTACACAGGCTAGACCTA
 TTCTGCATGGAAGAGACTATACCATGGGGTGAATACCAGAAGCAGGGCTATTGAAGGCCAGC
 TTCAAGGGCGGCTACACATTCCCTTTCAACAGTATGTCATGAACATCTTTCCATGCCAATAGA
 10 GCAGATGAATCTTACCATTTTTAATGACTACATGTAAGTGTAGCATAATTTATTTAACCAACCT
 CCTGTAGTTG GGTATGTGGGTGTGTCTCGTTTTTTGATAGTAGAATTAATCATCTTGAA
 TATCCATCACCAAACCTTGTATATTATTTTCTTTTGATGAATGAAAAAGAAAATCAAGTCATGT
 CTGTCAATCAGAACCCTGAGCAACTAAGAAATGGGGGTACCACTGGGACATAGAGCAAGGTC
 CCTTCTGATTCTGCTCTTGTCTTTCTCTCCCCATGAAATGGGGAGTTCATCTACTGAGACA
 15 TCCTAGCCCA CAGCTGCACAGTTCTGTCTTTTAGAAAGCTCTAAGCAGAAACAATGTTC
 ATCCATCCTCCTCGGGACAGCCCTTGAGCTACTGAAGACTCTAAGCATGTCCTGGTCATCCTCC
 ATGAGCCATCATCTCTGAGGCCCTCCCCCTTCTTGGCCCCCTCTTCTCTGGACAGGTTCTGGACAG
 TCTTGCCCTTCCAAAATTCTGAAAGCAGGAACGTTCCTGCTACAATGACTCTCAACTCCAGT
 GCAGTAC AGACTGTTGGTGTCACCCCTTATCCTGAAGAAGAGGCACTGAGACAGGAC
 20 AAGGGTGGGTGCCCAGGAGGGCTGGCATGAGTCATGAGAATCTGGTCCCGGAGAATTAGACG
 GTGTGGGGAAGTAGGGGTGTTGGGCGGCTTTCTGGCCTCATGGATGCCAATGAATATCAGCAG
 GTGGCTCCCAGAAAGGAACTCTAGGGGATGCCTGTTGCTCTAAATAGAGGCTAGAGAGGGCA
 CTGGCAGTTCAGT CAACCAAGAAAGGGGGCCCACTTGCCTCAGCTTCAGGCTTTGTACACATC
 CTCAGCCTTTCTTGAGAACTGAATTTAGATTCTCCTCCCCTGTGCTGTGTGCTTGGCCCAGAAG
 25 AAGGGCAAGTCTCGCTGGGTGGCTGCTTCTTGGCCTGGCTGAACCAGAAGGCCCCAGTGCCAC
 TCCAAACCTGGGTGTGAGCCCTGCCCCCATGAGCAAACAGTAGCTCAGAGCTGGGGGCTGTG
 GGGGTCAAGTGG CCTGTACATGAGATCTGATGAGGCCATCTCTGCTCTATATTGGGAAAGG
 GATCAATTGTATCAAGGGCTTTCTTGGGAGTGATCACTCTGGCCATTGGCGAGAGACCTGGCA
 TTCTGACAAGGCACCCTCCATACCCTGACCCACTTGCCAGCTCCAGCTAATTTTAGCAGGCTTT
 30 GGCAGGTGCCAGCAAGTACATAGCATGTGGATGTCACTCCCAGGTGAGCCCAAGGAGAGGCC
 TGGGCCAGAGC CTGGAAGTCATGGTCTATGCCCATGGAGGCACCCAAAGCAAGCCTGAGGC
 CTGGACTTTGCAGTCACAAAATTAAGAATGATACCCCTGTTTTTTGTTTG
 TTTTGATCAGTTGGCCACCTTCCTCCACCACCCCTTCCCCAAGTTCCAT
 CAGACCCCTGGATTGTATGAAATGCAAATCGAACCTCTCTGCAGATGAA
 35 AATCCACTGGGGATCCCCCTGCCTCCAAGAGCAAGTCCAGACCTGCACCA

GCGCGGGCCAGGCCCCCTTAGGACCCCCTCCCTGTCCAAGGGCATTTCAG
 TAAGTGTCTGTGGCCAAGGCAGCCTGGTGACTTTCTGCCCCGACAAGGC
 TGAGGAATGGAAGATGGGTAGGCTGGCTCTGCACACCCCCTCCTGCTGGG
 CAGCAATCCCTACCCCATGTTACAGAGTGTGGCCGGCTGCCCCATGGCT
 5 CTGTCCCCGTGGCCCTGTCAACTGTTACCCACATGGCCTACCCTCCCTTT
 CTGCCCTGCCTCTGACCCCATGGCAGGGGGCAGAGTATTTGAGCAGCCGC
 CAGGCTGAGCCCTTTCAGTGCAGAAGCCCTGGGCTGCCAGCCTCAGGCAG
 CTCTCCATCCAAGCAGCCGTTGCTGCCACAGGCGGGCCTTACGCTCCAAG
 GCTACAGCATGTGCTAGGCCTCAGCAGGCAGGAGCATCTCTGCCTCCCAA
 10 AGCATCTACCTCTTAGCCCCCTCGGAGAGATGGCGATGGATGTCACAAGGA
 GCCAGGCCCAGACAGCCTTGACTCTGGTAAGGGTCACACCAAAGTTAGGG
 ACTTTGCACTGGGAGAGCAGCACCCAGGGCAGGGCCCTTGTTTTCGAGA
 TTACCAAACTAAGGCTGGGGGCAGGGAAGGCGAGCAGGCTTGGGGCACC
 TTGGAAGGAGGCACATGGGCCCTTGGGGGTCTGGCTAGGGCAGCTGTGCCTGCCACTGGCCCT
 15 CTGCCCACCACCCCTCCTCACTGTGGCTATCCAGTGTCCAGCCTCTCGAGGGGTCTAGGGTAC
 TTATTCCTGGAGCTAACGGTGACCCAGGACACCAAGTGTCCGGGGCCTGGCCTGGGGCTTTTAT
 GGGGGGAGCT GGCTGGCTGCCAGGGCTGTCTGGCTCTCTGGGGGCTCTGCATGGCATT
 CCAGGGGTGGTGATCAGGGATTCTGTCCCTCAGGAGAATGTGGGCACTAGCCCAAGGCCA
 CTCATTCTGTGTACATAGCCACCTGAGGGCCCAGGAATGGAGGGGGCCAGGCTACAGCTGG
 20 ACATCTGGCACTCGGATGGGCTCTGGAGCCCCCAGGCCTGCAGCATCTGCCCAGGGACTGCCC
 TGGCCCTTGGCCA TTTCTCAGGGACCCACAGCTCCACCAGCCGGCCCCCTCCCAAGTGCTGGAA
 TAGACAGTTCCTCAGTCCACATCTGCCAAAGGCGGCACTAGAAGGCATCCTGCCTTTTTTACT
 GCGTTCTGGAGGTGGGGTCACAAAGCACTGCTCACTGCATAAAAGGGACAGCATCCTGCCCCCT
 GGCAGCCCTGCCTGACCAGCTCCGCCTCTCCCACTGCTATCCAACCTGTACACCCTGGTGACC
 25 ATGTCCAGGCC AGTGGCCTTAAGGACTGTCTCTGTACTGATGGCTCCACATCTACCTCTCC
 AGCCAGACTCTCCTCTGAACTCGGGCCTCACATGGCCAACCTGCTACTTGGAACAAATCGCCCC
 TTGGCTGGCAGATGTGTTAACATGCCAGACCAAGATCCCAACTCCCACAACCCAACTCCCAG
 GTCAGATGGAACCTCTTCTTCCCAGGCCCTTCTGTTCTCTCCTCAGCCCCCTCCCACCTCCCTTC
 AGAATAAGT CTAGACTCTTATCGCTTTCACCAAGCCTGCGCCCAGCATCCCTGCACAGG
 30 GATTGTTAGGACAGCCTGACGCCCTGCTTCCACCCTGCCCCAAGATGCCCCTGCTCTGCAGCC
 CGGCGCCTCCAGGCTTCTCACCTCCTGCTGCTCACAGCTCAGCCTCACTCCCTCCCTCCCCGCC
 TCTGCTCCAGCCTCAGTGCAGGT
 CCCTGCTCCCATCTTCTGGCAGCAGCTGCCCCGACCTGGTCCCTCTTCATCTGTCCCCATTCTTC
 ACCCCCCAGCCTGTCCCCAACTTGACTGAGGTTCTTTCCTGCAGATCCCCGCCCTTGAGAGGG
 35 GTTGGTCCCACTGTCAACTCTGCTTCTGTGCCCTGTGCCGCACCTGGCATTCAAGTGAGCATCTG

CTGAAGA GATGAGGGTCAGATGCCCTGCAGGGAGTGTGGGGGCGTCCTCAGGCAAGA
 AAAGTTGTACGTTTGGCTGTGGGCCCTGATTATGTGTCCTGTGACCTCTTGGGTGAGGTCAGC
 AAGAGAAACCTCTGCAAGCTGGCTGGGGCTGCCTCCCAGAGGCTGCCAGGGGGAGGGACAGG
 CTCTGTCTGTGCTCTTCTTCCGAGGCTACACCTGGGGCGCCAGGCTCTCAGGGCTCCCCAGGTA
 5 CCACCACATTT CCTACACTGCTTGGGAAAGCCCTGTAAGTTTGCACAGACACCCAGCATGA
 GGCTCGCCAGAGAGATACTTGTAGCTGGGGTCTGGGCACCAGGAACAGCTTGGTGCTGGGCC
 TGAAGTCGGGCAGGATGCAGCCTGGCCAGGTGAGAGGAAAGCTTGGAGCCAGTGCCTGGGTT
 CAAACTCCTCTGTGGCCTATGGTTCTGTGGGCTTGGGGAAGGGTTTGTACCTCTGTGTCCAGTT
 TCCTCACTTATA AAAAAAGGAGATAATAAAAGTACCCATGTCCCAGGGTGGCTGTAGCAATA
 10 ATAGGGAGGGGTGCCCAGAGCAGGTCTGGCACACAGGAAGTGTGCATCAG
 CCTCAGTCCCTGCCATTGGGCTTGTCTGGGAGTCTGTGAAGCCAACCTC
 TGCTCCACAATGTGACCCCCAGGCTTGTGAGACCAAGCTGGGTCAGAGCT
 TCCTCCTCTGGGGTTGCACCAGGAGGGGAACCTTCTGCAGGCCCAGATGCA
 CCCTGAGGAAAGGGCTTGTTCACCAAGAACAAGGCTCACCTTTGGAGG
 15 ATGCTCCCCACATGAGAGGTGAACCCCCAGGTCTACTGGTGA CTGCAGCC
 TCGGAAGCTGACAGCATCTATCCTCCAACCCATGCCCACTGGGAAGTGTG
 TGAGGGGTCCTCATAGGCCCTGCGGTGTGGACAATGCAGAGACCCTGTAG
 CATCTGGCTAGGGCGGGGCCAGATAAGAGCCCTGTGCCAGGAGAGCCTG
 GCCGGTTCTGCCACTGTGGGGAGACAGGCTCCCCACCCCATGTCCCCTG
 20 CTTCCCTGCAGCCCACAGAGAATACAGACCTACTTTTACAGAAATCCAGA
 TTTTGTGTAAAGTGTCTCTATTTTAAGTAGATTTTAAGTGGTGGCAGC
 AAATTTAAGCTTTTGAGAATATTATACAGAAACAAATCAGATTACAGGCC
 AGATGCAACTTTATTTACAGAAATGGGATCAGGTCCTACCTCAGGTCCCA
 TCTCACGTTTTCACTTATGCCTATACGTCTCCTTACGGGAAAGGCCACA
 25 AGAGGCCCTGCGGTAAGTGTCCCGGTGTTGATTTAAAGTCCCCAACAGTG
 AATATGAGGGTCCTCACTGTTGCAGCAAGAGGATACCCCCCTGTGTATCT
 TGGAAATGCCTGCAGCCCTCTTGCTGCAGAACAGATTCTTAGGAGAGAAA
 CTGTCAGATCAAAGTTAACTTAGAGAACTCCAAATTGCCCTCTGAACA
 GACGGTATCAGTTTGACATCATCCAATACCGGGATTCTCGGGGAGAACT
 30 TTCTGGCCTAGAAGGCAGTAGAGCCAGGACTTCACCCAGTCAGTGGCAGG
 GCCACACGTGGGCCTTGATACAGAGGGGGAAGACTTGAGCCTCCTCGACA
 CCCTACAGGGCCCCAGCCTCCCAACATGTGATAAGAGAAACAACAGCCAAC
 TTGTACCTAGCTCTCCTTATTCTCCAAGGGCTGGGCCAGTTCTCCCCACA
 GCCCTGCAAGGGAGGATCACTCAAGGGCCCCAACTGTCTGACAATACAGC
 35 CACACTCTGATCAGCCACCTGGGCATAGGCTCCATGCCATTGTCTCCGC

CAAGACCTCAGACTGAAATGTTGGCTCCTCCCATGAAGAACCTGGGGCCA
 AAGGACCAGAGTCCAGGTCCGTGGCTGCCAGGATGGGCCACTTGGAGAGA
 GGCACAAGGGTGGTGCCAGGCAGGTGTGAGGGCTGGACCTTTGCAAGAGC
 AGCATCACTTTTGTGAGAGCCACAGGTATCTTATAATTGGGTCCTAGG
 5 ACTTCCTGCCAGTAGCCATTGTGTGCATGGATTTGGGTGCTGGCCTCACC
 ATGGTGTGCTGGCTGCCCATGCCTGCAATAATGACTTCTGTAAGCCTTTC
 TTCATCTGCAAGATGGGTGCTGCTGGCACCTCCTCCCCGGTGCTGTGGTG
 ACAGGGCATAGTGTGTGAGGCTGCTATGTGAAGCACCTAATGCAGGGCCT
 GGCATATGGAGGAATTCAGCAAATGACAGATGCCTTCACAGTTAGTTCCT
 10 GGCATCCTCTACATTGGTGGGTGTAGGAAAGAAAGACAGAGGAGGCAAAA
 GTTGTAGCTGTGGGGCATTGAGGACAGCCTGGATTGTTCCACAGAGCCCT
 GAGGACATCTCCAGGGGTGTGCTCTGCAGGGGCAGCTGGATTGGAGGGTT
 AGGGGTCGGGGAGGGCGTGCACTCCCACCCATGCTCACAGCCTCGGAACA
 GTGCCTGCTCAGCCAACATGGGTGTTTGATTCTGTGTCTTTTGTACAGA
 15 CTTTATCAGCCCCATCCCTTTCTGACCTTGCCTCAGTTTAAATTTTACAT
 GTGGGGCCTCATTAAGAGACATGGTTCTTAACTAAAGATCTGTATCCATT
 AGGAATGCTTTGGGCTGCAGGAAGACAAACACCTGACTCACTGTGGCATA
 AGTGGTTTTCGTCTGCTCCCATAGCTGCACGTGGAGGGTGGATCTGGCA
 TTA CTCTCTCTTCCCTACATTTGCAGTATGCTAACAGCTTTAACCTCCAG
 20 CCTTGTTTCTTCATGGTTGCAGGGTGGCTATCACAGCGCTGGCCATCACA
 TCCTTACACAGCTGTGTTTACAAATTTAGGGGGACATTGAAGCTCCTCCC
 CTGCTAAAATCAGGCTTCCCTTCACCTGTCATTGGCCAGAACTGGGTGAA
 ATGCCCAACTCTAGACCGATCATCAGTAAGAGGAGTATAGAATTGCTGTG
 CCCACCTTAGATTAATCATGGCGCAATGTGCTCCCCATACCAACAAAATC
 25 TGAGTTCTAGAACTGAGGAAGAAGAGGAAAATGGCCGTCTTGCCTCCTG
 GCTGGGATTCAGAGCATCTCCAACCCTCTGAGCTTATGTGTAAGACTGTG
 GGCAAAAGTGTGTGAGTTTTTGTGGAATGGATCCACGGCTTTTATCAGAG
 CATCTTTCCTTTTTCTTTTTGATTCAAGATGAAAATATTCTTATGATTAT
 TTTTCTCACCACTGCCCAGAGATAACCAGCACATTAACATGGCCTTTTCT
 30 CCATGAATAGCACTAGGGTGCCAGTGGACAGACACATAGCTGTCCACAC
 ACCAGCTTGCTGGGGATGCATAGGCAGAGTCACATCTGCACTACGGCCT
 GTCCTCACACTGCCATGTGGAGAGCCAGCAGCCACACCATGGGCCGTCCA
 TGCTCACGGGAGTGGCAGTATCAGATCTGAGCTTCGTGTGCCAGGCGTC
 TCTCACATCAGTGCATAGGGACCTCTTTGTTCTGTGGCCAGTGTGCCC
 35 ATGCCACAGATGGCTTCAGTCAGCAGACACCTCCTTCTAGACACTCACAC

TCACTCCTGGCTGGCCCTTAGCACACCTGTGCAGACAGGCCCATTTATTT
 TCTTGTGTAAATCCCAAGTAGGAGGACTGGGTCTCTCTGACAGCAATGCC
 AGCTGCCTGGCACCCTCCAGACAGGTGGCTCAAGCCCCACCTCGCCAGCT
 CTCCCAGTTAGCCCCCTCCTTTCCCTGGCTCTGACCTGAGGGACGAAGCAG
 5 GGTGCTACAGGACGCTGTGCCACAGGGATATCGTCAGGGACAGAAGCTAC
 TCTGCCCTCTGCTGCTCACCCCTCCAACACGCTGTGGGCTGCATTTGTTG
 AGTGGCTGGTACCAGACTCTGCTCTTCTGACTTTCCAGCTGGTTTTACCT
 GTAGTAAAGTTTGAGAAGATGGGTCACTCCTGACCCCGGGGTCAGAAGACA
 GAAGGAGGCCCATGGCGTGTGGGGGAGATGCCCCGTGAGGCCCTCGGTGT
 10 GCAGATGCCTGGTGACAGCCCCACCCTGAGGTCCCCAGCCTACCCCTCC
 CCAGCCCGACTGCTCCCATCCCCCTCCCTGTGCAGGTAGAGCAGATCCTG
 GCAGAGTTCCAGCTGCAGGAGGAGGACCTGAAGAAGGTGATGAGACGGAT
 GCAGAAGGAGATGGACCGCGGCTGAGGCTGGAGACCCATGAAGAGGCCA
 GTGTGAAGATGCTGCCCACCTACGTGCGCTCCACCCAGAAAGGCTCAGGT
 15 ACCACATGGTAACCGGCTCCTCATCCAGAAGCAGCTGTGGGCTCAGCCCT
 AGCTGGGAGAAGCACCCAGGCACTCCAGACTCACAGCCAGCCCGAGAC
 AGAATCTCCTGGGGAGCAATGAAGTCCTCGACTTGGGCCAGTTCTCACCC
 TTGGCTCCTCTGGTCCGGCCCTGGGGCACTCGGGCTCACCTGGAGCTGG
 CAAACCTCAGGAAAACCTGGCGTTTTAAATCTCACTCCTGGCCAGGTGCAG
 20 TGGCTCACCCCTGTAACCTTCAACACTTTGGGAGGCCAAAGCAGGCGGATC
 TCTTGAGGCCAGGAGTTTGAGACCAGCCTGCCCAACATGGTGAAACCCCG
 TCTCTACTAAAAATACAAAAATTATCCAGGCATGGTGGCACATTCCTGTA
 GTTCCAGCTACTCGGGAGGCTGAGGCATAAGAATTGCTTGAACCCGGGAG
 GCCGAGGTTGCAGTGAGCCAAAATCGCGCCACTGCACTCCAGCCTGGGGT
 25 GACAGGGTGAGACACCATCTCAAAAAAAAAAAAAAAAAAAGACCTCACTG
 CTCCCCATGGGCACTTAGGGAACTCTCCCAGCCCAGTTCTGCAGCTGGGC
 CATTGCACTAGATCCTCAGTTGGTCCCTGGGCTCTCGGTGACTGTCCAGG
 GCAGGAGTTTCCCATTGACTTTTCCCTGGTTGACCTTTGACCCCTTCCAC
 AGTTGACACTGGTGTCCCCAGGTGTCTGGTGGCCCCCTGTCCAGCTCCCT
 30 TAGTCCCTTGTGCCTTCCCTCCTCCTCTTTGTAATATCCGGGCTCAGTCA
 CCTGGGGCCCCACCCAGCCCAAGGCCAGCCTGTGGGTGTCCCTGAGGCTGA
 CAACTTCTCTCTGTGCCTTTAGAAAGTCGGGGACTTCCTCTCCCTGGACC
 TGGGTGGCACTAACTTCAGGGTGATGCTGGTGAAGGTGGGAGAAGGTGAG
 GAGGGGCAGTGGAGCGTGAAGACCAAACACCAGATGTACTCCATCCCCGA
 35 GGACGCCATGACCGGCACTGCTGAGATGGTGAGCAGCGCAGGGGCCGGGG

CAGGGGGCCAAGGCCATGCAGGATCTCAGGGCCCAGCTAGTCCTGACGGG
 AGGTGCCACCTGTCTACCAGGGGTGGGGAGAGCGGGGGCTGGAGGACCAC
 CCAGCCTCAGAGGCAGCTGGAGGCCTGGGTGAACAGGACTGGCCAACATG
 TCCCAAGTCCCACAGTCACCATCTGGCCAGCATTGAGAGGGGAACGGGC
 5 TGAGGAAGAGTTAGTGGCAAGAGGAACCCCAGCCAGTCACACCTTGTCCA
 GTTTACCAGAGGAAAAACCAATGTGTAAGAACAGAAATGTGACCCGGCAG
 CCAGTGCACTGCCCCCTCTCCAAAGGCCACCCCTCACCTCCACCAGCA
 TGCACAGAAAGTGGGGTGACAGCAATCACAATGTCTACCCAGGCAGCAAG
 GACCCCTGACCATGGGGAGGACTGGGGTGACAGGGAACATAGAAGCAGAAT
 10 GAGGCCTAGGGGGAGTTGGGCAAGGCCAGAGCCCTAGCTGCAGCCAAGCA
 CATGGCCAAGGCCAGCTCCTGGAAGGGCAGGGCTCCGAGGCAGGAGGCAG
 GAGGCTGCCCCTGGCTACCCGTCTCACACCCCTGCAGCTTGCTAGTCTG
 TCTGTGGGCTGGGTGTGAATCAAGGCAGTGGGATGGTGTGGGGACCTCCC
 TGGCCCCAGCAGCCAGTGAGGAGCCTGGTCAGTCAGCAGAGCATTAGCA
 15 GTATCCAGTTCCATGGAGAGGCCCCGTGTGAGGGGAGTCGGGGCTGGTCTT
 CAGTAAGGATGGGTGGCCAGGGCCCCCTAGAAGTAGAAAAGGAGACTCCGG
 GTGCTGGAGACAGAAATCAAGGATGTGCCTCCATGTGGAGCCTCAGGAAT
 AGCTGGCCAGGCCTGAGGCTGAACCTCACAAGGTTAGCTGGGAGGGCTA
 GGCTGACAGAGCACAGCCGGGCCAGGGACCAGCCTGCCCTGTGTTGCCTT
 20 GTCCCGAGGGCCACTGTCAGCAGGTCTCTGGCATGGGGGAGGCTTAGGGC
 CTGAGCCCAACAAGCAGCAGCGGAAGAGGAGAGGGAAACTGTGGACAGGC
 CTGGCATTAGTGGCCAGGTGTTGCAGTGTCCCTGAGGAATAGCTTGGCT
 TGAGGCCGTGGGGAGGGCTGCCGGCCAGCGCACCCCCCATGCCAGATGG
 TCACCATGGCGTGCATCTTCCAGCTCTTCGACTACATCTCTGAGTGCATC
 25 TCCGACTTCCTGGACAAGCATCAGATGAAACACAAGAAGCTGCCCCCTGGG
 CTTACCTTCTCCTTTCCTGTGAGGCACGAAGACATCGATAAGGTGGGCC
 GGGTGGAGGGGCAGAAGGCAGATGAGGGGAGGCACAGGCACCCCAGAGGA
 ACTCTGCCTTCAAATGTAGCCCCCATACCATGTGCTCAGAAGGGAGATCT
 GGATTCAAATTTGTGGCCATGTCACCTGCCACCTCTAATGCTGTGGAAAAG
 30 AAGCATCACATTAGCTAATTCTGGCTGTGCGCCTTGTGAGGCACCAGCTA
 TGATACCCCACTCCAGTGGAAGAGCAGCTGGCAGTAGGGTGGGGCTCA
 AACTCAGGCAGCCGGGCTCTGGGTACCTGCAGGCCACGGTCATGTCACA
 CTGCCTCTAGCTGAGTCAGAAATGTGAAGGAACTGAGATTCTACCCTTCC
 TGCAAGCTAGCAAAGTGGCCTGCCAGTTACATCTGTGCATGCACACACAC
 35 ACACAGTTATATATGCACACACATAAAACACGAGACCTTTGGGTCAGGGA

GGATTTGAAGACTAGCTGGCCAACAAGGTGTAACCTCGTCTCTACTAAAA
ATACAAAAATTAGCTGGGTGTGATGGCGCATGCCTGTAATCCCAGGTACT
CAGGAGACTGAGGCAGGAGAATTGCTTAAACCCTGGAGGCAGAGGTTGCA
GTGAGCCAAGATCACGCCACTGCACTCCAGCCTGGGTGATGGAGTGAGTG
5 AGACTCTGTCTCCAAATAAATAAATAAATAAAAACTGGAAGTCTAA
GCATCACTGAGCCCTGATTCTATGTGGCAGCTCGACTGACCAGCATTGT
AGTTGCTGTCCCTGACAGCTTTGGGGGTGTGCAGCCCACACAGTCATGCT
AGCTTGAGGCTCTGCTGTCAGCAGTTTGAAACTCTTAATAACTTGTGAAC
AAAAGACTCCATGTTGTCACTCTGCACAGGGGCCAGCAAATTACAAAATT
10 CCATATCCGGAATTGTCTACAGGAGCCTCTGGGCTGCTCCCAAGGGCCCA
CACCATGCCTTACTCACTTTGGGTTGCCATCCAAACATGTCTCATGACAA
AGAAGCTCAAACATGTGCATGGACAGTGCCAGAAAACAAGGGTTCGTACAT
AGACAAAATAAAATGATAACGTCCCAACAACCATTTCTTTGATACACACTG
TTTCTCTCAGTCCTCCCAACCACTAGGTAACAGGCAGGGAAGGTGTTAC
15 TGTTGCCTGTTAGGAAAGAGGACAGCCCTGAAAGCTGTCCCTGGCCACTG
AAGCAACCCAGGTCTTCCAGCCCCAGGGAGAGCCGCCTTCCATTGTTCC
AGACAAAGCAGAGACAGGCATGGGGGAGCGGGAGAGGGACTCCTGTGGGC
AGGAACCAGGCCCTACTCCGGGGCAGTGCAGCTCTCGCTGACAGTCCCCC
CGACCTCCACCCCAGGCACGGGCTGCAATGCCTGCTACATGGAGGAGATG
20 CAGAATGTGGAGCTGGTGGAGGGGGACGAGGGCCGCATGTGCGTCAATAC
CGAGTGGGGCGCCTTCGGGGACTCCGGCGAGCTGGACGAGTTCCTGCTGG
AGTATGACCGCCTGGTGGACGAGAGCTCTGCAAACCCCGGTCAGCAGCTG
TAAGGATGCCCCCCTCCCCACAACCCAGGCCCTGGGCCGCTCTGGTGCA
GCGGCAGATGGGAGCCGGGCCATTGCAGATAATGGGCTTGTTTTTAAACA
25 ACTCTGGGGAAAAGCAAAGTACAAATCCGTTTCGTAAGCTCCATCCCTTCT
GCTCAGTCATGACCTGCCCCCTGTGAGAGATGAAGGGTTAGTCCCAGTTGT
GATGTGATAAGCCCAGACCTCTTTCCTTCCGACAGGTGATCGTGTCATGCA
GAGGAGGCTCTGAGACGCCCCAGCAAGGTTCTGGGTTTAACCCAACAT
TCCCCAAAGTATGTATTTGGCCACATTCACAGAAAGAATATTAGTCTTTT
30 GTGGAATGCTGCGGGTTGACAGTCACAGCTTGGAACCAACCCACAGAGA
GCTCATCATTAATCATGGCTATCACTTGTTTACCACCTACTGTGCCAGGC
CTATGCTAATTACTTTATTAGCGTCCTCTCTGCCGCTCGCAGGCCTCTAT
TATTATAGGTCAGTAGTATTCGATTTATTAAATTAAATACGGAAGGTCA
TAGATTAAGCAAGAAAGTGCCAGCAACATGGTGCGTGCCTCTGACTGGGC
35 ACTAACCCTCCAAGTCTTAGTTTTCCCAACCATAACTGGCCAATGAACAG

CAGCTCTGGATGCAGCTAAAGGAAGACTGAAGCTGTAGGTCCCGTGCTCG
 GCGCAGGGCCCCCTGCAAGGAAGGTTTCGGAGGGACTGGATGGGGTCTTT
 GAACTATCTGTCTTTCCCTTTACTGCAGTGGGCCCAGGGGCAGGCCAAAG
 TTGCTCCCGTGATTGACTTGAACGTGCACGTTCTAATCCCTGACATTTC
 5 TAAAGCTCTGGCTCATTAACGAGGGAAAGACGTGAACCAGCTGGGGGAGT
 GGGGATCGCAGTGCCCCACGTGGCCGCCTCGTGACCTCAGTGGGGAGCAG
 TGGGGCCGGCTCCCGGCTTCCACCTGCATGAGGGGCCCTCCCTCGTGCCT
 GCTGATGTAATGGACCTGCCCTATGTCCAGGTATGAGAAGCTCATAGGTG
 GCAAGTACATGGGCGAGCTGGTGCGGCTTGTGCTGCTCAGGCTCGTGGAC
 10 GAAAACCTGCTCTTCCACGGGGAGGCCTCCGAGCAGCTGCGCACACGCGG
 AGCCTTCGAGACGCGCTTCGTGTCGCAGGTGGAGAGGTGTGCGGAGGAGG
 AGGGTGGGTGCAAAGGGCAGGGGCTGGGGACGCCCGGGCACTGCAGACTT
 GGTCTCAGGGCGACGCTGAGTCCCAGGCCCGGGGCGCAGGGATGGGAAAC
 TAGGGCCTGGGGCGGGATTCCGGGCGTGGGCGGGGCCCCGGGGCGGGGCAC
 15 AGGGGGCGGGGAGTGGGCGGGGCCCCGAGGCCGGGCGCTGGAGGCGAGGG
 CGGGGCAGGGACGGGTCCAAGGGCAGGAGGCTGGGACAGGACGGGGATGC
 AAAGGGAGGGGCGGGGCCCCGAGACGGGGAGGAGGGGGAGGGCCCAAGGGG
 AGGAGGCGGGGTCCGGACGGGGATGCCAAGAGCAGGGATGGGAGCGAGCC
 TGCGTCCGGGCACTGGTCCCCATCCGTGAGTCCCCTCGGTGCTCCCTGCC
 20 CGCCGTGGCCATCCTCTCACATCACTCACAACCCCAAGGCGCGGCATGGT
 TGACACCCCCACGTTAGGACGGAGACCCTGGGCTTAGTTAGAGGGGGCAG
 TACTAACCAGTCCCTGGCGGAAACGCTTTGGCTGGGTGAGGTGAGCGGGA
 TCGCCCCCATTTCTCCAGAGAGGGGTCCCGGCTCAGCGAGGGAAAGAGGC
 CGCCGCTGGGGGGACGGCTGGCCGGGGCCCCCTCCCTGGAGAACGAGAGGC
 25 CGCCGCTGGAGGGGGATGGACTGTCGGAGCGACACTCAGCGACCGCCCTA
 CCTCCTCCCGCCCCGACGACACGGGCGACCGCAAGCAGATCTACAACA
 TCCTGAGCACGCTGGGGCTGCGACCCTCGACCACCGACTGCGACATCGTG
 CGCCGCGCCTGCGAGAGCGTGTCTACGCGCGCTGCGCACATGTGCTCGGC
 GGGGCTGGCGGGCGTCATCAACCGCATGCGCGAGAGCCGCAGCGAGGACG
 30 TAATGCGCATCACTGTGGGCGTGGATGGCTCCGTGTACAAGCTGCACCCC
 AGGTGAGCCCCGCCCCGCTCTCTCCCTGGTAAAGTGGGGCCCCAAAAGCGC
 GCGCTCCAAGGTTCCCTTGCGGTTCCTCAAGCTCCAAGATTTCTAGTCCTC
 TTCTCGTCCCCCTTGGCCTAGATTTGGGGGAAGGGTCGACTGCGTGACAGG
 GCGCCCCGTAATGAATGTGGAGGATGAGGTGGGAGGAGGGACGGCAGCCC
 35 TGCTTCTCTTCTGCCCAGCTTCAAGGAGCGGTTCCATGCCAGCGTGCGCA

GGCTGACGCCCAGCTGCGAGATCACCTTCATCGAGTCGGAGGAGGGCAGT
 GGCCGGGGCGCGGCCCTGGTCTCGGCGGTGGCCTGTAAGAAGGCCTGTAT
 GCTGGGCCAGTGAGAGCAGTGGCCGCAAGCGCAGGGAGGATGCCACAGCC
 CCACAGCACCCAGGCTCCATGGGGAAGTGCTCCCCACACGTGCTCGCAGC
 5 CTGGCGGGGCAGGAGGCCTGGCCTTGTGAGGACCCAGGCCGCTGCCATA
 CCGCTGGGGAACAGAGCGGGCCTCTTCCCTCAGTTTTTCGGTGGGACAGC
 CCCAGGGCCCTAACGGGGGTGCGGCAGGAGCAGGAACAGAGACTCTGGAA
 GCCCCCACCTTTCTCGCTGGAATCAATTTCCCAGAAGGGAGTTGCTCAC
 TCAGGACTTTGATGCATTTCCACACTGTCAGAGCTGTTGGCCTCGCCTGG
 10 GCCCAGGCTCTGGGAAGGGGTGCCCTCTGGATCCTGCTGTGGCCTCACTT
 CCCTGGGAACTCATCCTGTGTGGGGAGGCAGCTCCAACAGCTTGACCAGA
 CCTAGACCTGGGCCAAAAGGGCAGCCAGGGGCTGCTCATCACCCAGTCCT
 GGCCATTTTCTTGCTGAGGCTCAAGAGGCCAGGGAGCAATGGGAGGGG
 GCTCCATGGAGGAGGTGTCCCAAGCTTTGAATACCCCCAGAGACCTTTTC
 15 TCTCCCATACCATCACTGAGTGGCTTGTGATTCTGGGATGGACCCTCGCA
 GCAGGTGCAAGAGACAGAGCCCCCAAGCCTCTGCCCCAAGGGGGCCACAA
 AGGGGAGAAGGGCCAGCCCTACATCTTCAGCTCCCATAGCGCTGGCTCAG
 GAAGAAACCCCAAGCAGCATTCAGCACACCCCAAGGGACAACCCCATCAT
 ATGACATGCCACCTCTCCATGCCCAACCTAAGATTGTGTGGGTTTTTTA
 20 ATTA AAAATGTTAAAAGTTTTAAACATGGCCTGTCCACTGTTCTTTGACT
 TCTGTGCATTAGGACTGTGGGGACAATCTATAAAGAGTCTGCGTCACATG
 CATGAAGACACTTCAGTATCTCGGCAATGCCCTCCAGACAGCTCCTCCAG
 CCATCTGTGCCAAGGGGAGTGTGAGGAGTGACAGACCAGGCTGTAGGAAC
 AGGAATGGGGTGTGATGGGGGATGGCAGAGCAGTGGACAGTACACTGCCT
 25 GGCCCGGGCCCCCTGCTTGCCCTGCCCATGGAATGTGTGCAGAGGGAGTGCC
 AGGCCAGGTGCTGCTCTGGAGAAGTGGGGGAATGAGGCTGGTCCTGCTGC
 AGGTCAGTCTCAGCACCGTCCTGTCCAGTCAGAGTCACTTAGGTTTGCCA
 GTGAGTAGGGGCCCAGATACATGTTGGATTTCTAAGGTCCCTCCAGATGC
 TCCTGTGAGTGGAACGCCTATTTAGAGTTAGCCAAGCGTAGGCATAATGC
 30 CATCTTTCTGCAGCATAAAATACAGTGACATAGAAACATATTTGTGTGAT
 TTTTCATGCATTCCTTTTTTGATGAGAGATATTACCCAGCTAATTAGGAAC
 AACTGTTTTGTTTCCTTCAGATCATAACCCAAAGTTGTGATTTTGAAAAG
 TCATGTCCCCCTTCAGATTTCTTGTTTTCTGCTACTTCTCATGTGGAATT
 GCTTTGGCTCTTCTTAGTTCTCTTGAGTCTAAATTATTCCTTATAAGTTG
 35 GTGCAAGCATCTGATTATTTTGTTATCATTACTGTTATGCTCAAGCATTC

ACAGAGTGGAACACATTTTAATATCAATTGCTTTCTATTTCTCCTTTATA
 TTACAGTTCAGGACATTGTATTAATTATTAATAATTCTATTCGTAGGTAGG
 TTATATGACTGAATTGAAATAGATAAAATGAATTTCTTTTCTAGATAACA
 AAGGAGGTGTCATAAAACACTTGTTATGGGCCAGTGTGATGGCTCATGCC
 5 TATAATCTCAGTGCTTTGAGAGGCTGAGGTGGAGGATTGCTTGAGGCCAG
 GAATTTGAGACCAGCCTGGGGCAACATAGCAAGACCCCATCTCTTAAAAA
 AAAAAGGGTGGGGCGGGGGGGGCACTGCTGGGCGCGGTGGCTCATGCCTGT
 AATCCCAGCACTTTGGGAAGCCAAAGCAGGTGGATCAAAAGGTCAGGAGT
 TCGAGATCAGCCTGGCCAACATGGTGAAACCCCAACTCTACTAAAAATAC
 10 AAAAATTAGCCGGGCATGATGGCGGGTGCTTATAATCCCAGCTACTCAGG
 AGGCTGAGGCAGAAGAATTGCTTGAACCCAGGAGGCGGAGGTTGCAGTGA
 GCAGAGATTGCACCACTGCACTCCAGCCTGGGCAACAGAGCGAAACTCTG
 TCTCAAAAATGAATTAATTAATTAAGAAAAAGAAAAAAAACACTGGGCA
 GGGTGGTGTGCACCTGTAGTCCCACTACTCCAGAGGCTGAGGCAGGAAG
 15 GAGCACTTGAGCCCAGGAGGTTGTCTGCAGTGAGCTCTACTCATGCCACT
 GCACTCCAGCCTGGGTGACAGAGCTCAGTGGCTTACACCTGTAATCCTAG
 CACTTTGGGAGGCTGAAGCAGGCAGATCACCTAAGATCAGGAGTTCGAGA
 CCGGCTGGCCAACATGATAAAACCCCGTCTTTACTAAAAATAAAATAAAA
 TAAAAATATATATAAAAAATTAGCTGGGTGTGGTGGCACATGCCTATAAT
 20 CCCAGCTGCTTGGGAGGCTGAGGAACAAGAATGGCTTGAACCCGGGAGGC
 AGAGGTGGCAGTGAGCTGAGATCGCGCCACTGCACTCCAGCCTGTGCGAG
 AGTGAGACTCTGTCTCAAAAAAAAAAAGGGAATTTAAGAAATTTAAAAG
 AAAACTCTTGTTATATAAAAAGGGTATTGGGTCTGACAGATAAGAGCTCC
 TGCACTCTACCAGCCAGCTACTGACAGACATAGGTCTGGCTCCAGTGGAG
 25 GGGCAGCAGCCAGTGAGCCCAGCCTGGGGTGGCCCACTCCTGCTGCCTCC
 AGGATGTCCCCTGTTTCCCCAGCCCCTCTGCTGTGCCCTCGGCCCCAGAA
 GCTGGCGAGACTGCTTCTCTGGAACAGCATCACGCAGGCCTGCCCATCGG
 CCCACTGTGCACCAGGCCTTCTGGGGATACAGATGTCAACCAGGTGGGGT
 GCTCAGGAGGGGCACAGAAGCCAGGAATGACAAACACATCAGCCACCAGG
 30 CAAATGGGAAATGTGCCCCAGAAGCTCCCTGCTGAGGATGTTAGGGAGAG
 CATTCTGAAGTAGTGTGGTTGAGATGAGGCTTGAGGAAGGCAAGGCTCCA
 AACAGCAGGGCAGACTGGGAGCAAGGTAGACTGCATGGGAGGGCAGCTGA
 TGGAGCTCCTTAACCCTCTGGAATTGCCCCAAAGCCAAGCAAAGTGTCT
 TCTTGGGGTACAGCTAGCTCAGGGATGCCTTCTGCCCCCTTGGTCAGAGG
 35 GGCAAAAGGTCAGAGCCTAGGGTCACCAAAACCTCTGGGAAGCCCCGGGG

GTCTCAGGCCACAGACCATCCTCAGAACTACACACTGCCCTCCCATGCCT
 GGCGGGGGCCCTGGACTGGCCCTCACCAGCTGTCTTCTTGCACTGGCCAG
 GGTTCCTGGCTGGACTGGCAAGGAGGGGTGGTCAGATACAGGAGTAACTGG
 ATCCCTTCATCAGGACCTAGGGTGGTGAGAGCTTTGAGCCTGCTCTGCTC
 5 CAGGCAGACATTGTGTCTGGCCCTGCCAGGATGGATAGACAGCAGGATGT
 TACACGTTGAGGACATGAAGGTCATCAGGAATGTGGCTGGAATCTGTTAG
 GCCTCCCCCAGCCCAGGCGGGGGCTGCCAAGTTTGGGCCTATCCTCTGTT
 CCTCTCCTTATTTGGACCTTCAGGTGATAAGGCTGAGACATAAAGGAGGC
 TGGGCCCTGCCACCACGACAGCAGCCACACCTCTGCAGAGAGAATGGTGA
 10 GTGCCTGCTGGGGAAGAAAGGCTAGCGGTCTCCCAGGTGCTGGCCTTTGG
 GCTGGGGGAGCAGAGTTTTCTGTGCTTGTGTTGGGTTGAGGGTGGTCCCC
 AGGGAGAGGAAGAGGATCCTGGCCCTGGCTCTCCTGGGAATGCTCTGGGA
 CTGTGCATGATGGGTGGGGTGGGGAGACTCTGAGGAGTTGGGGAGAGGAC
 CCCTCCCTACTCACAGTGTTGCAGGCCAGCAGGAAGGCGGGGACCCGGGG
 15 CAAGGTGGCAGCCACCAAGCAGGCCCAACGTGGTTCTTCCAACGTCTTTT
 CCATGTTTGAACAAGCCCAGATACAGGAGTTCAAAGAAGTGAGTGCCAC
 TCCCAGTAGCCTCAGATCCCATCCTGGCCCCCCCCACCCACCCACATAC
 ATACCCCCCTTCTACCCTGACCTTGCTCTCACACCACCCAGGTCTCTCC
 CCCACCTCCCACCTTCCCTAGAGCTGGGGGCTGCTCCCACCTGAAGGCCC
 20 CCATCCCACAGGCCTTCAGCTGTATCGACCAGAATCGTGATGGCATCATC
 TGCAAGGCAGACCTGAGGGAGACCTACTCCCAGCTGGGTGCGTGACCCCA
 CCTCCCACCCTGCGCACTGGGGTCCCTACTCTGAGCTGCTGGGCGGGTGG
 GAGTGGCTGGGGGGACAGGACTCTGCTCCCCTGCTTCCCCTCCTCCCCGT
 CTCCTCACACTGCCCTTCCCCCTTGTACGCCTTGCTTCCACTTCACCT
 25 TCCCGACCCACAGCTGCCTCTGCCCCCTCCAGCCCCTGTGGCCAGGATGGA
 GGGAGGGCGGCCTGGGCCTTCTGGGGGACACCCAGGGTCCCTGTGTGCAC
 CTCATGCCCCACCCCAACAGGGAAGGTGAGTGTCCCAGAGGAGGAGCTG
 GACGCCATGCTGCAAGAGGGCAAGGGCCCCATCAACTTCACCGTCTTCCT
 CACGCTCTTTGGGGAGAAGCTCAATGGTGAGCCTGGGACAGAGCTGGGCA
 30 CCCTTGGCCAGGCAGGGAGCCTGCACCCTGCCTGAACCCCACTGAACCC
 TGCCTGAACCCCACTGAACCTTACATGAACCCCACTGAACCCCTAACTG
 AACCCCACTGGACCCACCTGGACTCTTCCTGGCCATGACCCATTCCAAG
 CACATCCTCTGCCCCAGAATCCCATGTGCACTGGTCACCCAGTGCTGAC
 TTGGAGCCAGGAAATGTGCCTTCAGCCCCACCCCAAATTCCAGTCTCC
 35 CAGCCAAGCTGCCCCGCTCAGGAGGATGACCATTCCCAGCCCCACTGATC

CCCGAGAAACATTTTATGTTAGGGAATACCCCCACCTCTTCTGGGATGTG
 GGAGGCTCCTCATGCAGCCCAGTTCCTCCTGCGGGGGACCTGGGATGCTG
 GAGACATGGATGCTCACCTGGCTGCCTCGGCCCTCCAGGGACAGACCCCG
 AGGAAGCCATCCTGAGTGCCTTCCGCATGTTTGACCCAGCGGCAAAGGG
 5 GTGGTGAACAAGGATGAGTAAGTATGGGCCCAGCCAGATGAGGAGCACCG
 TGGTGAAGCAGAGAGCGGGGTGAGGCCCTAGTGAGGGGGGCTGCCTGT
 GCTTCGGGGCCTTAACTGCTCTTTGGGGTGCAGCCAACCCTTCCCTGCG
 CCATGGGAGCCTCCGTACCCACCTTCCCTGTGCAGTCACTCCCCCGCAGT
 CTCCTGCTCAGACCCTCCTACCCCCCAGGTTCAAGCAGCTTCTCCTGAC
 10 CCAGGCAGACAAGTTCTCTCCAGCTGAGGTGAGGCTGCCCAGCCCCCTTCA
 ATACTCATCCCCAGCACCTTCTCTGGGCCTTCACCCATGACCCAGAGCCC
 AGTACCAGTGAGGCAGTTGCTGGAAGGGTGAGCCGAGGGCCCTTCTGGAG
 GAGGTGCCATCTCTGTTGAGACCTAGAGGGTAAAGATGTGGAGTCAGAAA
 AGAGGGCAGGGTGCGCCAGGCAGGGAGACTGTGCACAGACCTGGGGGGAA
 15 GTGGATAGGGAGAGGTTTCGTACACTCGGGGTGGGCCTGTGCCTGTGGCT
 GGAGGGGGCGTCCTTTGCCTCTTGGCCCACATTTGCACTGACTCCTCACTC
 TGCCCAGAGTCAGCCAAGAGAAAAACATTAACCCAGAGTCTGGGGTCTAG
 GGTTGAAAAGCTAAGGCAAAAAGCACAGATGCAGGGGGCAGACAGAAAGG
 CCACAGGACTCAGGTGAGGTCTCTGCCGGGCTGGGCCAGGAGCCAGGGGA
 20 CTGCCACTCACCAGTGTCCCCTGCAGGTGGAGCAGATGTTGCCCCGACA
 CCCATGGACCTGGCGGGGAACATCGACTACAAGTCACTGTGCTACATCAT
 CACCCATGGAGACGAGAAAGAGGAATGAGGGGCAGGGCCAGGCCACGGG
 GGGGCACCTCAATAAACTCTGTTGCAAAATTGGAATTGCTGTGGTGTCTT
 GTCTGTGACAGATGGGTTGGGGACCAGCCAAGGGGGATCCCAGGGTCTCA
 25 GTGCGCACATCACCATGATCATGGCCACCATCTACCTCCTGGGAGCTGGC
 CCCTCGCCAGCTCACCTTGATTCACTCCCATGATGCCAAGTGAAGTGTGA
 ACTATGATCATGCCTAGTTTACAGATGAGGACACTGAGGCCCAGAAAGTG
 TGAGCATCTTACCAAGGCCAGCCCTCTAGAAGAGGAGATGGTGGGATTTA
 CACCACCTCCACCAAGCCCAGGAATGAGCCACAAAGTGGGCACTGCCAG
 30 CTACTTGGGGCTGTGCAGAGAAGAGGCTGCTTGCTGGGCACTCAGCAAAC
 TCTGCCCAACAGCCCAGCGGGTGGGCAGCAGCCCTGGGACCCCCACACCC
 AACCACACAGCCTCCCCTGGCCCACTGCTCGCACCCCATCTCAATACT
 GGCTTGGGTGCCTCCCTGCATGGGCCCTTTGTGAAAGGCAGAGAGGTACC
 CATTTGAAACACAACCAGCTTCTCATTGCAAATACAGGCAAGGCACTAAG
 35 ACATGAGGAACATGGACACCAAAGCAGGGGCCAGGTAACATGCAAATTC

TAGAGGAAATGCCCAGAACCTGGCATCATGCCTCCTGAGCCCCTCATGCG
 CCGTGAGGGGTAAAGAGGGTCAGACAGCTGGAGTGTAGGGAGACGACTTCT
 CAGGAGAGAATAGTTAGTGCTCCCGTCACCCCTTCATCTGAGAACCCAAGA
 GCTAGAGGAGAAAGTGATCCTCATGAGTACCAGAGGAGCAGCAGGGGACA
 5 TCCAAAGCACCAGAGAGAGAAACAGAGACAGAGAGACAGGCAGTGACAGC
 TCAAACCTCAGCCAGATCCAGAGCATACAAAGTCTCCTGCCTACAGGACA
 GCCCAGTAAGAGCTCTCAGCTTGCCTCCTTCCCTCCCCACAAGCCCTGCT
 GCAATCCCTGTACCTGGGGGTGAGTGGGAAGGAGGTGAGCGAGAAAGGAG
 GGGCACCCCTTCTGAAGGCCCAAGAGGAAAGGCGTTTTACCCAGACA
 10 GGTGTTTCAGTTTTGATTTTATCTGGCGCCTGGCAATTTAATTACTAAATT
 GAAACTTGAGACTTTCTGGAATTATGGCATTCTGTTGCTTAGAGAGAT
 TACAAAAGTCACGAACTGCCTGAGTTTCCATCCTGAAAGCAGGCCACCAG
 CCCACTCCACTGACCATGCTGGAACAGTGGATGAACAAAATCAAGTACCA
 TTAGGATTCTACCACATGAGTCTGCTTGTTCACAAGCTGATTTCATAAA
 15 GTAAGGGATCATGTTATAATCCAAGCTCTACAGGGGTAAATTGTGAAAGA
 CTAATAATGAACCAAAAAGATCATAGGTGTCCAGTTATCTGATTTGATGGG
 GTGTCTGAACCTTTTGTTATCTTTGAGCTGTTTCAAACTCTCTAAATTA
 TTATTATTATTTTTGAGACAGAGTCTCTCTGTCAACCAGGCTGGAGTG
 CAGTGGCATGATCTCAGCTCACTGCAACCTCCACCTCCCAGGTTCAAGTG
 20 ATTCTCATGCCTCACCCCTCCCAAGTAGCTAGTATTACAGATGGGCACACC
 TTGCCTGGCTAATTTTTGTATTTTAAATAGAGACGTGGTTTCACCATGTT
 AGCCAGGCTGGTCTCGAACTCCTGACCTCCGTTGATCCACCTGCCTCTGC
 CTCCCCAAAGTGCTGGGATTACAGGGGTGAGCCACCGTGCCCTGCCACAAC
 TCTAAATTATAACTAATAGCAAGGCAATGGTTCTTCTCTATTAACGTGCA
 25 AATAAATGTTGTCCAGTGGAAAGCACAACCTGATTTTTCCCTTCTCTGTGGA
 AGAAGCCAATTTTGCATCTATTAAGCAAATTCATCTGGGCATTCCTAACC
 GTCTACACATGCACCGGCTCTTTGAATTCTTCTCTGAACCAGGCCAGGA
 ATAAGCCACAAGATGAGCACTGCCCAGCTCCTTGGGCTGTCACATCTTAT
 TGATTCCCACATGAATTCACAAGTAAATAAAATATTTGGCGGTTGTTAC
 30 TTAGTATGCAAGTCAATATTTTGCTTTAAAAATATTATCCTTTCACTC
 CTGATATAGTTGTCTGATAAGGTTAGTCCTTCCCACACCAAACTGCCTG
 TATTAGTGTGTTTGGGAATAAACTGAGGGTAGAATGTATATGGTGTGTGT
 ATGTGGTGTGTGTGTTTGTGTGTGTGTGTGTGTGAGAGAGAGAGAGAC
 AAAAGAGAGAGACAGAAGGATAGAGAGAAACAGATGGGCACAGACCCAGG
 35 ACATGAGTTCAGCCTACACTGACCAATATGACAGCCACTGGCCACTTGAA

ATGTGGTGTGAGTTGGGATATGCCAAAAGTGTAATGCACACAATATTT
 TGAAGATTTTCATACAAAAAGAATGCAAACATCTCATTAATAACTTTTAT
 ATAGATCACATGTTGAAATGATAATGTTTTGGATATTAGATTATTACTAA
 AATTAATTTTACCTATTTCTTTTCACTTTTTAAATGTGGCTACTAGAATA
 5 TTTAGAATTCCATAAGTGGCTTGCATTTCTGGCTTTCACTCCTGTTGGAA
 AGCACTGAGTTAGACTGTGTAGTACGTCTATTTAAGACTGCAGTTTCCAG
 GCCGAACACCGTGGCTCACGCCTATAATCCCAGCACTTTGGGAGGCCGAG
 GCGGGCAGATCACCTGAGGTCAGGAGTTTGAGATAAGCCTGGCTAACGTG
 GTGAAACCCTGTCTCTACTAAAAATACAGAAATTAGCCAGGTGTGGTAGT
 10 GCATGCCTGTAGTCCCAGCTACTAGGGAGGCTGAGGCAGGAGAATCTCTT
 GAACCCAGAAGGGGAGGTTGCAGTGAGCCAAGATCAAGCCACTGCACTCC
 AGCCTAGATGACAGAGCAAGACTCCATCTCAAAAAAAAAAAAAAGTAGAATA
 AAAATAAATAAATAAATAAAGACTGCAGTTTCTGGGAGACTCTGAGGCAG
 GCATTAGCCTTCTCTGCAGAGAGTACTTGCAGCAGGGAGCAGCAGTTTTG
 15 ATGTCCTCAAAGGAGCCAATTTCAATTTGGGTAGGGTTGCCTCTGAGTAT
 TCTAGCAGTACAGACAGAAAGGAGAGAAGGCTGTTTCCAGAAAGCAGAGA
 TCATACGAATTACTTGTGAGACCAAACCTTGTTCCTCAGGTGAAGCTCAGG
 CATCCCTTATGTGGAGTGTCTAACAGTCTACACCTGAGGATGTTGGACAT
 AAGGGGGTGTGAGGTGGGCATGGCTGGGGAGAGCTCTGGGAGGGGGAAAA
 20 CCAGCTCCATGTTGTCCACCCACTGAAAGGAAAGCTCCCTCTGGGGGAGG
 TAGATGCCCCCTGGCCAGGCCTGCAGGGCCCTGCTCACTGTGAGCCCTGT
 GTGGTCTTGGCCTGGGTCCCACCAGCCATTGCCAGGCAACAGCTCCCAGT
 TGGAAAACAGAGCAAGGCTCCCTCTTAGAAAAAAAAAAAAAGAAAGAAAGA
 AAAGAAAAGAAATACAACAGGTAATAAGCATGACGGCTCACGCCTGAAA
 25 TCCCAGCTACTTGGGAGGCCAAGGCAGAGGATTGCTTGAGACTGGGAGGT
 TGAGGCAGCAGTGAGCCAGGATTCTGCAATTGCACTCCAGCCTGGGTGAC
 AAAGTGAGACCCTAGTAAAAAAAAAAAAAAAAATAGAGACAGAGAAAGAAAGA
 CATGCAACAGGGCCAGGCGCAGTGACTCATACCTGTGATCCCAACACTTT
 GGGAGGCAGAGAAGGGAGGATTGCTTAAGACCAGGAGTGCAAGACCAACC
 30 TGGGCAACATGGCAAAAACCCATCTCTTCAAAAAATAAAAAAATTAGCCT
 GTTGTGGTGGTGCGCACCTATAGTCCCAGATATTCAGGGAGCTTGAACCA
 GGTCCAGGCTGCAGTAAGCCATGATCGTGCCACTGCACTCCAGCCTGGGT
 GACAGAGCGAGACCTTGTGAGAAAGAAAAGAAAGGAAGGAAGGAAG
 GAGGGAAGGAGGGAAGGAGGGAGGAAGGGAGGAAGGAAGAATATAGGACC
 35 CAAAGGCCTAAATGCCCCTACTGTGCCCCAGTTCTGCGTGACTCAGGACC

AGCCTCCTCCACACTCCCACCACCACAACCCTGCACCCTACTTGTTCCTG
 GGGGCCCCAAGGGGAGCCTCACCAGAAGCCTCCTCATAAACCCACTGCCC
 CTTACCTTTTCTGTCTTTCTAGAAAGCCTCAGAAGCCTTGCCACTCTAAGG
 ACACCTCCATCTGAGCCAAGGCGCTCGCTCCAGATGTCCCAGAGCTCCTG
 5 GTCTGGGTGTCCCTGCCACACAACCCCCCATGGAGCCCTGCTCTGGCTC
 AAGCCCCCTGACTGTGCATGAGCAGGCCTGTTGCCCTCACTGGGACTGTC
 CAGAGCCTTCCCATCTCTCTGGAGGGACTTCCATCAGTTTCTGCCCCTTC
 TCCTCTGCCAAGAACTCACGTTTCACTGTGATAGCAGAAGAATCATCTGGC
 ACCCTCCTGAATGGAACCCAGAGTACCTCCTTTGTGGACCGGTCTCTGGA
 10 TTTTCCCCACTCTCTCCCTTACAGCCATGCTGATGGCAGAGAAGGTAAGAA
 CTTCCAGCCCACTTCTCTGGCGAGGGGAAGTTGTCATCTGGGTCTGCAGA
 GAAGGTTCCACCTTATGCTCATAGTACATTATCTTTACTATGTACTAGGA
 TATCACATTTAAAAGGACAAAAAAGGCCAGGCAGTGGCTCATGCTTGTA
 TCCTAGCACTTTGGGAGGCTGAGGCAGGTGGATTACCTGAGGCCAGGAGT
 15 TCAAGACCAGCCTGACCAACATGGCGAAACCCCATCTCTATTAATAATAC
 AAAAATTAGCTGGGTGTCTGTCGTCGTCATGTGCCTACAATCCCACTACTTGGG
 AGGCTGAAGCAAGAGAATCACTTGAACCCAGGAGGCAGAGGATGCAGTGA
 GCTGAGATCGTGCCACTGCACACCAGCCTGGGCGACAAACCGAGACTCCA
 TCTCAAAAAATAATAATAATAATAACAACAAAATAAAAGAACAAAAAAA
 20 AAGAAATGTAAAATACTTGAAGGGGCTTGTATAACATTAATAGGATTGAC
 AGTATCTGCTTTCCAGGCTGAAGTGATTCAATTCATTATTCTAGACGTCTT
 TAGTCCTTTGCAATTTGTGGTAATTAGGCTTTTCTTTTAAACATTAAAAA
 TATACAAAAATAAAAGGCCAAAAAAGCATCATCCCATTAGTCTGACCTTC
 CCTCCTCCATCCCTGCCCCAACACCCTGAAGACCCTGGATGCAAACAAA
 25 GGCCCGAGGGAGCCTCTTCCCTCGCAGTGCAGGCCTCACCTGGGGCTCAG
 AGTCAGAATCTGCATTTTATTCCCTAGGACAACCTCTAGTCAGGGCAGAG
 GCCGGCTGTGCTGCCAAGTGCCCTAACCTAGCTTTGAGGCACCAGAAG
 GGCAAATGCAAATTAAAAATGAGAATAAGTTTATTCTCCTTGGTGAAAAA
 AAAAAAAAAGACTTTCCCTCTCCTTTTCTTTAGAAAATCTATCATTG
 30 CAAGTTCCCTCCTGGACTTTTTTTATGTAGATCTGTTCAAAGCTAAATA
 AGCCTCTTTCAAGTTTCACATCCCAGGAATGTCTCCTTAAGGACCTAGGA
 GCCACCATTTGAAGTGTAATCACCAAGGGAGATACATCCTTATCTCCCAG
 TTTCCGTGGGCAAAGGGGAGCCTAACTTTAGCCCGGTGCCTAGCTCAAGT
 TGCAAACACACTTCCAGTCTTAAAGGAATGAATTTATTTTTTTTCCTTTA
 35 GGCAAACCCAGGTAGCCACCACAGTTACCTGGGGATTACAGAGAACTGT

GTGTGACCACTGGTGCTGTCAAGTCCTCTTACCTGAGCACCTGTGACGTT
TCCCTTGAGAACGTGTACGGGATGGGTTGCACCTGGTTATATACAAGCGT
GAGACTTCTTTCTGCCTTTGTAATTTATTAGCAGATTATCTGTGATGAGC
ATCGCAATCTGTTTAATGCCTATTCAATAATTAAATTTTTCTTTCTCTTC
TTTTGTGGAAGGTTTTCTGCATTGGCAGGAGATTTTTGTTTTCGATTAT
GTCCCCAACATGCCTGATGTTCCACCCCTCAAGAGCCTCAGCCTTGCCCA
GGGAGGGCATGGGGGTGAGTGGCCTCTCCACAGAGAGTGCTGGCCAAGT
TGGCCCAGGTGCGCAGCAAGGGCTGCTGCCCAAAGGCTCCCTCCTGGTTG

10

The human liver glucokinase genomic DNA is 46,000 base pairs in length and contains ten exons (see Table 2 below for location of exons).

15 The human adipocyte enhancer binding protein has the amino acid sequence depicted in SEQ ID
NO:3:

[illegible]

35 and is encoded by the genomic DNA sequence shown in SEQ ID NO:7:

CAGCAGGGCCAAGGTCTTGTGACAATGTCTGGAGGTGCCCCTATTGTCACACTGGGGGTCTCC
 TACTGGCCTGCAATGGGAGGAGGGGCTGCAGCCCCACATCCTGTGCAGAGTGCTAGTGCTGA
 GGCGGAACCCTCCTCAGAGCTGCCCCTTCTCCTCCAGGTTGTTACCCCTTCTACAAAAGTACC
 5 CGTTCATCTTCCCAGAGTGCCCGCATGTCTACTTTTGTGGCAACACCCCCAGCTTTGGCTC
 CAAAATCATCCGAGGTAATTTTTGTCTTCTGGGGGCCAGGCTGATTTGCTGATTTGCTCTCAC
 CTGGGGACAAGGTTACAGAGAAGAAAACCTGCATTGTGGAGTCCCCCTGGCCCTTGTGGGA
 TGGACAGCTGAGGTCTTCTGCACAGCTGCCATTTCACTGTGGGAGCCAAGCTGCCTCGCCAGC
 TGGGCAGGGACTGGAACGGCTCCCAGCCTGTGTGCCTCTCAAGGCTAATCTCTGGTCTCCT
 10 ATTGTCACTGCCCCACTGTGTGCCAATGGGGACTCCTGTTTATTTCTGGCAGCTTCTCTTTGAG
 GCAGGACTTACTTGGAACCTACAGTGGGTCTATGTGACTTCTTTGCAGGTCCTGAGGACCAG
 ACAGTGCTGTTGGTGACTGTCCCTGACTTCAGTGCCACGCAGACCGCCTGCCTTGTGAACCTG
 CGCAGCCTGGCCTGCCAGCCCATCAGCTTCTCGGGCTTCGGGGCAGAGGACGATGACCTG
 GGAGGCCTGGGGCTGGGGCCCTGACTCAAAAAAGTGGTTTTGACCAGAGAGGCCCAGATGGA
 15 GGCTGTTCAATCCCTGCAGTGTCGGCATTGTAAATAAAGCCTGAGCACTTGCTGATGCGAGCC
 TTGAGCCCTGGGCACTCTGGCTATGGGACTCCTGCAGGGGTGCCACAGTGACCATAGCCCAT
 GCACCCACCAGCCGGTCTCCCTCCTCCCCATCCCTGACACCTCAGAATGTGAGCAGTCCGTGC
 CATGAGCTTGTTTTATTGGAGTGACCTTGGCTCCCTCCCTCTGCCCCCTACTCCAACACTGCAGC
 AACCCCATCTCTTACGAGACTGGCAGGTGGAGCAGGAGCCTCTACACAGCCTCTGGCTCTTAG
 20 GTCCCAGTCATGTTTGCACCCCCTCAAAGGGGCAGGACCAGCCCTTCCTTTCAAGTGTCATAC
 CAGGGGCCTTCCATGTGCTGATGGGTGATGTGACTGTGGTCAGCAGGCTTGGGAAGTGC
 TGCTGCTGTAGCTTGAGTTGGGCTGGGGTCTTGGTAGGACGCTGATCTCAGAAGTCCCCAAAG
 TTCACTGTGTAGGTCTCTACTGTTGTGAAGGGGAATGCCTGGCCAGTGGCTATCTCCTCCTCTT
 TCTCCTCCTCCTCCTCTTCTCAAACCTCGGGTTCAGCTGGGTCTCGAACTCAGGCTCCAACTG
 25 GGTCTCAAACCTCGGGCTCCACCTTGGTCCCAAACCTCGGGCTCCACCTCGGTCCCAAACCT
 CTGTCACCACCTCTGTGTAGGTCTCAGTCTCCGACTCCTCCCAGCCAGCGGTGGTTGGCGGTAT
 GAGGCCCCAGGGCTCTATGGTAGTGCTCAGGGTGGTGGCAGGGGCAGGGGGCAGCGTGGGAG
 GCACAGTGTTGGGGGCCTAGGGTGGTGGTGGCGTTGAGGCGCCGCAGCCGCATCTGTGCCCCGA
 AGCCGCAGGCGGTGTTGTAGGCGTCGCTGCTGCAGGCGTCGCTGTTGGGGGGTCATAGGGCG
 30 CGATGGGTCTATGTGTGGGATAGGCCGGTTCCTCGTTTCATGGCCATGATCTCCCGGATGCGCTT
 CCAGTTGGAGCGAGCCAGGATGAAGTTGCACTGAGTGGCCCCGATGTCATAGTCAACATTGC
 AGGTCTTGGCGCTCGGGGTGTAGCCCTCCGCGTGGGCTGTACGCGGTACTACCCGGGTTC
 AGATTGCCAGTAATCACCACCACTGGCTGCGGAGGGAGAACGATCCGGCTGCCCCAGAGCG
 CCCCTCCCAGGCCCCCACCCTCCCCTCAGTCTGCCCCAGCCCCGCCCTCCCCCTCTGAGTT
 35 CCGCCCCCAGCACCGCCCTCCCTCTCTGAATTCGCCCCCAGGCTCCCCAGACTCTACCTGCT

CGCTGAGTTCCTCAAGCCCCACCCTCTCTGGCGGGTCCTCCCTCAGAAAGATGGGGTAAAGG
 TGTGCACACTAGGTACCTGTCTTCACGCCGTGATTAATGCCACTCACAGAGATGGTGGCGTTG
 GCAATGGGGATGCCTTGCTCGTCCGTACCAACCCCTTAATGCCGCGGTGCACCTAGGGAAGC
 AGGTGAGGGCTGCTGGTCCTCAGGAAGGTCCAATGTGGTCCGCTGCTCCCTCCCGCCCATCCA
 5 GGAGCCTGTGCAGCCTCCTCTCCCCAGGCATTGCCCTAGCCACCCCACCTGCTCCATGAAGGT
 GAGCAGCGCCTCCTTGTTGTTCTCCCACTCGCGGGGCAGCTCACTCTCATGAGGGAACTTGTC
 ACAGCCCAGGTAGAAGGAGAGCTCCAGGCAGTTGGTATGCAGGTAAGTGAAGTCATTGATAG
 CTGGCCGGGGACAGATACAGACCCAAAGTCAGCCCTCTCCGGACCAGGCCCGCCACAGC
 CCTCCCAGGCTGACTCACTCCCGGTCCGGGGGTTCCACTTGCCCCGTTGACGATGCCCATG
 10 CCGCCGGTGTAGTCCTGGGCTTGCGAGCCTCCGCGGTAGGGCTCGGTCAAGGTGAGGTGTGCG
 GAGGCGAAGGAGATGGCAAGCCACCGGAAGATGGCGTGGTCTGGAGTCTCTGGGCCTCGGA
 GACCTCGTCCTCATCCTCCCCCGGGCTGCTGCCATGGCTGCGGCCAGCAGCTGCTCCTGGGT
 AGGCGTGCGGGCCATATCGTAGGGGTAGGATACTAGCCGCTCGCCGCCGTTTCAATTTGCTCC
 CAGCACGAAGGGGTTCTTCTCCATCCAGGCAATGATGGCCCGGACCTCCGTGGATACCTGGAG
 15 TGGCCAGCACGTGTGAGGCCAGGGCTGCAGCTCCGGCCACTATCCCCAACCTAGCCCGATCAC
 CCTCCATGAAGCTTCACACCAGTACTCGCACGATCCCCTGTCCCCCAACCCCCAGAGCCTCAG
 CGTCTGGAGTTCAGGCACCGTCAGCCCCACCCCAAGCCAGAACACCAGGACCCAGGGTC
 CAGCTGCTCCCTCCTGCCCTTTCAGCCAGGCTGTAGCCTCACCGTGGCATCTGGCGAAAGGTA
 GCGTTCAGGGATGGGCAAGTTATTGTTGGGGACCCGGTAGGGGACCCATTTCTCTCCTCAGC
 20 TCCCCAGAGCACAGAGTTGAGATCCGGGAAATCTTCAAAGATGTCAAAGCCCTCCTCAGTCCA
 CAGTCCCAGCGCCAGTTCCCAAACCTCTGAGCCCTGTGGGGAGCCAGCAGGGTAGGCATCGG
 CTACCCACACCCCCACAACCCCCAGCTGCCTGGACCCTGGCCAGCCTCACCTTCAACCCACC
 ATCTGCGCTGCCACCTCGTAGCCATCAGGGTTCAGTGAGGGCACCAGGTGGATGCGTGTGTCC
 TGCACCAGGCTGCGCACACGTGGGTTCCCATCGCGGTACTCTCGGCACAGGTACTGCATGAGC
 25 AGCAGCAACAGCTCTCGGCCAGCACCTCGTTGCCATGGATCCCAGCAGTGATAGCGGAACTCG
 GGCTCCCCTGCAAGGGCGGGAGCCTCAGTGAGCACTCAGTCTCCCGAGGCCAGGGCAGCTG
 AGGAAGGACCCAGACCCACCTCATAACCGAGGGTCTGGGGGACAGCTGGGGCTCCTAGGGCC
 CTGTAAGACAAGCCAGAATCCCCAGAGAGGCTCCGGAACAGGCGGGAGGCAGTGAGCTCTGC
 ACATCAGCAGCAGAGGCCAGCTGCTGGCCCCACAGACCCTCCCCAGTTTATGCTCCCCAGG
 30 GTTGTCTGAGATCTCCATGGCATAGATCTTGAGGCCTCGTGAGCTCTTGCCCAGGCTGTAAGT
 GCGGGTGATGGTGGGGCACTCCTCGTTCACCACCTTCATGAGCTGGCGCAGAGGGGGAGGAC
 GTGGAATCAATCATGCAATCCGTCCCCCGCTGACCATGCCCCCTTCCACTTCCAGGGCCTGCTCT
 ATGGCGAGGGACGGGCATGACCCCTTACGCAGCCCCCAGGTACTGGCCTCCTTCTAAGGTG
 AGGGACAGCCAGCATCCCTGGAACCAAGTAGGGACTGGGCCAGTGACAGAAGCACCAGGCAC
 35 AACTCCCGTCAGCCACAGACAGGTCCCACCCCCAGCCCCAGGATATATGCTCCCAACCTGGC

GCATGTCCTTGTAGCTGTGGTGCCGGAATCCAGGTCATCGGTGGCCACCACCTCATTCTGTG
CGTAGTAGCTGTAGACAGCTGCAAGGGAGGCGGGGTTGTCTTTAGCTGGGTGCCGGCTGGCCC
ACCCTAGCACCCACCTCCACTCAGAGCCCCTGCCAGCCCTCCACACTCACGGGGCCACAGAGC
ACCCACAGCACCTCCAGGCGCATGCACAGGCTGCCATTCCAGGTGAGTGGGTAGATGCGGATG
5 AAACGAGCCACCACCGGCTCTGGGAGCTCACTCAGCACGGGTGTGTCTTGTCCACGTTCCCA
TGAAAGGTCTGGGGAGAGGCAGGCCTCAGAGCAGTACTGCCAGCCCCCTCTGAGAGCCCACCC
CTCGCCCAGACAATGGGAGCAGAGCCAAGAGCCTGGGCATGGTGCCCAACATTTCTCATAG
CCGTTGGTGTACATACCCATGTCTGGCTGTCAATTGCTGAAGCCCACGAAGAAGGTGGTCACA
AAATCGTCACTGTGGAGTGGACAGTGGTCAGAGCAAGGGTCTTCCCCCTCCCAGGCCCTCAGG
10 TGGCCTGAGCCTCCCTCTTCCGAGCCCCAAGAATTTAAGAGCTAGCAGGGTGGTGCTGCACG
GCCCAGGTGTTGAGCCTGGGTCCTATGCCCCGTACATAGCCATGGGCAGGTGATCTGTCCCTA
AACTCATGTGCTATCAGGACACAGGGGCTGACTGACCAGGCTGAGGAGTGGGGATGGGCAGG
GTGAGTCCCTCACTGATCTTTTTGGCCTTCTTTGGCTGGGCCAAAGAAGGGCCCACTGGAATCT
CCTTAATGGGACACAGAGCCATGCCTATGTAGCCACTCCCCTCTGCCAACTATCCATGAGC
15 CTGGCCACGCACTGGATGCTGGAGTCTCTGCCCTGGGTGATGACGCCTGTGAACCGGGTAGTC
CTCCTGGTGTCCACCTCTATCCACTGGGTCCTGGCATCGTCCTCGGCACACCACGCACCATCAT
AGTAGTCGTCTCAGTGGCACCGGTCTGTCCAGGGGGCAGGGGAGGCTGAGCATGGGCGGAG
GAGTCCCTTATCCCAGTTGGGAGATGGGCCCATCCCAATGCCACCTGCATGTTGAGCCGG
CCGCGCTGTGCCCCCAGGCCGTGGCGCAGCATGGAGGAGGCTCGGATCTGGTTGTCCTCAATA
20 CGGTGTGACTCCATCCCAATGGGGGGACACTCTGAGGACGCGTACCCACAGAATGGTGGCTCA
CTAGCTCCATCCTTCCCTCCACCAAACCCAGAACCAAGGAGCCCAGAGCCCACTCCCGGCACA
TCGGGGGCACAGTCAGAGGGCAGCTCTGGTCAGCTGGTGGCTCCCTGGTGCCCTGCACCAGC
CCACCTGGAATCGACTCAAAGCCAGGCCAGGAGCTGTTTCCAATCCCAGCCTGTGCTTCCCTT
CCCTGGGCCTCAGCTGCCCCATCTGGAGAACGGGCTGACCATGCCCAGCTCTCAGGGGACACA
25 CGTGAAATCACAGGTAGAGCTCCCCCAGGGCGCAGCCACAGATGTCATCCAGATGGGGACCG
TCTGCACAATGGCCCTGCAGGGATACCTGTGAAGGTACCTGAGGTCTCACTCCCCACCAAGG
CCCCAGGTCTCCCCCTACCACGCCCAGCCACTAGGGGCCCTGGGGAGCTGCCACCCTCCTGA
AGCAGGCCAGCCTGGGGTCCAGGGCTGGGGCAGCCAAGCGAGGCTATCCTGGGCTCCCGGGG
CCCCTCCCTTCTGGGTCCCAAGAATCTGAGTAGGAAAGGGTTCCGGGGACCTGGGTCTCTGTTT
30 GTGACATTGGGCCAGTCACTTGTCCCAGCACCCCCATCCTGTGGCCCCCACCCTCACCCCTTG
TGCCCCCACTTACTGACTTTTCTCCGTAGGCGTCCACTCCTCCTCCAACCTCCTCGCCCTTTCGG
GGCTCTAGGGACAATGAAGGGAGGACATGGCACCAAGGGCCCGGGAGGCAATCAGGAGTCC
AGATGCTGCCCCACAGGGACCCAGGCCCAAGCCCCAGCCACACACCTTTGTGGTCTTGGCC
TTCTCCACTGCCCCACTTGTCTGGTCTCCTCCTTGGGGCTGCTGTCTCTCTTTTGGGTTTCTCTGG
35 AAGGTGCAAGGTAGGAGGGGCCAGTCAGCCTGGCTCTGGGCTTTGAGGACCATGTGGGGTGG

ATCAGGCAGGCCCCAGGTGGCCTTCAGGGCAGGCCTGGTGTGGGAAGTCCTTGGTCCCCTCA
 CTCAGCTCCTCCTTCTCTTCGTCCGTCTGGCGCTCAGCATCGGGCTTCTGGGGCGGAGGAGGCC
 CAAAGTAATAGTCCACTATGGGGAGGGAGAGCCAGCTGAGGCTGCCCTGACCCTGCTGCGGG
 GCCTCAGCTCCTGGGTCCACAGGAGCTCAGCAGGACAGGACCGCGCCAGAGGGGAGGAGGAC
 5 GGGAGATGGGGGACAGCTGAGTTGGGAGAGGGTCTTGCAGGAGTCAGGAGCAGCCCGAGCTC
 AGGGGCAGCTGAGCAAGACCCTGCTGAAGTCACCAGCCCGGCCTTCCAGGAGCATCTGGCCT
 GGGGAAAGGACTCGAGGCCCAGGGCATGGGAAAGGCCTGGAGGGACAACCTGGCACCTGTGC
 CTGGGGTTGCGGGCTGGGGGGTGAGATGGGGAGACATTGGAGGCACTGATGGGGACCTGGGG
 GCAGGGAAATGGCGATGCACGGGCTGCCACCCAGGAGGAAAGGGAACCTGAGGGCTCCAGG
 10 GACGCAGGGGCATGAGCAACAGGGAGGCAAAAGCCCTCGGGCTCCCTGAAGAGAGTGGGGC
 AGTGGCCACGAGCCAGCGGGAAGCCAGTTAGAGCACAGGACTGGGAGGGCTGGAACCCACA
 TGGGTGACAGGGCAGAGTGTGTGCCTAGGGACACCCCTGTGGGGGTACAGCCAAGCAGGAA
 CCAGGGAAGCGGCCAAGGAAAGACCAGCCTGAGGGCAGAGGAGACAGGGCAGTGGCTGGGG
 TGGGCACGCAGGGACAGCAGGGACAGCGAGGTAACCACGGGCACAGGTGGGGTTGCAAGGT
 15 GGGTGAGTTGCCCCAGCTGGCTCCTGACCACACCCAGCCCCGACCCCCACCTGCCTATGTCC
 CTCAGACTCTGGGGTGCTGGGTACTCACTGTCATCGTAGTTGGGGATCACGTAACCATCACCA
 TAGTCAGGGGGCAGCGGGGGCAGCAGAGGCTTCACAGGAGGCTCTGGGGAGGCGGGGAGGT
 TAGGAGGGGGCCAGAGCGCCGTGGCCATGGCACCTCCTCTCCTGCCCCCATCCTACCAATCC
 TCTCCTCCGGGGCTGGGGCCGGGGCCTTCTCCTCAGGGGGCTCTGGCCAGACCCGCTCGGGCC
 20 TCCTCCTTCTGCTTGGGGGTGGCCTGGGTGCTTCTGGCGCCGAATGTACTCAACTGAGGGGG
 AGGCTGGCTCAGAGTGGGGCCCAAGGCTGGGATGGGCCCATTGGCACATCCCCCAGGCCAGG
 GGTCCGACCCAGGTGGGGCTGGCAGGACCCTACTCAAAGTCCTCATAGTCCTCCCTCTCGATC
 TGGTCATTGTAGTCCAGTGTGGGTGCTCGGTCTCCTCCTCCGGCTCTGAGGGGAAAGCGCTG
 GTAGCTGCCTGACAACCCACCCAGGCCTACTCTGGGGAAGCCCTCAGTCCAACCAGCCAGG
 25 GCAGCTGGCCCCAAGGCCAGGCGGATGACGGCCACTACCAGGCTGGTGTCTCTGTGCCTCCA
 CATGGGTCTCCTCTCCTGGATTCTGCCAGTTATTTGAGAGGGGCGCCCCTGCAACACAGGAGT
 TCCAGAAGCAGGTGGGCGGGAGGCCTGCTCTGACCACCTTGGGAGCCTCAGGCCACCAGCCA
 CCCATAGAGCCCACACAGAGCCTGTGGACACCCTCCTGAGGCCGAGCTCACTCCAAGGAGGC
 CTGAGCTCCTCTGGCCTTCAGCATCCTGCTGGCATCTCATGGGGCCAGAGAGCTGGGCCCACC
 30 TTCTGGGGAACCTACTGTGCTGCTGGAGGCCCTACCACAAAGCTGTCCCCAGCGGGAGAAGG
 CAGGAGGGAACTCCATGGGCTCAGAGCCCAGGGACATCTGGGCAGGGGCCTGAGGGACAGA
 GGTCCCACCCAAAAGGCTGCCAAGCCCTCTCCCTACCCAAAAGAGGCTACAGCACTGAGGGA
 GCCCACCAATCAAATTGTGAAATTTATAGCAAAAGTGAGGTTCCCATCCAGTGGGGAGCTGA
 AGGTCTATAGGAAGCAGGGCCCCAGAAACCTGCCTCCCACTCCCTGCCTCCACCCGAGCAGGC
 35 AGTCAGAGCCCCATCACCCAGAGGAGCCCGGCACAAACCTCCCTCCTGGGGTAGCTCCTCGG

GGCCAGGGCTGGGGGGTGGGGGCAGTGGCCACTCCAGGGTTTCTGAGGGAGCCAGAATGGGG
GGCCTCTTCCCTGACGGGGGCTTCTTGGTGGCCTTGGGTGGCTTCTCTTTGGGCTTCTTGGTGG
CCTTGGGTGGCTCCTCCTTGGGCTTCTTGGTGGCCTTAGGTGGCTTCTCCTTGGGCTTCTTGGT
GGCCTTGGGTGGCTTCTCCTTCCCCCTTCTTGGGCGGCCTGGGGGACCCCTCCAAGGACTCCTTG
5 GGCACCTTGGGGCCTTTGTCTTTCTTGCCTTTCTTCCCTTTGTCTTTGGTCTTTTCCGGAGGCAC
TGTCGAAGATGCAGACTCGTGTCAAATGAACAGAGCCAGCTCTGTGCCCCCATGAGGCCCTC
TCTAGATGCCCAGAACCTGGGCACAGGGACTCTTGTCAAGTCCCAAGTGCAGGATCAGCAAAGT
AGAGGTTAAGTCATTTGCCCAAGTGGCAAAGTGGGATCCGGACCCAGATTTTCTGTCTGCAAG
TCTGGGGCTGTGACCACCAATCTCAACCTCTCTAAAGACTGAGCGTAGGGTCCCAAGTCCCA
10 GGGGAGGCCCTCATCCCCCACCTGCCAAAACCTCAATAGGGGTTCTTACTATCCACTCCT
CCACTATTCTGTTCTGGGCACAGAAGGGGCAGAGAGGTGACTGAGCCATCCAGGCCTGGAGG
AGCATCTGGTCATCCCTGCCAACTGCCATACAAAGGAAGGGACATGGGCCCAAGACCTTCCCC
TGGTCTCCTACGGGGCAAGAAAAGCTTCAAAGAAAAGGGACACTTGGTTGAGTATTGAAGCC
CAAAGAAGAGGAAGTGGTCTCCTTTCGAGAAGTAAGGGGTTTGGAATTGATTGGAAGGATAG
15 GGAGTCCTGGGGGGTTCAAGGATCACACAGAGGACAGAAAAGACAGGTAGGGAGCTTGTGG
CTGCACACTCATTTCAAGTCTGGGAGAGGGAGCAGGGACTGGTTGTGAGGATTCCCCATGG
GAATCCTCCCAGGACCCTAAGCAGGAGCTGCAAGTGTCTGTTGAGAACCTGATGAGAGGTGGG
GAGCATGAGGGAAGTTTGGCAGAAACACAGGAAAGCTACCAAATGCAGACAGCCAGGGGAC
GCAGGGCTGCTAGAGCGGTGCCCCAGAGCCAGGAGAGCAAGCCTGGAAGGAGAGCCAGAGG
20 CAGGAGGGGCACAGGCAGCCCAGGGTGTGGGAAGCAGCCAGGAAAGATCTAGAGCTGGGGT
GGCAGGGGAGGGGCTGCTGACATCAGGAATGTTGGATGGTGCCTTGGAATCTCCTGGGAGAC
AGGGATCACAAGACCCTCTGCCACCTTCCAGAGGGCCACGATGAAAACAGCTAAGATTTACT
GACAACTGATTATGCAAGAGGCCGTGGGTAAATGCTTCAGTGATGCATCACCTCATCTAATT
TCCTGTACTAATGTAGGACCACCCATTGCTCACCACCACCTGAAGCCCTGTGCTCACCACCAC
25 CTGAAACTCTCTACCTACGTGAGACCTCCTGGAGTAGGAGGGCAAAGGCAGGAGGGAGGGA
CGACGTGAAGCTGTGCCACCAACAGGGAGAGTGGTCCCATTAGTATGGCAGGGGGTGACACA
GCACAGTCCCCTGTGGCTCAAGCCTAGTACCTGTGCGTACTGGAGGAATGGGGATAAGCGA
CCCGTACAACCACAGCACCAACCCTAGAGCCACCGGCCCCCAAAGCGGCCCTGCCGCCGG
GTGCTGGATGTGCCTCCACGCCAGCGCTGACCTCGGCCTAGCACAGGGTCCCTCCAGGCATCT
30 GGGCTCGCGTGCGCATTAGTAAGCCAGCCATTCTCCCTAGCAGACTGGGGAGTGGCCAGAC
CCTACCGAATCCCCCTGTTCCACCTGAGATGCCAGCCCCCACACCCCCGCCCTGCCCTGGG
CTTTACCTTCTGCGGCCGTCCCTGGCCGCTTCCCTGGCTTGCCCCCGCCTGGGCTTTTCGGA
CCCGCGGGGTGGGCTCGGGAGGCGGCGGGGCTCCACGTCGTCCTCCCGGGGCTCAGGTTCTA
GCTCTGACAGGAAGCCCTCGAGGAACTCCTCGATCTCGTCGTCGGTCAGCACCGTCTGCGGGC
35 GCCCTCCAGGGCACAGGGCCAGCAACGCCAGGAGGCAGCTGAGCAGGGGCGCCCCGCGCAC

GGCCGCCATGGCCGCGGCACGCGCGGGGGGCTCCGGGGAGGGCGCGGGGGGTACAGGGGCTCT
GGGTCTCTGGGAAAGGGCGGAGAGGGGATCGAGACGGGTGAGGGAATCCAGGAAGGGGCGG
GAGAGAGGATGGGGTGAGCGAGGGAATCCGGGAAAGGGAGGGAGAGTGGATTAGGGTGGGC
GAGGGGACCCGGGAAGGGGTGCTGGGGGGCTCCGAAGCCAGAGGGGCTCAGGGGTGGTCGG
5 GCGCTCCGAGGTCTGGCGGCTAATAGGCGCTCCGGCCCCGCGTGGCGCACTCCCGCGCGGAT
AGCCGTCTCCAAAGCGCTGGCGGGGCCCCGGGGCGGGGGCGCCGGGGCTTCCGGAGCCGGCTC
CCCCCCCCGGGGAGGAGGAGGAGGAAGAGAAGGAGGAGCCGAGAGTGGACGGAGGGGCTG
CGGGGGGGCGGGGGGCGGGGGGCGGGGGGCTAGGGGCGGGGCAGGCGGGGCGGGCGCTGGCG
GCGAGCGTCCCAAGCCCGGAGACTTGCGCCTAGGACAGAGGGGCAGGGGGCGGGGCGACTG
10 GGAAGACAGAGGGCCTGAGGGAAGGAAAGGTGGTGGGGAGGGCCTGGGGTGCGGGTCTGAG
GGGGCCGACATCCCTCCTCCTTCTGCCCTAGGCACCCCCCTTAAGGCGGGACCCCGAGTCCAC
CGGGGCTCTGAGCCCTCCGCGGGTGACCAGGAACCCTGGACGGAAGCCGTGGTGTACAGGCC
TCTGAGACCTCTCTCAATTCGGAGGGCCACAGAAAGGCCACCCCATCCTTCCCAGGCTCTGGA
GCCTCTGCCCATGGGCCCTGCTGCATCCCAGCGTCAATTCATTCAGTCATCTACCAACCTCTT
15 CAGGTCGGTGTGGGGCCGGGCCCCGTGCTGGGCCCCAGGGAGGGACAGCACAGTGGGAACTC
ACTTTCAGCCAGGAGGCAGGTGCAAACTGCCCTCAGAGTGGCCAGCTGCCCCGCTGGGGG
TAGGAGTCCCATGTAAGGGCATGCCATCCCTCCCTCCGGGTCCCAACGTGGACAAATAGCCA
TTTATCACCTTCTTCTTACCAGAACTCATTTTTTAAAAAGTGTCTACCATACCTCCAGCTGCCA
CATGGACCCAGAGGGCCCAGAGGACCCAGAAGGCAGGTGGATTGAGTGTCAACTGATCCCAG
20 GATCCATCAGGGATGTGCACCTTGGTGCCTGGTGTGTTGCCATAAGGCTTCTCCAGGGCAAATG
TTGGCTGCCCTACAACGGCCATCAACAGGCAGAGTGGTCCCATTAGTATGGCAGGGCGTGAC
ACAGCACAGTCCCCCGTGACTCAAGCCTAGTCCCTGTCTCATACTGGAGGAATGGGGAGCTAA
GGACAGAGCTCCGAGGACATTCCCCCCTTAAAGGAATGAGGACACAAGAGAAAGCTCACAGGT
AGTCCATGGGCCAAGTGCAGAGGCAGACAGCCCTAAGCCACGATTGTCTGCGGGGTTTGGCC
25 CCAGTGAAGTAGTCAGGTAGGGAAGCCTAGGAGCCCCTGGGATGATTGACAGGGCAGAGTTT
GGACCTGGGGTCAAAAGGAAAGAGGAAAAGTGGGTACAGGAAGCACCTGGGTCCCCAGAGCA
GCCCCGAGTGAGTTGGAGCAGGCAGCAGCCGGGGAGGCCACAGTGGAGGCTGCTGGGCCTGG
GATACATGCCACCCCCTGGGAGCAGGACCACAAGGAGGCCTTGCCTCCTCTCACACCTGGTCC
TGCCAAGACCCTGCCTTTGCTTTCTCACTGCATCTCCTTGAAAAAGCAGTGGGACTGTGTGAG
30 GTTCTGGCTCTACCTCCCAGGCACCACATCTCGGCAGGTAGCCTCAGTGCCGTCCACCTGTGTC
CCTGTTCTCCTTGTCTGTTTATACAGGATCATGCATGTGCTGTGCCTAGCACACATTCTTGGCAC
TCACACTGCTGCCTTTTAGCTCTCATCATTTGCCCTCAGAGATCAACCTGAGCTGTGCCACTG
GGGCGCTCAGAGCAGACCCTGAGCCCCAACACCCAGGCTCCCTGTGCACCTGAGCCTGCCTCT
GCCTGCCACGTGCCCCCAGGCCAGTCTGGTGGCAGCAAGGATCCGCAAGCTCTCCCCTTTCC
35 TCATCCTCTGCAAAGCTCTGAATCATCTTTCTCAAACTTGTCTGGGAATTTGCTCCGTTGCC

CCAGTTGAGCATGTCAAGCCCGGCGGCCCAAGGCTGGGGTGAAGCAGCGTGGCACGTCACCTT
 CCCTGGGAACAACCTCACACATGGATTGGATTTGGGTCCAACATCCTCTGCCAGGGAAAATAGA
 AGCCATAAGAAAAACAAAAAAGGAACAGAAGGAGGCTTTTCTTCAGTCACAGCGAGTCACCAA
 CAAAAACATGTGCAAAAGCTCTCATGGAGAGCTGGGCCACAAGGAGGGCCATGATGTTGGGG
 5 GCCCTCTGACACCAAGGGTGTGGGCAGGTGGATGGGAGGCAGCTGCCCTCCATGCCAGGCTG
 ATGTGCCTCCCTTTGGGTGGTGGGGCTGGGACTCCCACTCCACTTGAAGACCTGCACCAAAAA
 GTCCTTTAGCCCTGTGCCCAGGCTCTGCCACGGGGCCGGTGAGGGGACTTCTCCCCTCTGCTG
 CCAGAGTGAAGCCAGTCAGGGGGATGGGAGGCTTGTAGCCAAGAGCACCTAGTGGCTTTCAG
 GGTCCCTTACCCCTGCCACTTAGCAGGGTCTGCACCTGCATCCAAGTGTCTCTCTGGGCTACAG
 10 TGGGGGGCTGGTAGACACTCTGGTGATCCACTTTCAGCTTCCACATGGATGTGGCAGGGACT
 GCTTTGGCATTTCCCTACCCCAAGGGACAGCCACTGCGGCAGGACTGGGCTGGGGAGGGTGG
 GGCCTGCGCTGGGGAGGGTGCCCCCTGTCCCTTGCTGCTGCTGGAATGGGAAGGAGAGTTGTT
 GAGAGAGCCAGAACTGTCCAAGGGTGGAAAGCTGGCGAAACTGACCTGCAGGGAACAGGGAG
 ACAGGGAGCATGGCCAGTGAGTAGGTCCTATGTAGCTCTGAGGCCATCAACCCTGCCATGA
 15 GGGCTGAGACCCCAAGAGAGAAGTTGAGGTTGGGTGAGGGGCCTGTTAGTGCCAGCTGAGGA
 GGGGGACAGGCCAGCCTCCTCCCACTGGGACCCAAGCTATAGCTCCTGAGCCTCCAGAGCTGC
 CTGGTGCCTCAACCTGGTCAGAGGTGGAACTCACCTGCCAGCAGGCCAGTGTGCCTGAGTT
 CTGACTGTGGGGATCTGCAGGGCACAGAAGGATAAGAGGTCATCAGGGCCTGGGGACAGGCA
 GGAGTGGCAGGGTCTGGGAGGCTGGGAGCAGACCCTCCCAACCTGCCCCATGGCCTCCGTGG
 20 CCCCCAGGACCCCCATGGCAGCAGCTCAGACACGGGTTGTGCCTCAGAAGGAAGTGAAGCTG
 TGTGTACCGAGATGGCCAGCAAACCTTTGTATGTAACTTCCGCCACAGCCCAGCTGTCCA
 GCACCAGCATGTGTATCTGGGGGAGGGGGATAAATAGAAGGTCTGGGAGGCCTGGGATCTGG
 CCAGCAGGCTACTGGGATCACAGATGCCAGCCCCTCCATATCTCCGCTTGAGTCTTGATCTG
 CCTCCTGGGACCAAAGGGGAAAGGACCAGGCTAGGCTCCTTCTTTTTTGTCTTCCCTCTTGGG
 25 GGAGGCTCCTAGAACTCCCCCTTCTCTGCCGCCCAAGTGCCTGGATATTACAGTGGGGTTA
 GCCTGTTTGGGCCCACAAGATGGGATGGCTCCCAGAGCCATGGGACCTGAGGTCTCCCAGAC
 AGTGTCTAGCCACCCTCACAACCTGGCAGAACAATTTCTTGGTTTTCAACAACCTGAAAAACA
 TATGTGATTTTCCACAGTCCGGTGCTTCTCAGGCCTGGCTGCTGAGTGAGCAGAGTTCATGCTG
 AATTCCTTCCACTCACCACAGGGCAGACAGCAAGCCCAGCTGTGGGGACTCGGTTGGGGTGG
 30 GGGTCACCACAGCAAGGCGCGGGGAGTGGGGAGGGGGGCAGGCTTCCAGCACTGATGAGTA
 ATTCTGCTGCCCCAAGATCTGGGAAGAGGGCATGTGACAACCTTAGTGCAACAATCTGCCAGT
 GTTAGGTCAGAAGGAAGGAGAGGTCGTTCAAATGGAGTCTGGTGGAAAAATAATGTTTGG
 CCCCACCTCATACCTCCCTCAAATTAACCTCCAGATTAATGAGGTAGATGTTAGAAGAGGAAC
 CAGGGAAGGACTACAAGAAAATATGGAGTCTTTATTTACATTGTGAGGTTTTCTTTAGGTTTT
 35 GTTTGTTTTTGTTTTTGATATGGAGTCTCACTCTGTCACCCAGGCTGGAGTGCAGTGGTGCGAT

CCCGGCTAACTGCAACCTCCGCCTCCCAGGTTCAAGAGATTCTCCTGCCTCAGCCTCCCAAGT
 ATCTGGGGATTACAGGCACATGCCACCATGCCCCGGCTTTTTTTTTTTTTTTTTTTTTGTATTT
 TTAGTAGAGATGGGGTTTCACCATGTTGACCAGGCAGATCTCAAACCTCCTGACCTCAAGTGAT
 CCACCCGCCTCAGCCTCCCAAAGTGCTGGGCGCCCCGGCATGTGTGCCCAGCCTATATTGACAT
 5 TCTTGATGGAGAAGTCTCTTAAGGAAGGACAGAGAAGTTTGGTTGCATAAAAGTTTTTACCTT
 CTGTACATCAAAATATACTGAAAATGAAAATAAAGAGCAAACAAAATACTGAGAAAGAATGC
 AGTGCTTAGAGAGCGAACATTCCTGGCCTCCTGTAGTTTTAGGAAGCAGCTGTGGCCTCAGAC
 CCATCTGCTGTGAACCTCTACTCCATATTTATTGCACCTTTCTGTCTGTGAGCGTCGGTTTTCTCTC
 CTCTATAACAATAGGATAATAATGACACTACCATGCCTTGCAAAAATGCTACAAGGGTTCCT
 10 GAGATAAATCTGGAGAGTCATGCCTGAAAAATAGTAAGTCGTTGATAAAGGGAAGCTGCTAT
 TAATAAATAAAGCTTTTTCTTTTTTTTTTTTTTTGAGATGGAATCTCACTCTGGCGCCTAGGCTGG
 AGTGCAGTGATGCAATCTTGGCTCACTGCAACCTCCGCCTCCTGTGTTCAAGCAATCCTCCTAC
 TTCAGCATCCTCAGTAGCTGGGACTACAGGTGCGCACCACCATGCCCCGGCTAGTTTTTTACATT
 TTTAAAGCTATTAATAGGCCAGCCACAGTGGCTCATGCCTATAATCCCAGCACTTTGGGAAGC
 15 TGAGGCAGGTGGATC

The adipocyte enhancer binding protein 1 is 16,000 base pairs in length and contains 21 exons (see Table 3
 below for location of exons). As will be discussed in further detail below, the human AEBP1 gene is
 situated in genomic clone AC006454 at nucleotides 137,041-end.

20

POLD2 has an amino acid sequence depicted in SEQ ID NO:4:

MFSEQAAQRAHTLLSPPSANNATFARVPVATYTNSSQPFRLGERSFSRQYAHYATR LIQMRPFLE
 NRAQQHWGSGVGVKKLCELQPEEKCCVVGTLFKAMPLQPSILREVSEEHNLLPQPPRSKYIHPDD
 ELVLEDELQRIKLKGTIDVSKLVTGTVLAVFGSVRDDGKFLVEDYCFADLAPQKPAPPLDTRFVL
 25 LVSGGLGSGGGGESLLGTQLLVDTVVGQLGDEGEQCSAAHVSRVILAGNLLSHSTQSRDSINKAK
 YLTKKTQAASVEAVKMLDEILLQLSASVPVDVMPGEFDPNTYTLPPQPLHPCMFPLATAYSTLQL
 VTNPYQATIDGVRFLGTSGQNVSDIFRYSSMEDHLEILEWTLRVRHISPTAPDTLGCYPFYKTDPFIF
 PECPHVYFCGNTPSFGSKIIRGPEDQTVLLVTVPDFSATQTACLVNLRSLACQPISFSGFGAEDDDL
 GGLGLGP

30 and a genomic DNA sequence depicted in SEQ ID NO:8..

CCTCCTCCATCCCTGCCCCAACACCCTGAAGACCCTGGATGCAAACAAAGGCCCGAGGGAG
 CCTCTTCCCTCGCAGTGCAGGCCTCACCTGGGGCTCAGAGTCAGAATCTGCATTTTATTCCCTA
 GGACAACCTCTAGTCAGGGCAGAGGCCGGCTGTGCTGCCCAAGTGCCCTAACCCCTAGCTTTGA
 GGCACCAGAAGGGCAAATGCAAATTAATAAATGAGAATAAGTTTATTCTCCTTGGTGAAAAAA
 35 AAAAAAAAAAGACTTTCCCCTCTCCTTTTTCTTTAGAAAATCTATCATTGCAAGTTCCTTCCTGG

ACTTTTTTTATGTAGATCTGTTCAAAAAGCTAAATAAGCCTCTTTCAAGTTTCACATCCCAGGAA
 TGTCTCCTTAAGGACCTAGGAGCCACCATTGGAAGTGTAATCACCAAGGGAGATACATCCTTA
 TCTCCCAGTTTCCGTGGGCAAAGGGGAGCCTAACTTTAGCCCGGTGCCTAGCTCAAGT
 TGCAAACACACTTCCAGTCTTAAAGGAATGAATTTATTTTTTTTCTTTAGGCCAAACCCAGGTA
 5 GCCACCACAGTTACCTGGGGATTACAGAGAACTGTGTGTGACCACTGGTGCTGTCAAGTCCT
 CTTACCTGAGCACCTGTGACGTTTCCCTTGAGAACGTGTACGGGATGGGTTGCACCTGGTTAT
 ATACAAGCGTGAGACTTCTTTCTGCCTTTGTAATTTATTAGCAGATTATCTGTGATGAGC
 ATCGCAATCTGTTTAATGCCTATTCAATAATTAATTTTCTTTCTCTTTTGTGGAAAGGTT
 TTCTGCATTGGCAGGAGATTTTGTTCGATTATGTCCCCAACATGCCTGATGTTCCACCCCT
 10 CAAGAGCCTCAGCCTTGCCCAGGGAGGGCATGGGGGTGAGTGGCCTCTCCCACAGAGAGTGC
 TGGCCAAGTTGGCCCAGGTGCGCAGCAAGGGCTGCTGCCCAAAGGCTCCCTCCTGGTTG
 GCATGGGTGCGGACCCTGTTGTGTTGTGTTTTCGCTCTTTTTTCGTAGAGTTCAAGGGGGTCTG
 CTATGTTGTCCAGACTGGTCTTGAAGTACCTCAAGGGATCCTCTCGTCTCAGCCTCCCAAAGT
 GCTGGGATTACTGTGCCCAGCTTTGTGTTGTATTTTCTGATCTTATCCTGCAACCTCTTGAGCC
 15 CCCAACCTGGGCCCCAGTTCTGCTGTGCCCCAGCCTGCCAGCCCTCTCTCTCTGCAT
 ATTCTTTCTTTAGCTGAGTTAACACCACTGATAAGGTTAAAGACAGGCTCTTAAATTTCTGCCC
 TGGCATGAGAAATATGTGACCCACATGCTTCTCCAGCTTAGCTGTCCAGTGTAAGTGTGAGG
 ACTGATGGGCGCGTGCTGGCCCACAGCCCACCTCAGTCCTGACCCTCCCTGACAGGCTGAGAG
 AGGCCCCAGCCTGAACCTGGACTCCCCCATGTTCTGATATTCCTGCACAAGAGTGCAGAG
 20 GCCTGGTTAAGCTGGAGAAACATAAGGAATAGGTAGGTCTGCACACACTCACCTCTTCCTTTG
 CAGTGAACCTTCTAGAATCTTCTAGATGGAAAAGCTGGGGGTGTGGAGGTGTAGGGATAGGA
 CAGCTGGGGGAGGCCTTGGCCAAGGTCAAGGAGTAGGCCAGTCTCCCTCTCTGTGTGCCTGT
 CTGGGACTCGGTTTCCCTGTCTGTGAAGCAGGGCTGGACGGGATATTGACAGCACCTGATGGTC
 ATTGAGCTCCTCTGCCCCAGGCACTCAGCTGCTGGGCACAGTGCACACGTGGCAGTCCGGTGC
 25 CCTCTCACGCTCCGTGATGACTGAGTCTGTAGTTACACCCCTGGCCTCAGAATAAAGACTACA
 CTTTCTGCCTCCCTCACTGGCAGGTATGACTAGGTGTGGTGGCAGTTTTCTCCTTAAGAGACAG
 ATGTTTGTGCCTCCCTCCAACCCGCTGGCTAACACCTAGCTGGCACACAGCCTCCTGGGGCTA
 TGAAGATGAGGGCCACAGCCACAGGGTGGGGGAGCCGTGAGCTGGGTCTGGCTGCGTCTCTG
 ACATATGGGGGCATCACACATCACCTCTACCTCCCATCGAATGCTACACGAAGAGAACAACT
 30 CCACCTGATGGAAGCTGCTGTTGTTTGAAGTCTTTCATGCTCACAACAGAACCTAACCCCAAC
 CAATACAGTATGAGTATTGGCCCCACGTGGTTAAGCAAGCTGTCCAAGGTTACACACAGCTGG
 GAGGTGGTGGAGCTGGGTTTGAAGCCTGTTATTGACCTTTGTGCAGACAGACCTCAGAGCAGAG
 CACAAGGCAGCAAGGCTGTGGGTCTGGGGCTCCCTCTCCAGGAGAATCAACTGGCTGCACAC
 AGCCTGGAGAGCCCATGGGCAACCTGAGTCCTTGACCTGGAAGTTTCTGTGTCCACACATA
 35 TCCAGGAGCTTAAAATGAAGATGTCTGAATTACCCAACCTCTTGATAGCACCAACCCAACCTT

CCCAGCCTCCTCTTCTGAGGTCAGCCCAGAGCAAGCCCCCTTGCAAAGCTGATTTAACTCAGAA
 CCACTGGGCATACCCACAGGGCAGTGACCCTGCAGCCCTCGATCAAATGTGCAGATGGACTTG
 GGGGTGGGCTGGTACCCAGATGGCCTCATTCTCCAGGGTTGCAGAGCCCCCTGAAAGCCACA
 GCCCTGTGTGCACACCACTGGGGAGTCATCACAGGATACTTCAAGAATTCAAGTGCCAGGCAA
 5 GGTGGCTCATGGCTGTAATCCCAGCACTTCGGGAGGCTGAAGCGGGCAGATCACCTGAGGTC
 AGGAGCTAGAGACCACCCTGGTCAACATAGGGAAACCCCATCTCTACTAAAAATACAAAAAT
 TATCTGGGCGTGGTGGCGGGTGCCTGTAATCCCAGCTACTCAGGAGGCTGAGACCGGAAAAT
 CGCTTGAGCCTGGGAGGCAGAGGTTGCAGTGAGCTGAGATTGCACTGCTGCACTCCAGCTTGG
 GGGACAGAGTAAGACTCCATCTCAGAAAAAAGAGTTCTGTGTATCATTTAATGTGGAGATCCT
 10 CCCATCACGAGGATGAGGCTGTTTCTCTACTCCCCAGATCTGGGCTGGCCTGTGGTTTGTGAC
 CTCAGCCTTGTAAGTTCTCACTTTCCTGGAACCTGAATGCCACCACGCGACATCCATAAGACAA
 AGCCCAGGATAAAAGATCACTTGAGAGACAGGCCTGGCCTGGCACCACCCCGGCTGAGGCT
 GGACCCCTGGGAAGGAGACTCTGATGGACCTCCAGACCCAGT
 CAAATGACCACTTCCAAGGTCAGGCAAGAAGGGACAAAGAGCCACTGGCTCAGCCCACAGCA
 15 TCTGAGAAATAAGAAACCGCTGCATTTTTTGAGCCAGTAAGATTTGACAGGTTTGTTTTGCAG
 CAATAGATGAGTGGTACCTCATCTTAGCCCATGTTCTGATGAAGACAAACAGTAGCATTGACA
 AAGTTTTAAGAAAAGTTAACCAAAAACTGGGATTCTTTCTTCATTTTGACCCTTTGTTACAAG
 AAACAGAGGCCCCACCCACAGACTCACTGTTCACTGGTCCCTGAGTGCCTGTGAGTCTCAGT
 GGGAGTTACCTTGAGACCAGCCCTTCTGAGTGGAGGGTGTGGGTGCTGAGGTCAAGTCGAG
 20 CTCAGTCCAGGCTAAAAGGAGAGCAGCTCTGGCCAGGCTGTCAGGGCTGTGGCCTCCCCAAG
 AACCTCCTACCCTGGCCCCCTCAGGCTTTGCTGCTATGGTTGTGTGAGGGGAGTTGCTGTCCCA
 GCATTCTGGCCCCCTTGCCCCAGCCCCCTCCCTGACCTCCACGGGCTTCAGGCCTCAGTCCAGA
 GTCACCTCCTCTAGGAAGCCATCCCCCAGTGCAAGTCTGGGCAACATTCTCCTTGCTGGCC
 CACCTGCTCACTCTCATGCTATGGCTTTCTGTAAGCAAACACAAAGATAGGAACAACCTCTGTC
 25 CCTGGCACAGAGCAGATGCTCTGGCAATATCTCATGAGTGAATGAAGGCACATGACAAACCT
 CCAGACCTGTGGAGACTGAAGGCTGAGAGCCTTTATAGATGCTGTGGGGCCGAGGAGTTTGC
 CAACTACAGCAGGTCATGCCCAGAGGTTTCTCTCTGGGTAGCAAGGTGTGTCTCCACCAAAG
 GCCATTGGCATGGGGCCCCGCCCTGCTGACCCGAGGCAGTGCACAGCAGAGGCCAGATGCAGT
 GAGAAGGAGCCTCTCCTTGCCCTGCTGTCTGCTGCCATGCCTGTGGGGGCGTGGACACAAGTG
 30 TGTGGCATAGAAGGTGGTGTGGCAGGTGAGAGGTTGGGGGTGTGTATGTAGCAGGTGTCTGT
 GTGTGTATGTGCATGTGGGGGTGTGTGTGCATGCATGTGTGTGTGTGCATATGCACGTGTGTG
 CATATGCATGTGTGTGCATGGAGAGAGAAGACCTCCTCTTTCTGGCCCCCTCCTAGCTGCCCC
 CCTCCCTCCTGCTGCCAACACACTGTCAACCCTTCACTGTCTTTTTCCTTGGGACTCGTTGATCT
 GTCTCTACCATCCCAGGTGTCTGGAGCAGCCTCTAACCTTCCATCTGCCAAGGTACTTCAGCCC
 35 CACCCCTCCCAGCTGTGGAATGTCCCCTAGGATGTGCCACTGACACAAAGAGCCACACAGCTC

CAAAATAGAATATTATCTAACCCACTGCTCCCTTTGCTGTCAGCAACACCTCCACCATGCTTCT
 CCCAGGACCCCCCTTGAACCTCTCTGCTTCCTCCCTGAGGCCAAAGGAAAGACAGGAAAGGGG
 CCACCTTCCTGTCCTTGGGTCCACAGAGATGTATCCTTGTAATGAAACCTACTTTATGCTTGA
 GTTGTATCCAGTTAGTTTCTGTGGCTTGCAATCAAGACCCACACCCACCTCAACCCAGGCTCTA
 5 GAGAGTAGACCCTTGTTTTGCCTGGCTTGGGTGCACCTGGCACCTGCCAGGGTCCCAGCCTC
 TGAGTCAGCCACCTTGCCCTCATCGGTGCCACCTCCAGGCGGTGT
 ACATAGACTCTGGCTTCTGCCCTGGCCTGGCCTCTGGGAACTGCAGCTGTCTGCTTCCATCCTA
 TGTGGATGGTGCCTGAAAGTGAATAGGGATCAGTTACCAGCCCAGTATCTGTCCCCTTCTCAA
 TAGCACTGATTCTATGGGGAACTGCTTTTCTTGGAATATGTATGGGTTTGGTGGGAGGGTAG
 10 TTCCTGTAACCAACCCTACAGGGTGTAGGAACCTAGACTCTCAGCAACATAACAGGCAGC
 AGGCTCCCAAGCTAAGTCTGGCCAGCTGGGCCACCTCTCCAGATTCTGTTTCATGAGAGCAT
 CATCCAAGAGCAGTGGGAACACTGGGGACGGTCCAGCCTAGGACTGGTATGCAGATCAGAGA
 ATCCCAGATAGAAGGTGATTGCTGTTCTTCCAGTTTCTTGCCCTCCAGAGCAACCATACTTCC
 CATCTGCCCCAAAACCTGATCCTCCAAACTCCCACCATTTCTGTGCATCCCCAATATCTAA
 15 TAGATCAACTGCCTTTTACATTTGTCACAACCAAATGATACACCTGCCCTTACCCACTA
 CTGAACTGCAGCTGGGTAGTCCAAATTCAGGGCCCACGTGTCATTTCAAGCCTGTCTTGAAT
 AATGTACACCTTCCTGCAATGTGAGGATGGCCACCACCTTGGTCTTATACCCACGGGTGTCCT
 GAGCTACATTTCTCATAATCAAAAATAAACTCAACACATCACTCCAGCCTGAGCAACAGA
 GCAAGACACTAGCTCTAAAAATAAAAAATAAAAAACAAACAAATGAAAAACCCAGCAAACCTT
 20 GGGGAAAGAGGAAGCACCTGATTTCCAGAGTTTCCACATCATGAGATGCAAATGTCCAGTTTT
 CAACAACAACAACAACAACAAAAAATAACAAGGCATACAAAGAAATAGGAGACTAAG
 ACCCACTCAAAGGAAAAGAATAAATAAGCAGAAGCCATACCAGAGGAAAACCAGATGGCTG
 ACTTACTAGACAAATACTTTAAACAACCTGTCTTAAAGATGCTTGAAGAGCTAAAGGAAAAT
 GTGAACAAAGTCAAGAAAGTGATGGAACAAATGGAAATTCCAATAAAGTGATAGAAAACCTT
 25 TTGGAGTTTTTTTTCTTGGTAGCAAAAAATTATGAAGCTGAAGAATACAATAAATTCCCTAGA
 GGGCTTCAAAGGCAGATGTAAGCAAACCTTGGCCAGGTGCAGTGGCTCATGCTCATAATCCAG
 CACTTTGGAAGGCTGAGGCAGGAGGATTGCTTGAGCCCAGGAGTTTGAAACCAGCCTGGGCA
 ACATAGAAAAACCTATCTTTAAAAAAACTTATATAAAATTTAAAAATTATAAAATTTATTTA
 AAAAATCAGCAATTTGAAGACTGGACAGGGAAATTATCAAATTTGAGGAACAGAAAGGAAA
 30 AAGATGGAAGAAAAATAAACAGAGCCTAAGAGACCTGCGGGACACCATCAAGCAGACTAAT
 ACCCATTTGTGGAAATTCAGAAAGAAAAGAGAGTGAAGGACCAGAGAGATTATTAGGAGAA
 ATAATGGCTGAAAATGTCTCAAATTTGATGAATGACATGAATATGAACATTCAAAAATCTCGA
 CAAACTCCAAGTAGGAAAAACTCAAAGATACTCATACTGAGATTCATCATAATCAAACCTGCTG
 AAAGCCAAAGACAAGGAGACAATATCAAAGCTGCAAGAGAGAAGTGACTCATCACATACA
 35 AGGGATCTTCAAAAAGATTATCAGATATCTTGGCTGGGCACGGTGGCTCACACCTGTAATCTT

AGCACTTTGGGAGGCCGAGGCAGGTGGATCACTTGAGGTCAGGAGTTTGAGACCAGCCTGGC
 CAACATGGCAAAAACCCATCTCCATTA AAAAATACAAAGATTGGTGAGGCATGGTGGTGCATG
 CCTGTAATCCCAGCTACTCGGGAGGCTGAAGCAGGAGAATCACTTGAACCTGGGAGGCGGAG
 GGTGCACCAAGCCAAGATCGTGCCACCACTGCACTCCAGCCTGGGTGACAGAGTGTGACCTTG
 5 TTTCAAAAAAAAAAAGAAAAAGAAAAAGAAAAAAGATCATCAGCTATCTCATCAGAAACCT
 CAGAGGCCAAAAGGCAGTAGATTGATATATTCAAAGTGCTAAAAGAAAAAAATAAATCTGTC
 AGCTGAGAATCCTGTATCTGTATCTCACTTAACCATTATTTTAAAATAAGGGAAAAATGAAGAC
 ATTCCCAGATAAACACAAGCTGAGGGAGTTCAATTACTAGATCTGCCCTGCAAAGAAAGCC
 AAAGAAAGCCTTTCAGGATGAAATGAAAGGATACTAGACAGTGACTCAAAGCTGAATAAAGA
 10 GGCCAGGCATAGTGGCTCACACCTGTAATCTCAGCACTTTGGGAGGCTGAGATGGGCGGATC
 ACCTGAGGAGTTGGAGACCAGCCTGGCTAATATGGTGGAACCCCATCTCTACGAAAAATACA
 AAAATTAGCCAGGTGTGGTGGCACATGCCTGTAATCCCAGCTACTTGGGAGGCTGAGGCAAG
 AGAATCACCTGAACCCAGGAGGCGGAGGTTGCAGTGAGCCGAGATTGTGCCACCGCACTCCA
 GCCTGGGTGACAGAGTGATACCCTGTCTCAAAAAAAAAAAGCCGAATAAACGAATAAAGATCT
 15 CATCTATGGCCGTACCACCCTGAATGTGTCCAATCTCAGAAGCTAAGCAGAGTTGGGCCTGGT
 TAGTACTTGAGGGGGAGAAATAACGGTCTATGCTAAAGGAAAATTCAGGTGCAATTAAAGTA
 AAATTAATTATATAAAAGAGAATACATTAAGCTAGTATTATTGTAACCTTTGGTTTGTAATT
 CCACCAAGTGGAATTTGTTCTGAAATGCTAGAATGGTTCAACATAAAAATCAATAAATGTAA
 TAGACCACATTAACAGAAAAAAAAACCCACACGGTCATCTCAATTGATGTCAAAAAAGTATTT
 20 GACAAAATTCAACACTCTTTTGAAAGAAGAAAAAGCTCAACAACTAAGAATAGGAGGAAAC
 TACCTCAAATAATAAAATCCATAGGCCAAATCCCCAACTCACAGCTAGCAACATATTTAATG
 CTAAAGACTGAAAGCTTCCCCTTTAAGATCCGGAATAAGACAAAGATGCCCACTTTCACCACT
 TCTACTCAACATAGTATGGGAAGTTCTAGCCAGAGTAATCAGGTAAGAAAAAAGAAATAAAA
 AGCATCTGAATTGGAAAGGAAAAAGTAAATTTATTTGTTTGCCCAATACATGTACAATGTTTC
 25 AGGTGAAGGCTCAGAACAGTACAACCTTACCAGCAAGAGTCCTGCTGTCTCTGTGTGAATCCC
 AGCTATTACTCACTAGCTACATGATCTCTCTTGCCCTCCCTGCCTCAATTTCTCATGTGTAAA
 GTGGGAGAAAAATAATAGTTTCATGCTTCAAAGGTTTTTTGTTTGTTGCTTGTCTTGAGACAGC
 GTCTGGCTCTGTGCTCAGGCTGAAGTGCAGTGGTGCAATCTTAGGTCACTGCAACCTCAGCC
 TCCTGGGCTTAAGCGATCCTCCACCTCGGCCTCCCAAAGTGTTGGGATACAGGCGTGAACCA
 30 CTGTGTCTGACCCAAAGGATTATTTGAGGAGCAGATGAATTAATGTGTCATAACCTCAAAGCA
 GTTGCAAAGGCGTTTAATAATTAAAATATCACATTTTAAATTAATAAAGGCTGGGCGTGG
 TGGCTCATGCCTGTAATCCCAGCACTTTGGGAGGCTGAGGTGGGAGGATCACTTGAGCCCAGG
 AGTTCCACACTAGCCTGGGCACCATTTGGGAGACCCTGTCTCTACACACACACGCACACACACA
 CACACACACACAACTTAAAGTAGCCAGGCGTGGTGCTGCGCGCCTGTTGTCCCAGCTACTCG
 35 GGAGGCTGAGGCGGGAGAATCACTGGAGCCTGGGAGTTCGAGGCTGCAGTGAGCCGAGATCG

CACCACTGCACTCCAGCCTGGGCCACAGAGCAAGACGCTGCCTCAAACAAACAAACAAAAAC
 AAAAATTAAAAATATTAAGTAATAATTAACGAGTGTTAATATCCACTCGTTGTGGAGACAAGAC
 CTGGACTTAGGAAACAGGCCAGGGAAGTAGCAGAACAGTAGCGCTAGAGGACGCCTGGGA
 GAATCAGCGCGCGGCGGGAAGAGCCCGGGAAGCTTAGTGGGGAAGCGTCTCTTGATGGGGTG
 5 AGGAATTCTATAAATTAGTGGAGATGGAAAAAAAAAAAAAAAAAAGTATTCCTAAAGTGGGAG
 ACAGCACTCAGAAAGACGTGGTGGTAAGAACGAGTATGAGTAACGGGGACAACGAGGACAC
 TGGAGATTGGGGAGTGTTGGGCTGGAAGCTGGTGTGCAGCTGTGGGCAAGCTAGGGAGGACC
 CCGAAACCGCCAATGCGTTTCCCGGACGCAGACGCTGGCAGGACGGGAGGAACCCCGAGACC
 CCGCGCCATCCCTTCAGGAAGAGTTACTTCTCCCGGCCAAGTTAGTGGGCCTTGGGCCTTCTT
 10 TCTGTTGGGATCCTCCTCGCGTGTGCGCATCGCTACAAGTGGGCAGCTCTGCGGGGAAAGCTG
 GGACGCTGGGGGCTTCACCAAGGAGGCTGGCGGCCGACCACTGGGAGGTCTGGCGGGGTGAC
 GACCACTGGGAGGTTTGGGCAGGGCCTGACGGGGTGACGCGGTCAGCCCACTGGAGGCCGAC
 ACCCCCCGTCAGCCCAACCCCTGCACGCGCGGCCGCAACCAAAGACCCGCGGCGCCGGCCT
 GCGAGCCCCCGCCCCGCGTTGCCAGGAAACCGAGGGTGTGGCTCCGCGTTCTCTGGGCGTCC
 15 CAGGGACTGGGCGCACAGTGGTCGGCGGGATGAGGCGCCTGGTGACGGACGGGGCGAGGAG
 GGCAGCGATTGGTGAGATTAGGCGATGGGCGGGGAAGCCGCGCGGGGATTAGCGAGTTGCGG
 CGATGGGCGGGGACAGGCGCGCGGGGATTGGCGGGATGCGGCGCGCCGCGCGTTGAGTGGGGT
 CCAGGGAAACGGGGTCAGCTGGGGGTGGCAGTTCCAGGCCGCGAGGCCGGGCTCCTGGGTCTG
 GTGGGCTGGTGTCTTGGCGGACGTCCCGCAGCTGCCGCGTGGATCCGAGCCGGGGCACCCGCC
 20 GTGACTGGGACAGCCCCCAGGGCGCTCTCGGCCCCATCCCGAGTAGCGCGGCCTGGCTGCTGC
 CGCCATCAAGCACGTTTCGAGCCAAAAGCTCCTAACGAGTCACTCGTTAGACACGTGTGCGGA
 GCCTGTGTCCCAGGCCAGTGCTGTCCCGTGGAGATAGATTGCAAGCCGCTAGGGAATTTTTTA
 ACTTTCTAGTAGGTGTACGAAAAAGTAAAACGAAACAAATCAATTGGAGTAAATCCATAAA
 TATATTCAAATATTATTTCAATTGTATGTGAAAAATTATTGGGATATTCTTTGTACTATTCTT
 25 AGAAATCCATTGTGTGTCCAACCCAAACATCACAGTTGGACTCACCACATCTCCTGTACTTCG
 TAGCCCTAGGTGGCTAGTGGCATAAGACACAAAAATCTCAGCTCTCCTGGAGCTTATGGTCTA
 GTTGGAGCAGGCAGACAATACATTTAAAATATACAGTTTGTTAGAAGGTAAATGTTGTAAACA
 ACAATAACAGTTGAAGTACTGGGGAGAGTTGCAGTTGTAAATCAGATGGGCAGGGCACAAGG
 TAACATTTGAGTAAAGATGTAAGAACTTGAAGGAGATGGGCAAGTGAGCTCTATAAGTATAC
 30 GGGAGAGGGGCAAGCAAGAGTTCAGAGGCCCTTGTCTGTGGGGAGGGATCCAAGGTGGAGG
 AGTGGGAACCAGGAGGGGAGAGGACCACTGGAGCAGATCTCATAGGCAGTTGTAAGGACTTG
 GGGCCTTATTCAATGAAATGAGGACACTTTGGAGAGTTTTTGAACAGAGCAGTGACTGATTTAT
 GTTTTGGTTTTGGTTTAGTTCTATTATTATTTAATAATAGGCTTATTATTTACAGAAGTTTTAT
 TTAATAAGGCAGACCTCTTGTCTGGAAATGAGACAGGTGCCGGAGAGCTGGATGGAGGCAGA
 35 TCGGGAATTCCATTTGGGGCAAACCTGAACTTGATTGAGACCCTGGTAGTTGTCCAGATGGAAC

AGGACACCTGAGTCTAGGGTTCGGGAAGAACTCCAGATGGGACAAACACTCCTAGCTTTCCTT
 TTCTCTTTTTGGATGACCGCTACAGGGTGAGACATCGGTATCCAGGCACGATAAAATTTCCAAG
 TGGACACAATGTCTGGTGTCAACTACAGCTGTTCTCCTTCTTTTCCCAGTATCCTTTGGGTGCA
 GTGAGACACCAGGAGAGCTGCTGCTTTGGGGGATGGACAGGGGCAGCAGGAATGCCTTTGTG
 5 TTTTCGCAGTGAACCTCCTTGGCCTGGGCGAAGCTGTGTGGACCAAGCAAGTCAGGAGTGTGG
 CCATGTTTTCTGAGCAGGCTGCCCAGAGGGGCCACACTCTACTGTCCCCACCATCAGCCAACA
 ATGCCACCTTTGCCCCGGGTGCCAGTGGCAACCTACACCAACTCCTCACAACCTTCCGGCTAG
 GAGAGCGCAGCTTTAGCCGGCAGTATGCCACATTTATGCCACCCGCCTCATCCAAATGAGAC
 CCTTCCTGGAGAACCGGGGCCAGCAGCACTGGGGTAAGTGAGAGTTTGGGAAGGTGCTTCCC
 10 CCACAGCATCCCTGAACCTTAGAAGTGTCTGCAAGAGAATGGGAACAGTTTATCTAATTGATC
 CCACTTCCTGTTACCTTGGGAAAATTAACCTCTTTTTCCCTCAGTTTCTTCTTAAGATAGTAAC
 AAGGATTAAATTAAGTAATTTGTGGGTTTGGAGTTAGTTTTAGTTTCAGAGGCTGGTTGGAGAT
 GAGGACTTAGTTCTGGCGGTGATGGCGATTACTTCACTGGCAGAGGAAAATGGTTTTCTATC
 TTCAGTGCAGATTATTACAGGTATTTGCCTGTGCTGTAGCCAGAGAGCCCCCTCAGTGTGGCAAG
 15 CCTGGCGCCAGGCACCAGGAGCCAAGACTGGTGAGGATGCACTCTCTGGTCTCGAGGGGACC
 CCCTCTGTTCACTCATGTCTGTTTGCCTCTCCTCCTGGCCCCCATATTTGCTGGCCATGAATTTT
 CCTGTCCCTTGGGCCCTCTGTCTTTCCTAATAAAGTGGCCTGCCAACACAACCTTGTTCCTT
 GCCCCCATTTCTTCCCTGGTGATCTCTCCTGCAGTTGGATTACTCTTGGTGGTGAAGCAGGGAC
 CCCCATCTCCCCCTTTGAGTTTATTTGAGTTTLAGGTGCTGCTGCATTCCCCCATTCCTACCACT
 20 TACATAAGAGTGGCTTTCCAGGTAATTTTCAAATCCATCTCCTATTATATTTTTAAACTGAGGA
 TTTAGTAGGTGAGACCAGGTCTTACTCATTTTTACTGTCCTTGGCACCAGGCAAAATGGATCTC
 AGCCCTAGTTGCACATTGGAATCCCCTGGGGAGCTTTGAGAAGCCCATCTCATCCCATGCCAA
 GCCAAGATCAATTCTCGTTATAGGCAGGCGGAGAACCCTGGGCCTAGAAATCTAGCTAGAAC
 CTCAAATTCATTAGGGATATGTATTAGTCCATTTTCACATTGCTATAAAAAACTACCTGAGATA
 25 GGGTAATTTATAAAGAAAAGAGGTTTAATTGACTCACAGTTCCTCATGGCTGGGGAGGCCTCA
 GGAAACTTAACAATCATGGCAGAAGGTGAAGGGAAAGCAAGGCTCTTTTACATGATAGCAGG
 AGAGAGAGAGCAAGGGGAACTGCCAACCATTTTTAAACCATCAGATCGCATGATGGCTTGAT
 CTCACTCACCATCACAAGAACAGCATGGGGGAAATCCACCCCCACAATCCAGTCACCTCCCAC
 CAGGTCCCTCCGTCAACACCGTGTGGATTATAATTCCAGATGAGATGTGGGTGGGGACACAGA
 30 GCCAAATCATATCAGGATGTTTTCTGTTTTGTTTACCTGAGACAAAGTGCTGTTACCTCTCCT
 CTCCCACATAATCAGGGGCTCCCTCCTGCGGCTCCGGTAGCTTTTCCTCACTTTCCTTTCAGCC
 CTCGGGACACCTTCCTTGGCTCCTTTCAGAGCTCAGTTACTACTTGGGCCCAATGTCAATGCCA
 CCTTCTAGATTCTTTCGGCAGCACCTCCTCTGGTCGCACATTTCTCTTCCAGTTATTGGAGCT
 GTCAAAAAAGCTCCCCAGTGATGGACGATAGCGATTTCACTGTGCTCACAGACTGGTCAGGA
 35 AACCAAACAGCTGCCACAGTGAATGTGTTGATAGCAGCGGGGCAGCAGTAGCACTCGCTCAC

AGGCCTGGTGGTTGGTGCTGGCCCCCACCCTGAATACCTACATGTGGCTTCTCCATGTGGCCT
 GTGCATCCTCACTGAAGCTCAGCCTGTCTCTCCAAATTGGTCTTTCCACTCACCTGTTCCCCAA
 ACCTGCCCAGACCTTCCTGCTGTAGGCTTTTCCCTTCACTTGGCACACTCTTTCCCTTGTCTTCC
 CATGGCCCCATCTAAGCCCCACTGTCAGCTGAAGTGTTATATTCTTTGAGGGGGCCACCTGAAG
 5 CCACCTTGCAATGAGGGCCTCCGTTTTCTACCTCAGCTCACCATTTGTTACAGCACTTGTCAC
 TGTGGCGAGTTACTTGTCTATGGCCTGTTGTCTGTTCTCCTGCCTAGACCCAGTGGGCTGAGTGG
 GGGCAAGTGTTGGCTTTTATGTCCAGTTTTGATCTTGGTGCCAGCACATTGCCTGGGTGGAAG
 CATGTCCTACTATCGGTTACAGGGATGTCAATCTGCCCAGTGCTCAGGGGCATACACTTGGAT
 CCCAGTTGTGTGCCCTTGGACACATTGCTTAACCTCTCTGTGCATCAGTTGGGTGATAATATCT
 10 ACTCCTGGCACATTTTCAGCGTTGGCTGAGTTACATTACAGTGCTTAGGCCACCTGGGGGAGA
 GTAAGAGTGGGATACGTGAGGATGTGGAGTCTGTTGCATTTCTGTCTGCTGCTGGCATCCTTCT
 TGTCTTGTTTTGAAGTTGCTCGCTCTGTCTGCTCCCTAGGGCGTAGATTTGAGGAATATTCCTG
 GTTCTTCCCAGGCAGCAGGGGCTCAGGCTGTGCTGGAGTCAGCTAGGCTAAGGGGCTGGTCTG
 GCATCCGCGTTGTCCTGTACCTCCTTGGTGTTTTCTCCAGGCCTGGATCTGTGCTGTGTGGGC
 15 ACCTGTATTCTCCCTCCTGCCCTCACTGATTCTCCATACCTTTCTTCTCGAGAGTGCCAAGCC
 CCTCCCATGTGTTCTTGTTCATACCTAGGATCCCGGGAAGGGGCTGGGGAAGACGGTGCCAG
 GTGCCCTGGGTAAACAAAGCCACCTGACTCCACGGGAATGGAATGGGTGGAGGGGATCTGAG
 GTCTGCATTTTGAGTATCTCTGGTCTCAGAGGATGAAGCATTTGGTGGGGGTTGGGGGTGGGG
 GGTAGGGTGGAAGAATCTAAAGTCTTAAAGAAAATGGCAGTTATTTGTGGGACAGGGCTGT
 20 GTTGAGACTTGGCATGCTTCTTTTTAAGAGTCAGTGTTGTAATTTAGGTATAAGTGAAGCAGT
 ACTTTGTATTAGTTTCTGTAGGCGCTGTAACAAAGCACCACAACTGGTTGACTTAAACAA
 CAGACATGGCCGGGCACGGTGGCTCACGACTGTAATCCCAGCACTTTGGGAGGCCGAGGCGG
 GCAGATCACAAGGTCAAGAGATTGAGACCATCCTGGCTAACACGGTGAAACCCTGTCTCTACT
 AAAAATACAAAAAATAAATTAGCTGGGCGTGGTGGCACACGCCTGTAGTCCCAGCTACT
 25 CGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGACAGTGAGCTGAGA
 TCGCGCCACTGCACTCCAGCCTGGATGACAGCGAGACTCCGCCTCAAAACAAAAACAAAAAC
 AGAAACAACAATAACAGAAAAACACAGACATTTACTCTCTGGCAGTTCTGGAGGCCAGAAGT
 TGAAATCCAGATGTCAGCAGGATTGGCTCCTTCTGAAGGCCCGAGGGGAGGGTCCTTCCTGGC
 CTCCTCCCTGGTGTTCCTGGGCTTGTGGCCGCATCACTCCGCTCTGCCCGTCTTCACACTCCCT
 30 CTTGTCTGTGTGTCTGTCTCTGTCTCTCATGAGGACACTTGGCATCCAGGGCCCAACCACACC
 CAGAGTCCCTGGTCTCCTGTGGCTGACTCACTTTTTACTGTACCGTGAAAGTCCAGGGGGTCCT
 TGTACTTGATGTTCTCTCCTGGCAAGGCCAGGGCCCTGTGATTGGCCTCTCATGGAGTGCTGG
 GCAGGGCCTCCATGGCCTCTGTCTGGGCGGGGGGGCTACTTCATCTCTGAGTCTGTACCCCTCG
 TGTCCCAGGCAGTGGAGTGGGAGTGAAGAAGCTGTGTGAACTGCAGCCTGAGGAGAAGTGCT
 35 GTGTGGTGGGCACTCTGTTCAAGGCCATGCCGCTGCAGCCCTCCATCCTGCGGGAGGTCAGCG

AGGAGGTGAGGCAGGGTGCTACACAGTGGGGCCGCCAGGCAGACCTGGCCTCCCACTAGAAC
 ACCTCCCTGGAGGTGGGGTTGTGGGGAAGCAGGTTTCAGAGACAATGGACTCCAGAGGGGTGG
 GGGCTGCGGTGCCAGCTCACTAACACCAGAGCTTTGGTGGGCTCTGGCCCCAAGATTATACCT
 CCTGTCTCTGCATTCCAGCACAACTGCTCCCCAGCCTCCTCGGAGTAAATACATACACCCA
 5 GATGACGAGCTGGTCTTGGAAGATGAACTGCAGCGTATCAAATAAAAGGCACCATTGACGT
 GTCAAAGCTGGTTACGGGTAGGGAGCCCAATGAGAGGATGTGGGTGATGCAGGTGAAGAGCC
 CAGCGGTGGTGTGTTAGGGATGGTGTGAGTGGGGAGCCTGGGGGGAGTGGGGGGGTGTGGCC
 TGGGCACACGTGTGTTCTTGAGGAGGTAGGTGAGGCTCCAGGCGGTGCGAGGCCATCAGATT
 GGGTGAGACCTGGCTGGGAGATGGGTCTCCCCACCTCCATCCAAGGGCAGTGA CTCCAGGAA
 10 GCAGGCATGCATCCTGGAGTCCTAGGTGAGAATTCACCAATGTGGTTGTGGAGAACTGGCTTG
 TTTTGCCCGTTGGGGTGACTGGAAGGAGTGGTAGCACCTGGGGCTCCCTGCTCAGGCCTGATG
 CCACTGCTCCCCAGGGACTGTCCTGGCTGTGTTTGGCTCCGTGAGAGACGACGGGAAGTTTCT
 GGTGGAGGACTATTGCTTTGCTGACCTTGCTCCCCAGAAGCCCGCACCCCCACTTGACACAGA
 TAGGTGAGCAGCAGTTCTCGGGAGCTGGAACCAGCTCATGGTCAGTGGAATCTTTGAGTTGCA
 15 CCTAGGAGGGGGCTGCCTCCCTTCTCGGCACCCTGGAGGACCCACCTTCTCCCGCAGGTTTGT
 GCTACTGGTGTCCGGCCTGGGCCTGGGTGGCGGTGGAGGCGAGAGCCTGCTGGGCACCCAGC
 TGCTGGTGGATGTGGTGACGGGGCAGCTTGGGGACGAAGGGGAGCAGTGCAGCGCCGCCAC
 GTCTCCCGGGTTATCCTCGCTGGCAACCTCCTCAGCCACAGCACCCAGAGCAGGGATTCTATC
 AATAAGGTATGGAGCCCACTGGCTGCATTCAGCCCCAGCCAGGAGCCTGCAAGCCTGTAA
 20 GACCCTCCTTCCCCAGGGCGAGTAGGGTACCCTGTGAGGTCTCGCAGGTCCGTGGGAAGCGCC
 CTGCAGTGA CTCTGGGGCCTCCTGCAATGGGGCTCCTCATGCCAGGCCCTCGCTGAGGATGG
 TGGGAGGCTTGAAGGGAGTGAGGGTCTATGGGACAACA ACTGCATCTTCCAGCTGGTGGGGC
 TCTACTCTCCTCTGAGCCTGGGACTCGCCTGGGCCTGATGGCCTTCTGGGCTTCTATTCCAGGC
 CAAATACCTCACCAAGAAAACCCAGGCAGCCAGCGTGGAGGCTGTTAAGATGCTGGATGAGA
 25 TCCTCCTGCAGCTGAGCGTGAGCGAGCTGGGGGCTGGAGGGGTGATGGGGATTGCAGTCTTC
 AAAGCTGCCACTGGGCAACAGAAGGCAGGCAGGAGGGCAGGGGGAGTGGCCGGAGTTGGTG
 TAGGGGGCTCCTTCGGGGCCCTGTGAGCTCTCCCTGCCCTGTGCCTTCCAGGCCTCAGTGCCCG
 TGGACGTGATGCCAGGCGAGTTTGATCCCACTTACACGCTCCCCAGCAGCCCCCTCCACC
 CCTGCATGTTCCCGCTGGCCACTGCCTACTCCACGCTCCAGCTGGTCACCAACCCCTACCAGG
 30 CCACCATTGATGGAGTCAGGTAGCTGGCACAGCCACACTTCAGTCTGACCCAGCCTTTTGCCT
 CAGGAGGCACAAAGAAGGGAGGGGAGGGAGGGGCCAGGAAGGTGGCAGGGCTGCAGAGGC
 CCACCTAGCATCTGTTCTTCTCTCTGGGGCATCCCCACAAGAGCGCCAGATGAGCTCTGGGC
 TGACCACTATGGGTGGCACCCAAAGCCAAGAGTCAGCTGAGCTTTGCCTTGCAGATTTTTGGG
 GACATCAGGACAGAACGTGAGTGACATTTTCCGATACAGCAGCATGGAGGATCACTTGGAGA
 35 TCCTGGAGTGGACCCTGCGGGTCCGTACATCAGCCCCACAGCCCCGGACACTCTAGGTAACA

GGCTCAGCCATACAGGGTGGGAGCAGAGGGCCAGGAGGCCTGGCAGGACCCTGAAGTGCAC
 AGGGTCCCCCTGTGGGTTTGCACCTGCCAGCATTGCTGAGAACTGTCTGAGGAGAAGTTCAGA
 GGCTTGGCACCTGCTCTGGAAGCTACTCTGGAATCTTAATTCTAAGGCCAATGGCTGCCCACC
 CCAACGGGCAGCAACAGCAGGGCCAAGGTCTTGTGACAATGTCTGGAGGTGCCCTATTGTC
 5 ACACTGGGGGTCTCCTACTGGCCTGCAATGGGAGGAGGGGCTGCAGCCCCACATCCTGTGCA
 GAGTGCTAGTGCTGAGGCGGAACCTCCTCAGAGCTGCCCTTCTCCTCTAGGTTGTTACCCCT
 TCTACAAAAGTACCCGTTTCATCTTCCCAGAGTGCCCGCATGTCTACTTTTGTGGCAACACCCC
 CAGCTTTGGCTCCAAAATCATCCGAGGTAATTTTGTCTTCTGGGGGCCAGGCTGATTTGCTG
 ATTTGCTCTCACCTGGGGACAAGGTTACAGAGAAGAAAACCTGCATTGTGGAGTCCCCCTGG
 10 CCCTTGTGGGATGGACAGCTGAGGTCTTCTGCACAGCTGCCATTTCACTGTGGGAGCCAAGCT
 GCCTCGCCAGCTGGGCAGGGACTGGAACGGCTCCCAGCCTGTGTGCCTCTCAAGGCTAATCTC
 TGGTCTCCTATTGTCACTGCCCCACTGTGTGCCAATGGGGACTCCTGTTTATTTCTGGCAGCTT
 CTCTTTGAGGCAGGACTTACTTGGAACCTACAGTGGGTCCTATGTGACTTCTTTGCAGGTCCTG
 AGGACCAGACAGTGCTGTTGGTGACTGTCCCTGACTTCAGTGCCACGCAGACCGCCTGCCTTG
 15 TGAACCTGCGCAGCCTGGCCTGCCAGCCCATCAGCTTCTCGGGCTTCGGGGCAGAGGACGATG
 ACCTGGGAGGCCTGGGGCTGGGCCCCTGACTCAAAAAAGTGGTTTTGACCAGAGAGGCCAG
 ATGGAGGCTGTTCAATCCCTGCAGTGTCGGCATTGTAAATAAAGCCTGGCACTTGCTGATGCG
 AGCCTTGAGCCCTGGGCACTCTGGCTATGGGACTCCTGCAGGGGTGCCACAGTGACCATAGC
 CCATGCACCCACCAGCCGGTCTCCCT

20

The POLD2 gene is 19,000 base pairs in length and contains ten exons (see Table 4 below for location of
 exons). As will be discussed in further detail below, the POLD2 gene is situated in genomic clone
 AC006454 at nucleotides 119,001-138,000.

25 The polynucleotides of the invention have at least a 95% identity and may have a 96%, 97%, 98%
 or 99% identity to the polynucleotides depicted in SEQ ID NOS:5, 6, 7 or 8 as well as the polynucleotides
 in reverse sense orientation, or the polynucleotide sequences encoding the SNARE YKT6, AEBP1, human
 glucokinase or POLD2 polypeptides depicted in SEQ ID NOS:1, 2, 3, or 4 respectively.

30 A polynucleotide having 95% "identity" to a reference nucleotide sequence of the present
 invention, is identical to the reference sequence except that the polynucleotide sequence may include on
 average up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding
 the polypeptide. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95%
 identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be
 deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides
 in the reference sequence may be inserted into the reference sequence. The query sequence may be an
 35 entire sequence, the ORF (open reading frame), or any fragment specified as described herein.

As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the present invention can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. (1990) 6:237-245). In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be compared by converting U's to T's. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identity are: Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence because of 5' or 3' deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for 5' and 3' truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5' or 3' ends, relative to the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence that are 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence are calculated for the purposes of manually adjusting the percent identity score.

For example, a 95 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignment of the first 10 bases at 5' end. The 10 unpaired bases represent 5% of the sequence (number of bases at the 5' and 3' ends not matched/total numbers of bases in the query sequence) so 5% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 95 bases were perfectly matched the final percent identity would be 95%. In another example, a 95 base subject sequence is compared with a 100 base query sequence. This time the deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5' and 3' of the subject sequence which are not

matched/aligned with the query sequence are manually corrected for. No other manual corrections are made for purposes of the present invention.

A polypeptide that has an amino acid sequence at least, for example, 95% "identical" to a query amino acid sequence is identical to the query sequence except that the subject polypeptide sequence may include on average, up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query amino acid sequence, up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the referenced sequence or in one or more contiguous groups within the reference sequence.

A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Com. App. Biosci. (1990) 6:237-245). In a sequence alignment, the query and subject sequence are either both nucleotide sequences or both amino acid sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject amino acid sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence due to N- or C- terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for N- and C- terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence.

The invention also encompasses polynucleotides that hybridize to the polynucleotides depicted in SEQ ID NOS: 5, 6, 7 or 8. A polynucleotide "hybridizes" to another polynucleotide, when a single-stranded form of the polynucleotide can anneal to the other polynucleotide under the appropriate conditions of temperature and solution ionic strength (see Sambrook et al., supra). The conditions of temperature and ionic strength determine the "stringency" of the hybridization. For preliminary screening for homologous nucleic acids, low stringency hybridization conditions, corresponding to a temperature of 42°C, can be used, e.g., 5X SSC, 0.1% SDS, 0.25% milk, and no formamide; or 40% formamide, 5X SSC, 0.5% SDS). Moderate stringency hybridization conditions correspond to a higher temperature of 55°C, e.g., 40% formamide, with 5X or 6X SCC. High stringency hybridization conditions correspond to the highest temperature of 65°C, e.g., 50 % formamide, 5X or 6X SCC. Hybridization requires that the two nucleic acids contain complementary sequences, although depending on the stringency of the hybridization, mismatches between bases are possible. The appropriate stringency for hybridizing nucleic acids depends on the length of the nucleic acids and the degree of complementation, variables well known in the art. The greater the degree of similarity or homology between two nucleotide sequences, the greater the value of T_m for hybrids of nucleic acids having those sequences. The relative stability (corresponding to higher T_m) of nucleic acid hybridizations decreases in the following order: RNA:RNA, DNA:RNA, DNA:DNA.

Polynucleotide and polypeptide variants

The invention is directed to both polynucleotide and polypeptide variants. A "variant" refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential properties thereof. Generally, variants are overall closely similar and in many regions, identical to the polynucleotide or polypeptide of the present invention.

The variants may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, variants in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred.

The invention also encompasses allelic variants of said polynucleotides. An allelic variant denotes any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and may result in polymorphism within populations. Gene mutations can be silent (no change in the encoded polypeptide) or may encode polypeptides having altered amino acid sequences. An allelic variant of a polypeptide is a polypeptide encoded by an allelic variant of a gene.

The amino acid sequences of the variant polypeptides may differ from the amino acid sequences depicted in SEQ ID NOS:1, 2, 3 or 4 by an insertion or deletion of one or more amino acid residues and/or the substitution of one or more amino acid residues by different amino acid residues. Preferably, amino acid changes are of a minor nature, that is conservative amino acid substitutions that do not significantly affect the folding and/or activity of the protein; small deletions, typically of one to about 30 amino acids; small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue; a small linker peptide of up to about 20-25 residues; or a small extension that facilitates purification by changing net charge or another function, such as a poly-histidine tract, an antigenic epitope or a binding domain.

Examples of conservative substitutions are within the group of basic amino acids (arginine, lysine and histidine), acidic amino acids (glutamic acid and aspartic acid), polar amino acids (glutamine and asparagine), hydrophobic amino acids (leucine, isoleucine and valine), aromatic amino acids (phenylalanine, tryptophan and tyrosine), and small amino acids (glycine, alanine, serine, threonine and methionine). Amino acid substitutions which do not generally alter the specific activity are known in the art and are described, for example, by H. Neurath and R.L. Hill, 1979, *In, The Proteins*, Academic Press, New York. The most commonly occurring exchanges are Ala/Ser, Val/Ile, Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Ser/Gly, Tyr/Phe, Ala/Pro, Lys/Arg, Asp/Asn, Leu/Ile, Leu/Val, as well as these in reverse.

Noncoding Regions

The invention is further directed to polynucleotide fragments containing or hybridizing to noncoding regions of the SNARE YKT6, AEBP1, human glucokinase and POLD2 genes. These include but are not limited to an intron, a 5' non-coding region, a 3' non-coding region and splice junctions (see Tables 1-4), as well as transcription factor binding sites (see Table 5). The polynucleotide fragments may be a short polynucleotide fragment which is between about 8 nucleotides to about 40 nucleotides in length. Such shorter fragments may be useful for diagnostic purposes. Such short polynucleotide fragments are also preferred with respect to polynucleotides containing or hybridizing to polynucleotides containing splice junctions. Alternatively larger fragments, e.g., of about 50, 150, 500, 600 or about 2000 nucleotides in length may be used.

**Table 1: Exon/Intron Regions of Polymerase, DNA directed, 50kD regulatory subunit (POLD2)
Genomic DNA**

	EXONS	LOCATION (<u>nucleotide no.</u>)		(Amino acid no.)
5				
	1.	11546 ----- 11764		
		1	73	
	2.	15534 ----- 15656		
10		74	114	
	3.	15857 ----- 15979		
		115	155	
15	4.	16351 ----- 16464		
		156	193	
	5.	16582 ----- 16782		
		194	260	
20	6.	17089 ----- 17169		
		261	287	
	7.	17327 ----- 17484		
		288	339	
25	8.	17704 ----- 17829		
		340	381	
	9.	18199 ----- 18303		
30		382	416	
	10.	18653 ----- 18811		
		417	469	
	'tga' at 18812 – 14			
35	Poly A at 18885 - 90			

Table 2: AEBP1 (adipocyte enhancer binding protein 1), vascular smooth muscle-type. Reverse strand coding.

	EXONS	LOCATION (nucleotide no.)	(Amino acid no.)
5			
	21.	1301 ----- 1966	
		1158	937
10	20.	2209 ----- 2304	
		936	905
	19.	2426 ----- 2569	
		904	857
15			
	18.	2651 ----- 3001	
		856	740
	17.	3238 ----- 3417	
20		739	680
	16.	3509 ----- 3706	
		679	614
25	15.	3930 ----- 4052	
		613	573
	14.	4320 ----- 4406	
		572	544
30			
	13.	4503 ----- 4646	
		543	496
	12.	4750 ----- 4833	
35		495	468

	11.	5212 ----- 5352	
		467	421
5	10.	5435 ----- 5545	
		420	384
	9.	6219 ----- 6272	
		383	366
10	8.	6376 ----- 6453	
		365	340
	7.	6584 ----- 6661	
15		339	314
	6.	7476 ----- 7553	
		313	288
20	5.	7629 ----- 7753	
		287	247
	4.	7860 ----- 7931	
		246	223
25	3.	8050 ----- 8121	
		222	199
	2.	8673 ----- 9014	
30		198	85
	1.	10642 ----- 10893	
		84	1
35	Stop codon	1298 – 1300	
	Poly A-site	1013 - 18	

Table 3: Glucokinase

EXONS		LOCATION (<u>nucleotide no.</u>)		(Amino acid no.)	
5	1.	20485 -----	20523		
		1		13	
	2.	25133 -----	25297		
		14		68	
10					
	3.	26173 -----	26328		
		69		120	
15	4.	27524 -----	27643		
		121		160	
	5.	28535 -----	28630		
		161		192	
20					
	6.	28740 -----	28838		
		193		225	
	7.	30765 -----	30950		
		226		287	
25					
	8.	31982 -----	32134		
		288		338	
30	9.	32867 -----	33097		
		339		415	
	10.	33314 -----	33460		
		416		464	
Stop codon		33461-3			

Table 4: SNARE. Reverse strand coding.

	EXONS	LOCATION (<u>nucleotide no.</u>)		(Amino acid no.)
5				
	7.	4320 -----	4352	
		198	188	
10	6.	5475 -----	5576	
		187	154	
	5.	8401 -----	8466	
		153	132	
15	4.	9107 -----	9211	
		131	97	
	3.	10114 -----	10215	
		96	63	
20	2.	11950 -----	12033	
		62	35	
25	1.	15362 -----	15463	
		34	1	

Stop codon at 4817 – 19

Poly A-site: 4245 – 4250

TABLE 5: TRANSCRIPTION FACTOR BINDING SITES

	BINDING SITES	SNARE	GLUCOKINASE	POLD2	AEBP
5	AP1FJ-Q2	11			11
	AP1-C	15	15	7	6
	AP1-Q2	9			5
	AP1-Q4	7			4
10	AP4-Q5	36		5	43
	AP4-Q6	17			23
	ARNT-01	7			5
	CEBP-01	7			
	CETS1P54-01	6			
15	CREL-01	7			
	DELTAEF1-01	64	12	5	50
	FREAC7-01	4			
	GATA1-02	19			
	GATA1-03	12			6
20	GATA1-04	25	6		
	GATA1-06	8	5		
	GATA2-02	10			
	GATA3-02	5			
	GATA-C	11	6		
25	GC-01				4
	GFII-01	6			
	HFH2-01	5			

	HFH3-01	10			
	HFH8-01	4			
	IK2-01	49			29
	LMO2COM-01	41	6		27
5	LMO2COM-02	31	5		7
	LYF1-01	10	13	6	
	MAX-01	4			
	MYOD-01	7			
	MYOD-Q6	32	19	7	12
10	MZF1-01	99	40	15	94
	NF1-Q6	5			7
	NFAT-Q6	43	8	7	8
	NFKAPPAB50-01		4		
	NKX25-01	13	14	5	
15	NMYC-01	12			8
	S8-01		30	4	
	SOX5-01	21	20	4	4
	SP1-Q6				8
	SAEBP1-01	4			
20	SRV-02	5			
	STAT-01	6			
	TATA-01	8			
	TCF11-01	47	28	5	19
	USF-01	12	8	6	8
25	USF-C	16	12	12	8
	USF-Q6	6			

In a specific embodiment, such noncoding sequences are expression control sequences. These include but are not limited to DNA regulatory sequences, such as promoters, enhancers, repressors, terminators, and the like, that provide for the regulation of expression of a coding sequence in a host cell. In eukaryotic cells, polyadenylation signals are also control sequences.

5 In a more specific embodiment of the invention, the expression control sequences may be operatively linked to a polynucleotide encoding a heterologous polypeptide. Such expression control sequences may be about 50-200 nucleotides in length and specifically about 50, 100, 200, 500, 600, 1000 or 2000 nucleotides in length. A transcriptional control sequence is "operatively linked" to a polynucleotide encoding a heterologous polypeptide sequence when the expression control sequence
10 controls and regulates the transcription and translation of that polynucleotide sequence. The term "operatively linked" includes having an appropriate start signal (e.g., ATG) in front of the polynucleotide sequence to be expressed and maintaining the correct reading frame to permit expression of the DNA sequence under the control of the expression control sequence and production of the desired product encoded by the polynucleotide sequence. If a gene that one desires to insert into a recombinant DNA
15 molecule does not contain an appropriate start signal, such a start signal can be inserted upstream (5') of and in reading frame with the gene.

Expression of Polypeptides

Isolated Polynucleotide Sequences

The human chromosome 7 genomic clone of accession number AC006454 has been discovered to
20 contain the SNARE YKT6 gene, the human liver glucokinase gene, the AEBP1 gene, and the POLD2 gene by Genscan analysis (Burge et al., 1997, J. Mol. Biol. 268:78-94), BLAST2 and TBLASTN analysis (Altschul et al., 1997, Nucl. Acids Res. 25:3389-3402), in which the sequence of AC006454 was compared to the SNARE YKT6 cDNA sequence, accession number NM_006555 (McNew et al., 1997, J. Biol. Chem. 272:17776-177783), the human liver glucokinase cDNA sequence (Tanizawa et al., 1992, Mol. Endocrinol.
25 6:1070-1081), accession number NM_000162 (major form) and M69051 (minor form), , AEBP1 cDNA sequence, accession number NM_001129 (accession number D86479 for the osteoblast type) (Layne et al., 1998, J. Biol. Chem. 273:15654-15660) and the POLD2 cDNA sequence, accession number NM_006230 (Zhang et al., 1995, Genomics 29:179-186).

The cloning of the nucleic acid sequences of the present invention from such genomic DNA can be
30 effected, e.g., by using the well known polymerase chain reaction (PCR) or antibody screening of expression libraries to detect cloned DNA fragments with shared structural features. See, e.g., Innis *et al.*, 1990, *PCR: A Guide to Methods and Application*, Academic Press, New York. Other nucleic acid amplification procedures such as ligase chain reaction (LCR), ligated activated transcription (LAT) and nucleic acid sequence-based amplification (NASBA) or long chain PCR may be used. In a specific

embodiment, 5' or 3' non-coding portions of each gene may be identified by methods including but are not limited to, filter probing, clone enrichment using specific probes and protocols similar or identical to 5' and 3' "RACE" protocols which are well known in the art. For instance, a method similar to 5' RACE is available for generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et al., 1993, Nucl. Acids Res. 21:1683-1684).

Once the DNA fragments are generated, identification of the specific DNA fragment containing the desired SNARE YKT6 gene, the human liver glucokinase gene, the AEBP1 gene, or POLD2 gene may be accomplished in a number of ways. For example, if an amount of a portion of a SNARE YKT6 gene, the human liver glucokinase gene, the AEBP1 gene, or POLD2 gene or its specific RNA, or a fragment thereof, is available and can be purified and labeled, the generated DNA fragments may be screened by nucleic acid hybridization to the labeled probe (Benton and Davis, 1977, Science 196:180; Grunstein and Hogness, 1975, Proc. Natl. Acad. Sci. U.S.A. 72:3961). The present invention provides such nucleic acid probes, which can be conveniently prepared from the specific sequences disclosed herein, e.g., a hybridizable probe having a nucleotide sequence corresponding to at least a 10, and preferably a 15, nucleotide fragment of the sequences depicted in SEQ ID NOS:5, 6, 7 or 8. Preferably, a fragment is selected that is highly unique to the encoded polypeptides. Those DNA fragments with substantial homology to the probe will hybridize. As noted above, the greater the degree of homology, the more stringent hybridization conditions can be used. In one embodiment, low stringency hybridization conditions are used to identify a homologous SNARE YKT6, the human liver glucokinase, the AEBP1, or POLD2 polynucleotide. However, in a preferred aspect, and as demonstrated experimentally herein, a nucleic acid encoding a polypeptide of the invention will hybridize to a nucleic acid derived from the polynucleotide sequence depicted in SEQ ID NOS:5, 6, 7 or 8 or a hybridizable fragment thereof, under moderately stringent conditions; more preferably, it will hybridize under high stringency conditions.

Alternatively, the presence of the gene may be detected by assays based on the physical, chemical, or immunological properties of its expressed product. For example, cDNA clones, or DNA clones which hybrid-select the proper mRNAs, can be selected which produce a protein that, e.g., has similar or identical electrophoretic migration, isoelectric focusing behavior, proteolytic digestion maps, or antigenic properties as known for the SNARE YKT6, the human liver glucokinase, the AEBP1, or POLD2 polynucleotide.

A gene encoding SNARE YKT6, the human liver glucokinase, the AEBP1, or POLD2 polypeptide can also be identified by mRNA selection, i.e., by nucleic acid hybridization followed by *in vitro* translation. In this procedure, fragments are used to isolate complementary mRNAs by hybridization. Immunoprecipitation analysis or functional assays of the *in vitro* translation products of the products of the isolated mRNAs identifies the mRNA and, therefore, the complementary DNA fragments, that contain the desired sequences.

Nucleic Acid Constructs

The present invention also relates to nucleic acid constructs comprising a polynucleotide sequence containing the exon/intron segments of the SNARE YKT6 gene (nucleotides 4320-15463 of SEQ ID NO:5), human liver glucokinase gene (nucleotides 20485-33460 of SEQ ID NO:6), AEBP1 gene (nucleotides 1301-13893 of SEQ ID NO:7) or POLD2 gene (nucleotides 11546-18811 of SEQ ID NO:8) operably linked to one or more control sequences which direct the expression of the coding sequence in a suitable host cell under conditions compatible with the control sequences. Expression will be understood to include any step involved in the production of the polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion.

The invention is further directed to a nucleic acid construct comprising expression control sequences derived from SEQ ID NOS: 5, 6, 7 or 8 and a heterologous polynucleotide sequence.

"Nucleic acid construct" is defined herein as a nucleic acid molecule, either single- or double-stranded, which is isolated from a naturally occurring gene or which has been modified to contain segments of nucleic acid which are combined and juxtaposed in a manner which would not otherwise exist in nature.

The term nucleic acid construct is synonymous with the term expression cassette when the nucleic acid construct contains all the control sequences required for expression of a coding sequence of the present invention. The term "coding sequence" is defined herein as a portion of a nucleic acid sequence which directly specifies the amino acid sequence of its protein product. The boundaries of the coding sequence are generally determined by a ribosome binding site (prokaryotes) or by the ATG start codon (eukaryotes) located just upstream of the open reading frame at the 5' end of the mRNA and a transcription terminator sequence located just downstream of the open reading frame at the 3' end of the mRNA. A coding sequence can include, but is not limited to, DNA, cDNA, and recombinant nucleic acid sequences.

The isolated polynucleotide of the present invention may be manipulated in a variety of ways to provide for expression of the polypeptide. Manipulation of the nucleic acid sequence prior to its insertion into a vector may be desirable or necessary depending on the expression vector. The techniques for modifying nucleic acid sequences utilizing recombinant DNA methods are well known in the art.

The control sequence may be an appropriate promoter sequence, a nucleic acid sequence which is recognized by a host cell for expression of the nucleic acid sequence. The promoter sequence contains transcriptional control sequences which regulate the expression of the polynucleotide. The promoter may be any nucleic acid sequence which shows transcriptional activity in the host cell of choice including mutant, truncated, and hybrid promoters, and may be obtained from genes encoding extracellular or intracellular polypeptides either homologous or heterologous to the host cell.

Examples of suitable promoters for directing the transcription of the nucleic acid constructs of the present invention, especially in a bacterial host cell, are the promoters obtained from the *E. coli lac* operon, the prokaryotic beta-lactamase gene (Villa-Komaroff *et al.*, 1978, *Proc. Natl. Acad. Sci. USA* 75: 3727-3731), as well as the *tac* promoter (DeBoer *et al.*, 1983, *Proc. Natl. Acad. of Sciences USA* 80: 21-25).

5 Further promoters are described in "Useful proteins from recombinant bacteria" in *Scientific American*, 1980, 242: 74-94; and in Sambrook *et al.*, 1989, *supra*.

Examples of suitable promoters for directing the transcription of the nucleic acid constructs of the present invention in a filamentous fungal host cell are promoters obtained from the genes encoding *Aspergillus oryzae* TAKA amylase, *Rhizomucor miehei* aspartic proteinase, *Aspergillus niger* neutral alpha-
10 amylase, *Aspergillus niger* acid stable alpha-amylase, *Aspergillus niger* or *Aspergillus awamori* glucoamylase (*glaA*), *Rhizomucor miehei* lipase, *Aspergillus oryzae* alkaline protease, *Aspergillus oryzae* triose phosphate isomerase, *Aspergillus nidulans* acetamidase, *Fusarium oxysporum* trypsin-like protease (WO 96/00787), NA2-tpi (a hybrid of the promoters from the genes encoding *Aspergillus niger* neutral alpha-amylase and *Aspergillus oryzae* triose phosphate isomerase), and mutant, truncated, and hybrid
15 promoters thereof.

In a yeast host, useful promoters are obtained from the *Saccharomyces cerevisiae* enolase (ENO-1) gene, the *Saccharomyces cerevisiae* galactokinase gene (GAL1), the *Saccharomyces cerevisiae* alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase genes (ADH2/GAP), and the *Saccharomyces cerevisiae* 3-phosphoglycerate kinase gene. Other useful promoters for yeast host cells are described by
20 Romanos *et al.*, 1992, *Yeast* 8: 423-488.

Eukaryotic promoters may be obtained from the genomes of viruses such as polyoma virus, fowlpox virus, adenovirus, bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and SV40. Alternatively, heterologous mammalian promoters, such as the actin promoter or immunoglobulin promoter may be used.

25 The constructs of the invention may also include enhancers. Enhancers are cis-acting elements of DNA, usually from about 10 to about 300 bp that act on a promoter to increase its transcription. Enhancers from globin, elastase, albumin, alpha-fetoprotein, and insulin enhancers may be used. However, an enhancer from a virus may be used; examples include SV40 on the late side of the replication origin, the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin
30 and adenovirus enhancers.

The control sequence may also be a suitable transcription terminator sequence, a sequence recognized by a host cell to terminate transcription. The terminator sequence is operably linked to the 3'

terminus of the nucleic acid sequence encoding the polypeptide. Any terminator which is functional in the host cell of choice may be used in the present invention.

The control sequence may also be a suitable leader sequence, a nontranslated region of an mRNA which is important for translation by the host cell. The leader sequence is operably linked to the 5' terminus of the nucleic acid sequence encoding the polypeptide. Any leader sequence that is functional in the host cell of choice may be used in the present invention.

The control sequence may also be a polyadenylation sequence, a sequence which is operably linked to the 3' terminus of the nucleic acid sequence and which, when transcribed, is recognized by the host cell as a signal to add polyadenosine residues to transcribed mRNA. Any polyadenylation sequence which is functional in the host cell of choice may be used in the present invention.

The control sequence may also be a signal peptide coding region, which codes for an amino acid sequence linked to the amino terminus of the polypeptide which can direct the encoded polypeptide into the cell's secretory pathway. The 5' end of the coding sequence of the nucleic acid sequence may inherently contain a signal peptide coding region naturally linked in translation reading frame with the segment of the coding region which encodes the secreted polypeptide. Alternatively, the 5' end of the coding sequence may contain a signal peptide coding region which is foreign to the coding sequence. The foreign signal peptide coding region may be required where the coding sequence does not normally contain a signal peptide coding region. Alternatively, the foreign signal peptide coding region may simply replace the natural signal peptide coding region in order to obtain enhanced secretion of the polypeptide. However, any signal peptide coding region which directs the expressed polypeptide into the secretory pathway of a host cell of choice may be used in the present invention.

The control sequence may also be a propeptide coding region, which codes for an amino acid sequence positioned at the amino terminus of a polypeptide. The resultant polypeptide is known as a proenzyme or propolypeptide (or a zymogen in some cases). A propolypeptide is generally inactive and can be converted to a mature active polypeptide by catalytic or autocatalytic cleavage of the propeptide from the propolypeptide. The propeptide coding region may be obtained from the *Bacillus subtilis* alkaline protease gene (*aprE*), the *Bacillus subtilis* neutral protease gene (*nprT*), the *Saccharomyces cerevisiae* alpha-factor gene, the *Rhizomucor miehei* aspartic proteinase gene, or the *Myceliophthora thermophila* laccase gene (WO 95/33836).

Where both signal peptide and propeptide regions are present at the amino terminus of a polypeptide, the propeptide region is positioned next to the amino terminus of a polypeptide and the signal peptide region is positioned next to the amino terminus of the propeptide region.

It may also be desirable to add regulatory sequences which allow the regulation of the expression of the polypeptide relative to the growth of the host cell. Examples of regulatory systems are those which cause the expression of the gene to be turned on or off in response to a chemical or physical stimulus, including the presence of a regulatory compound. Regulatory systems in prokaryotic systems would include the *lac*, *tac*, and *trp* operator systems. In yeast, the ADH2 system or GAL1 system may be used. In filamentous fungi, the TKA alpha-amylase promoter, *Aspergillus niger* glucoamylase promoter, and the *Aspergillus oryzae* glucoamylase promoter may be used as regulatory sequences. Other examples of regulatory sequences are those which allow for gene amplification. In eukaryotic systems, these include the dihydrofolate reductase gene which is amplified in the presence of methotrexate, and the metallothionein genes which are amplified with heavy metals. In these cases, the nucleic acid sequence encoding the polypeptide would be operably linked with the regulatory sequence.

Expression Vectors

The present invention also relates to recombinant expression vectors comprising a nucleic acid sequence of the present invention, a promoter, and transcriptional and translational stop signals. The various nucleic acid and control sequences described above may be joined together to produce a recombinant expression vector which may include one or more convenient restriction sites to allow for insertion or substitution of the nucleic acid sequence encoding the polypeptide at such sites. Alternatively, the polynucleotide of the present invention may be expressed by inserting the nucleic acid sequence or a nucleic acid construct comprising the sequence into an appropriate vector for expression. In creating the expression vector, the coding sequence is located in the vector so that the coding sequence is operably linked with the appropriate control sequences for expression.

The recombinant expression vector may be any vector (*e.g.*, a plasmid or virus) which can be conveniently subjected to recombinant DNA procedures and can bring about the expression of the nucleic acid sequence. The choice of the vector will typically depend on the compatibility of the vector with the host cell into which the vector is to be introduced. The vectors may be linear or closed circular plasmids.

The vector may be an autonomously replicating vector, *i.e.*, a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, *e.g.*, a plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome. The vector may contain any means for assuring self-replication. Alternatively, the vector may be one which, when introduced into the host cell, is integrated into the genome and replicated together with the chromosome(s) into which it has been integrated. Furthermore, a single vector or plasmid or two or more vectors or plasmids which together contain the total DNA to be introduced into the genome of the host cell, or a transposon may be used.

The vectors of the present invention preferably contain one or more selectable markers which permit easy selection of transformed cells. A selectable marker is a gene the product of which provides for biocide or viral resistance, resistance to heavy metals, prototrophy to auxotrophs, and the like. Examples of bacterial selectable markers are the *dal* genes from *Bacillus subtilis* or *Bacillus licheniformis*, or markers which confer antibiotic resistance such as ampicillin, kanamycin, chloramphenicol or tetracycline resistance. Suitable markers for yeast host cells are ADE2, HIS3, LEU2, LYS2, MET3, TRP1, and URA3. An example of suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take of the nucleic acids of the present invention, such as DHFR or thymidine kinase. An appropriate host cell when wild-type DHFR is employed is the CHO cell line deficient in DHFR activity, prepared and propagated as described by Urlaub et al., Proc. Natl. Acad. Sci. USA, 77:4216 (1980).

The vectors of the present invention preferably contain an element(s) that permits stable integration of the vector into the host cell genome or autonomous replication of the vector in the cell independent of the genome of the cell.

For integration into the host cell genome, the vector may rely on the polynucleotide sequence encoding the polypeptide or any other element of the vector for stable integration of the vector into the genome by homologous or nonhomologous recombination. Alternatively, the vector may contain additional nucleic acid sequences for directing integration by homologous recombination into the genome of the host cell. The additional polynucleotide sequences enable the vector to be integrated into the host cell genome at a precise location(s) in the chromosome(s). To increase the likelihood of integration at a precise location, the integrational elements should preferably contain a sufficient number of nucleic acids, such as 100 to 1,500 base pairs, preferably 400 to 1,500 base pairs, and most preferably 800 to 1,500 base pairs, which are highly homologous with the corresponding target sequence to enhance the probability of homologous recombination. The integrational elements may be any sequence that is homologous with the target sequence in the genome of the host cell. Furthermore, the integrational elements may be non-encoding or encoding nucleic acid sequences. On the other hand, the vector may be integrated into the genome of the host cell by non-homologous recombination.

For autonomous replication, the vector may further comprise an origin of replication enabling the vector to replicate autonomously in the host cell in question. Examples of bacterial origins of replication are the origins of replication of plasmids pBR322, pUC19, pACYC177, and pACYC184 permitting replication in *E. coli*, and pUB110, pE194, pTA1060, and pAMB1 permitting replication in *Bacillus*. Examples of origins of replication for use in a yeast host cell are the 2 micron origin of replication, ARS1, ARS4, the combination of ARS1 and CEN3, and the combination of ARS4 and CEN6. The origin of

replication may be one having a mutation which makes its functioning temperature-sensitive in the host cell (see, e.g., Ehrlich, 1978, *Proceedings of the National Academy of Sciences USA* 75: 1433).

More than one copy of a polynucleotide sequence of the present invention may be inserted into the host cell to increase production of the gene product. An increase in the copy number of the polynucleotide sequence can be obtained by integrating at least one additional copy of the sequence into the host cell genome or by including an amplifiable selectable marker gene with the nucleic acid sequence where cells containing amplified copies of the selectable marker gene, and thereby additional copies of the nucleic acid sequence, can be selected for by cultivating the cells in the presence of the appropriate selectable agent.

The procedures used to ligate the elements described above to construct the recombinant expression vectors of the present invention are well known to one skilled in the art (see, e.g., Sambrook *et al.*, 1989, *supra*).

Host Cells

The present invention also relates to recombinant host cells, comprising a nucleic acid sequence of the invention, which are advantageously used in the recombinant production of the polypeptides. A vector comprising a nucleic acid sequence of the present invention is introduced into a host cell so that the vector is maintained as a chromosomal integrant or as a self-replicating extra-chromosomal vector as described earlier. The term "host cell" encompasses any progeny of a parent cell that is not identical to the parent cell due to mutations that occur during replication. The choice of a host cell will to a large extent depend upon the gene encoding the polypeptide and its source.

The host cell may be a unicellular microorganism, e.g., a prokaryote, or a non-unicellular microorganism, e.g., a eukaryote. Useful unicellular cells are bacterial cells such as gram positive bacteria including, but not limited to, a *Bacillus* cell, or a *Streptomyces* cell, e.g., *Streptomyces lividans* or *Streptomyces murinus*, or gram negative bacteria such as *E. coli* and *Pseudomonas* sp.

The introduction of a vector into a bacterial host cell may, for instance, be effected by protoplast transformation (see, e.g., Chang and Cohen, 1979, *Molecular General Genetics* 168: 111-115), using competent cells (see, e.g., Young and Spizizin, 1961, *Journal of Bacteriology* 81: 823-829, or Dubnau and Davidoff-Abelson, 1971, *Journal of Molecular Biology* 56: 209-221), electroporation (see, e.g., Shigekawa and Dower, 1988, *Biotechniques* 6: 742-751), or conjugation (see, e.g., Koehler and Thorne, 1987, *Journal of Bacteriology* 169: 5771-5278).

The host cell may be a eukaryote, such as a mammalian cell (e.g., human cell), an insect cell, a plant cell or a fungal cell. Mammalian host cells that could be used include but are not limited to human Hela, embryonic kidney cells (293), lung cells, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese Hamster ovary (CHO) cells. These cells

may be transfected with a vector containing a transcriptional regulatory sequence, a protein coding sequence and transcriptional termination sequences. Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as dhfr, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

The host cell may be a fungal cell. "Fungi" as used herein includes the phyla Ascomycota, Basidiomycota, Chytridiomycota, and Zygomycota (as defined by Hawksworth *et al.*, In, Ainsworth and Bisby's Dictionary of The Fungi, 8th edition, 1995, CAB International, University Press, Cambridge, UK) as well as the Oomycota (as cited in Hawksworth *et al.*, 1995, *supra*, page 171) and all mitosporic fungi (Hawksworth *et al.*, 1995, *supra*). The fungal host cell may also be a yeast cell. "Yeast" as used herein includes ascosporogenous yeast (Endomycetales), basidiosporogenous yeast, and yeast belonging to the Fungi Imperfecti (Blastomycetes). Since the classification of yeast may change in the future, for the purposes of this invention, yeast shall be defined as described in *Biology and Activities of Yeast* (Skinner, F.A., Passmore, S.M., and Davenport, R.R., eds, Soc. App. Bacteriol. Symposium Series No. 9, 1980). The fungal host cell may also be a filamentous fungal cell. "Filamentous fungi" include all filamentous forms of the subdivision Eumycota and Oomycota (as defined by Hawksworth *et al.*, 1995, *supra*). The filamentous fungi are characterized by a mycelial wall composed of chitin, cellulose, glucan, chitosan, mannan, and other complex polysaccharides. Vegetative growth is by hyphal elongation and carbon catabolism is obligately aerobic. In contrast, vegetative growth by yeasts such as *Saccharomyces cerevisiae* is by budding of a unicellular thallus and carbon catabolism may be fermentative.

Fungal cells may be transformed by a process involving protoplast formation, transformation of the protoplasts, and regeneration of the cell wall in a manner known *per se*. Suitable procedures for transformation of *Aspergillus* host cells are described in EP 238 023 and Yelton *et al.*, 1984, *Proceedings of the National Academy of Sciences USA* 81: 1470-1474. Suitable methods for transforming *Fusarium* species are described by Malardier *et al.*, 1989, *Gene* 78: 147-156 and WO 96/00787. Yeast may be transformed using the procedures described by Becker and Guarente, In Abelson, J.N. and Simon, M.I., editors, *Guide to Yeast Genetics and Molecular Biology*, Methods in Enzymology, Volume 194, pp 182-187, Academic Press, Inc., New York; Ito *et al.*, 1983, *Journal of Bacteriology* 153: 163; and Hinnen *et al.*, 1978, *Proc. e Natl Acad. f Sci.s USA* 75: 1920.

Methods of Production

The present invention also relates to methods for producing a polypeptide of the present invention comprising (a) cultivating a host cell under conditions conducive for production of the polypeptide; and (b) recovering the polypeptide.

In the production methods of the present invention, the cells are cultivated in a nutrient medium suitable for production of the polypeptide using methods known in the art. For example, the cell may be cultivated by shake flask cultivation, small-scale or large-scale fermentation (including continuous, batch, fed-batch, or solid state fermentations) in laboratory or industrial fermentors performed in a suitable medium and under conditions allowing the polypeptide to be expressed and/or isolated. The cultivation takes place in a suitable nutrient medium comprising carbon and nitrogen sources and inorganic salts, using procedures known in the art. Suitable media are available from commercial suppliers or may be prepared according to published compositions (*e.g.*, in catalogues of the American Type Culture Collection). If the polypeptide is secreted into the nutrient medium, the polypeptide can be recovered directly from the medium. If the polypeptide is not secreted, it can be recovered from cell lysates.

The polypeptides may be detected using methods known in the art that are specific for the polypeptides. These detection methods may include use of specific antibodies, formation of an enzyme product, or disappearance of an enzyme substrate. In a specific embodiment, an enzyme assay may be used to determine the activity of the polypeptide. For example, AEBP1 activity can be determined by measuring carboxypeptidase activity as described by Muise and Ro, 1999, *Biochem. J.* 343:341-345. Here, the conversion of hippuryl-L-arginine, hippuryl-L-lysine or hippuryl-L-phenylalanine to hippuric acid may be monitored spectrophotometrically. POLD2 activity may be detected by assaying for DNA polymerase activity (see, for example, Ng et al., 1991, *J. Biol. Chem.* 266:11699-11704).

The resulting polypeptide may be recovered by methods known in the art. For example, the polypeptide may be recovered from the nutrient medium by conventional procedures including, but not limited to, centrifugation, filtration, extraction, spray-drying, evaporation, or precipitation.

The polypeptides of the present invention may be purified by a variety of procedures known in the art including, but not limited to, chromatography (*e.g.*, ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion), electrophoretic procedures (*e.g.*, preparative isoelectric focusing, differential solubility (*e.g.*, ammonium sulfate precipitation), SDS-PAGE, or extraction (see, *e.g.*, *Protein Purification*, J.-C. Janson and Lars Ryden, editors, VCH Publishers, New York, 1989).

Antibodies

According to the invention, the SNARE YKT6, human glucokinase, AEBP1 or POLD2 polypeptides produced according to the method of the present invention may be used as an immunogen to generate any of these polypeptides. Such antibodies include but are not limited to polyclonal, monoclonal, chimeric, single chain, Fab fragments, and an Fab expression library.

Various procedures known in the art may be used for the production of antibodies. For the production of antibody, various host animals can be immunized by injection with the polypeptide thereof,

including but not limited to rabbits, mice, rats, sheep, goats, etc. In one embodiment, the polypeptide or fragment thereof can optionally be conjugated to an immunogenic carrier, e.g., bovine serum albumin (BSA) or keyhole limpet hemocyanin (KLH). Various adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and *Corynebacterium parvum*.

For preparation of monoclonal antibodies directed toward the SNARE YKT6, human glucokinase, AEBP1 or POLD2 polypeptide, any technique that provides for the production of antibody molecules by continuous cell lines in culture may be used. These include but are not limited to the hybridoma technique originally developed by Kohler and Milstein (1975, *Nature* 256:495-497), as well as the trioma technique, the human B-cell hybridoma technique (Kozbor et al., 1983, *Immunology Today* 4:72), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al., 1985, in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96). In an additional embodiment of the invention, monoclonal antibodies can be produced in germ-free animals utilizing recent technology (PCT/US90/02545). According to the invention, human antibodies may be used and can be obtained by using human hybridomas (Cote et al., 1983, *Proc. Natl. Acad. Sci. U.S.A.* 80:2026-2030) or by transforming human B cells with EBV virus in vitro (Cole et al., 1985, in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, pp. 77-96). In fact, according to the invention, techniques developed for the production of "chimeric antibodies" (Morrison et al., 1984, *J. Bacteriol.* 159-870; Neuberger et al., 1984, *Nature* 312:604-608; Takeda et al., 1985, *Nature* 314:452-454) by splicing the genes from a mouse antibody molecule specific for the SNARE YKT6, human glucokinase, AEBP1 or POLD2 polypeptide together with genes from a human antibody molecule of appropriate biological activity can be used; such antibodies are within the scope of this invention.

According to the invention, techniques described for the production of single chain antibodies (U.S. Pat. No. 4,946,778) can be adapted to produce polypeptide-specific single chain antibodies. An additional embodiment of the invention utilizes the techniques described for the construction of Fab expression libraries (Huse et al., 1989, *Science* 246:1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity for the SNARE YKT6, AEBP1, human glucokinase or POLD2 polypeptides.

Antibody fragments which contain the idiotype of the antibody molecule can be generated by known techniques. For example, such fragments include but are not limited to: the F(ab')₂ fragment which can be produced by pepsin digestion of the antibody molecule; the Fab' fragments which can be generated

by reducing the disulfide bridges of the F(ab')₂ fragment, and the Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent.

In the production of antibodies, screening for the desired antibody can be accomplished by techniques known in the art, e.g., radioimmunoassay, ELISA (enzyme-linked immunosorbent assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitin reactions, immunodiffusion assays, in situ immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention. For example, to select antibodies which recognize a specific epitope of a particular polypeptide, one may assay generated hybridomas for a product which binds to a particular polypeptide fragment containing such epitope. For selection of an antibody specific to a particular polypeptide from a particular species of animal, one can select on the basis of positive binding with the polypeptide expressed by or isolated from cells of that species of animal.

Immortal, antibody-producing cell lines can also be created by techniques other than fusion, such as direct transformation of B lymphocytes with oncogenic DNA, or transfection with Epstein-Barr virus. See, e.g., M. Schreier et al., "Hybridoma Techniques" (1980); Hammerling et al., "Monoclonal Antibodies And T-cell Hybridomas" (1981); Kennett et al., "Monoclonal Antibodies" (1980); see also U.S. Pat. Nos. 4,341,761; 4,399,121; 4,427,783; 4,444,887; 4,451,570; 4,466,917; 4,472,500; 4,491,632; 4,493,890.

Uses of Polynucleotides

Diagnostics

Polynucleotides containing noncoding regions of SEQ ID NOS:5, 6, 7 or 8 may be used as probes for detecting mutations from samples from a patient. Genomic DNA may be isolated from the patient. A mutation(s) may be detected by Southern blot analysis, specifically by hybridizing restriction digested genomic DNA to various probes and subjecting to agarose electrophoresis.

Polynucleotides containing noncoding regions may be used as PCR primers and may be used to amplify the genomic DNA isolated from the patients. Additionally, primers may be obtained by routine or long range PCR, that can yield products containing more than one exon and intervening intron. The sequence of the amplified genomic DNA from the patient may be determined using methods known in the

art. Such probes may be between 10-100 nucleotides in length and may preferably be between 20-50 nucleotides in length.

Thus the invention is thus directed to kits comprising these polynucleotide probes. In a specific embodiment, these probes are labeled with a detectable substance.

5 Antisense Oligonucleotides and Mimetics

The invention is further directed to antisense oligonucleotides and mimetics to these polynucleotide sequences. Antisense technology can be used to control gene expression through triple-helix formation or antisense DNA or RNA, both of which methods are based on binding of a polynucleotide to DNA or RNA. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription
10 or RNA processing (triple helix (see Lee et al., Nucl. Acids Res., 6:3073 (1979); Cooney et al, Science, 241:456 (1988); and Dervan et al., Science, 251: 1360 (1991)), thereby preventing transcription and the production of said polypeptides.

The antisense oligonucleotides or mimetics of the present invention may be used to decrease levels of a polypeptide. For example, SNARE YKT6 has been found to be essential for vesicle-associated
15 endoplasmic reticulum-Golgi transport and cell growth. Therefore, the SNARE YKT6 antisense oligonucleotides of the present invention could be used to inhibit cell growth and in particular, to treat or prevent tumor growth. POLD2 is necessary for DNA replication. POLD2 antisense sequences could also be used to inhibit cell growth. Glucokinase and AEBP1 antisense sequences may be used to treat hyperglycemia.

The antisense oligonucleotides of the present invention may be formulated into pharmaceutical compositions. These compositions may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g.,
20 by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or
25 intraventricular, administration.

Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional
30 pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.

Compositions and formulations for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets or tablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable.

5 Compositions and formulations for parenteral, intrathecal or intraventricular administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.

10 Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, and liposome-containing formulations. These compositions may be generated from a variety of components that include, but are not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids.

15 The pharmaceutical formulations of the present invention, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

20 The compositions of the present invention may be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the present invention may also be formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions may further contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

25 In one embodiment of the present invention, the pharmaceutical compositions may be formulated and used as foams. Pharmaceutical foams include formulations such as, but not limited to, emulsions, microemulsions, creams, jellies and liposomes. While basically similar in nature these formulations vary in the components and the consistency of the final product. The preparation of such compositions and formulations is generally known to those skilled in the pharmaceutical and formulation arts and may be applied to the formulation of the compositions of the present invention.

30 The formulation of therapeutic compositions and their subsequent administration is believed to be within the skill of those in the art. Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from

measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on EC50 as found to be effective in in vitro and in vivo animal models.

5 In general, dosage is from 0.01 ug to 10 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance doses, ranging from 0.01 ug to 10 g per kg of body weight, once or more daily, to once every 20 years.

Gene Therapy

As noted above, SNARE YKT6 is necessary for cell growth, POLD2 is involved in DNA replication and repair, AEBP1 is involved in repressing adipogenesis and glucokinase is involved in glucose sensing in pancreatic islet beta cells and liver. Therefore, the SNARE YKT6 gene may be used to modulate or prevent cell apoptosis and treat such disorders as virus-induced lymphocyte depletion (AIDS); cell death in neurodegenerative disorders characterized by the gradual loss of specific sets of neurons (e.g., Alzheimer's Disease, Parkinson's disease, ALS, retinitis pigmentosa, spinal muscular atrophy and various forms of cerebellar degeneration), cell death in blood cell disorders resulting from deprivation of growth factors (anemia associated with chronic disease, aplastic anemia, chronic neutropenia and myelodysplastic syndromes) and disorders arising out of an acute loss of blood flow (e.g., myocardial infarctions and stroke). The glucokinase gene may be used to treat diabetes mellitus. The AEBP1 gene may be used to modulate or inhibit adipogenesis and treat obesity, diabetes mellitus and/or osteopenic disorders. POLD2 may be used to treat defects in DNA repair such as xeroderma pigmentosum, progeria and ataxia telangiectasia.

As described herein, the polynucleotide of the present invention may be introduced into a patient's cells for therapeutic uses. As will be discussed in further detail below, cells can be transfected using any appropriate means, including viral vectors, as shown by the example, chemical transfectants, or physico-mechanical methods such as electroporation and direct diffusion of DNA. See, for example, Wolff, Jon A, et al., "Direct gene transfer into mouse muscle in vivo," *Science*, 247, 1465-1468, 1990; and Wolff, Jon A, "Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs," *Nature*, 352, 815-818, 1991. As used herein, vectors are agents that transport the gene into the cell without degradation and include a promoter yielding expression of the gene in the cells into which it is delivered. As will be discussed in further detail below, promoters can be general promoters, yielding expression in a variety of

mammalian cells, or cell specific, or even nuclear versus cytoplasmic specific. These are known to those skilled in the art and can be constructed using standard molecular biology protocols. Vectors have been divided into two classes:

- a) Biological agents derived from viral, bacterial or other sources.
- 5 b) Chemical physical methods that increase the potential for gene uptake, directly introduce the gene into the nucleus or target the gene to a cell receptor.

Biological Vectors

10 Viral vectors have higher transfection (ability to introduce genes) abilities than do most chemical or physical methods to introduce genes into cells. Vectors that may be used in the present invention include viruses, such as adenoviruses, adeno associated virus (AAV), vaccinia, herpesviruses, baculoviruses and retroviruses, bacteriophages, cosmids, plasmids, fungal vectors and other recombination vehicles typically used in the art which have been described for expression in a variety of eukaryotic and prokaryotic hosts, and may be used for gene therapy as well as for simple protein expression. Polynucleotides are inserted into
15 vector genomes using methods well known in the art.

Retroviral vectors are the vectors most commonly used in clinical trials, since they carry a larger genetic payload than other viral vectors. However, they are not useful in non-proliferating cells. Adenovirus vectors are relatively stable and easy to work with, have high titers, and can be delivered in aerosol formulation. Pox viral vectors are large and have several sites for inserting genes, they are
20 thermostable and can be stored at room temperature.

Examples of promoters are SP6, T4, T7, SV40 early promoter, cytomegalovirus (CMV) promoter, mouse mammary tumor virus (MMTV) steroid-inducible promoter, Moloney murine leukemia virus (MMLV) promoter, phosphoglycerate kinase (PGK) promoter, and the like. Alternatively, the promoter may be an endogenous adenovirus promoter, for example the E1 a promoter or the Ad2 major late promoter
25 (MLP). Similarly, those of ordinary skill in the art can construct adenoviral vectors utilizing endogenous or heterologous poly A addition signals.

Plasmids are not integrated into the genome and the vast majority of them are present only from a few weeks to several months, so they are typically very safe. However, they have lower expression levels than retroviruses and since cells have the ability to identify and eventually shut down foreign gene
30 expression, the continuous release of DNA from the polymer to the target cells substantially increases the duration of functional expression while maintaining the benefit of the safety associated with non-viral transfections.

Chemical/physical vectors

Other methods to directly introduce genes into cells or exploit receptors on the surface of cells include the use of liposomes and lipids, ligands for specific cell surface receptors, cell receptors, and calcium phosphate and other chemical mediators, microinjections directly to single cells, electroporation and homologous recombination. Liposomes are commercially available from Gibco BRL, for example, as LIPOFECTIN® and LIPOFECTACE®, which are formed of cationic lipids such as N-[1-(2,3 dioleyloxy)-propyl]-n,n,n-trimethylammonium chloride (DOTMA) and dimethyl dioctadecylammonium bromide (DDAB). Numerous methods are also published for making liposomes, known to those skilled in the art.

For example, Nucleic acid-Lipid Complexes--Lipid carriers can be associated with naked nucleic acids (e.g., plasmid DNA) to facilitate passage through cellular membranes. Cationic, anionic, or neutral lipids can be used for this purpose. However, cationic lipids are preferred because they have been shown to associate better with DNA which, generally, has a negative charge. Cationic lipids have also been shown to mediate intracellular delivery of plasmid DNA (Felgner and Ringold, Nature 337:387 (1989)). Intravenous injection of cationic lipid-plasmid complexes into mice has been shown to result in expression of the DNA in lung (Brigham et al., Am. J. Med. Sci. 298:278 (1989)). See also, Osaka et al., J. Pharm. Sci. 85(6):612-618 (1996); San et al., Human Gene Therapy 4:781-788 (1993); Senior et al., Biochimica et Biophysica Acta 1070:173-179 (1991); Kabanov and Kabanov, Bioconjugate Chem. 6:7-20 (1995); Remy et al., Bioconjugate Chem. 5:647-654 (1994); Behr, J-P., Bioconjugate Chem 5:382-389 (1994); Behr et al., Proc. Natl. Acad. Sci., USA 86:6982-6986 (1989); and Wyman et al., Biochem. 36:3008-3017 (1997).

Cationic lipids are known to those of ordinary skill in the art. Representative cationic lipids include those disclosed, for example, in U.S. Pat. No. 5,283,185; and e.g., U.S. Pat. No. 5,767,099. In a preferred embodiment, the cationic lipid is N4 -spermine cholesteryl carbamate (GL-67) disclosed in U.S. Pat. No. 5,767,099. Additional preferred lipids include N4 -spermidine cholesteryl carbamate (GL-53) and 1-(N4 -spermid) -2,3-dilaurylglycerol carbamate (GL-89).

The vectors of the invention may be targeted to specific cells by linking a targeting molecule to the vector. A targeting molecule is any agent that is specific for a cell or tissue type of interest, including for example, a ligand, antibody, sugar, receptor, or other binding molecule.

Invention vectors may be delivered to the target cells in a suitable composition, either alone, or complexed, as provided above, comprising the vector and a suitably acceptable carrier. The vector may be delivered to target cells by methods known in the art, for example, intravenous, intramuscular, intranasal, subcutaneous, intubation, lavage, and the like. The vectors may be delivered via *in vivo* or *ex vivo* applications. *In vivo* applications involve the direct administration of an adenoviral vector of the invention formulated into a composition to the cells of an individual. *Ex vivo* applications involve the transfer of the

adenoviral vector directly to harvested autologous cells which are maintained *in vitro*, followed by readministration of the transduced cells to a recipient.

5 In a specific embodiment, the vector is transfected into antigen-presenting cells. Suitable sources of antigen-presenting cells (APCs) include, but are not limited to, whole cells such as dendritic cells or macrophages; purified MHC class I molecule complexed to β 2-microglobulin and foster antigen-presenting cells. In a specific embodiment, the vectors of the present invention may be introduced into T cells or B cells using methods known in the art (see, for example, Tsokos and Nepom, 2000, J. Clin. Invest. 106:181-183).

10 The invention described and claimed herein is not to be limited in scope by the specific embodiments herein disclosed, since these embodiments are intended as illustrations of several aspects of the invention. Any equivalent embodiments are intended to be within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.

15 Various references are cited herein, the disclosure of which are incorporated by reference in their entireties.